

**(12) STANDARD PATENT**  
**(19) AUSTRALIAN PATENT OFFICE**

(11) Application No. **AU 2018364993 B2**

(54) Title  
**Targeted CRISPR delivery platforms**

(51) International Patent Classification(s)  
**C12N 15/86** (2006.01) **C12N 15/79** (2006.01)  
**C12N 9/22** (2006.01)

(21) Application No: **2018364993** (22) Date of Filing: **2018.11.09**

(87) WIPO No: **WO19/094791**

(30) Priority Data

(31) Number	(32) Date	(33) Country
<b>62/596,375</b>	<b>2017.12.08</b>	<b>US</b>
<b>62/667,084</b>	<b>2018.05.04</b>	<b>US</b>
<b>62/584,310</b>	<b>2017.11.10</b>	<b>US</b>

(43) Publication Date: **2019.05.16**

(44) Accepted Journal Date: **2022.10.06**

(71) Applicant(s)  
**University of Massachusetts**

(72) Inventor(s)  
**SONTHEIMER, Erik Joseph; IBRAHEIM, Raed; XUE, Wen; MIR, Aamir; EDRAKI, Alireza; ILDAR, Gainetdinov**

(74) Agent / Attorney  
**Spruson & Ferguson, GPO Box 3898, Sydney, NSW, 2001, AU**

(56) Related Art  
**ZHANG ET AL.: "DNase H Activity of Neisseria meningitidis Cas9", MOLECULAR CELL, vol. 60, no. 2, 15 October 2015 (2015-10-15), pages 242 - 255, XP055451491**



## (51) International Patent Classification:

CI2N 9/22 (2006.01) CI2N 15/86 (2006.01)  
CI2N 15/79 (2006.01)

## (21) International Application Number:

PCT/US2018/060126

## (22) International Filing Date:

09 November 2018 (09.11.2018)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

62/584,310 10 November 2017 (10.11.2017) US  
62/596,375 08 December 2017 (08.12.2017) US  
62/667,084 04 May 2018 (04.05.2018) US

(71) Applicant: UNIVERSITY OF MASSACHUSETTS  
[US/US]; One Beacon Street, 31st Floor, Boston, MA  
02108 (US).(72) Inventors: SONTHEIMER, Erik, Joseph; 236 Islington  
Road, Auburndale, MA 02466 (US). IBRAHEIM,  
Raed; 11B Hartford Turnpike, Shrewsbury, MA 01545  
(US). XUE, Wen; 78 Woodland Street, Natick, MA (US).  
MIR, Aamir; 285 Plantation Street, Apt. 1015, Worcester,  
MA 01604 (US). EDRAKI, Alireza; 192 Dominion

Road, Worcester, MA 01605 (US). ILDAR, Gainetdinov;  
67 Frank Street, Apt. 177, Worcester, MA 01604 (US).

(74) Agent: HOWERTON, Thomas, C. et al.; Medlen & Carroll,  
LLP, 1440 Broadway, Suite 1010, Oakland, CA 94612  
(US).(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,  
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,  
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,  
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,  
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,  
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,  
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,  
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,  
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,  
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

## (54) Title: TARGETED CRISPR DELIVERY PLATFORMS




Figure 1

(57) **Abstract:** The present invention is related to compositions and methods for gene therapy. Several approaches described herein utilize the *Neisseria meningitidis* Cas9 system that provides a hyper-accurate CRISPR gene editing platform. Furthermore, the invention incorporates full length and truncated single guide RNA sequences that permit a complete sgRNA-NmeICas9 vector to be inserted into an adeno-associated viral plasmid that is compatible for in vivo administration. Furthermore, Type II-C Cas9 orthologs have been identified that target protospacer adjacent motif sequences limited to between one - four required nucleotides.

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

**Published:**

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments (Rule 48.2(h))*

**(88) Date of publication of the international search report:**

20 June 2019 (20.06.2019)

## Targeted CRISPR Delivery Platforms

### Field Of The Invention

The present invention is related to compositions and methods for gene therapy. Several  
5 approaches described herein utilize the *Neisseria meningitidis* Cas9 systems that provide  
hyperaccurate CRISPR gene editing platforms. Furthermore, the invention incorporates  
improvements of this Cas9 system: for example, truncating the single guide RNA sequences, and  
the packing of Nme1Cas9 or Nme2Ca9 with its guide RNA in an adeno-associated viral vector  
that is compatible for *in vivo* administration. Furthermore, Type II-C Cas9 orthologs have been  
10 identified that target protospacer adjacent motif sequences limited to between one – four required  
nucleotides.

### Background

Clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR associated  
15 (Cas) is a unique RNA-guided adaptive immune system found in archaea and bacteria. These  
systems provide immunity by targeting and inactivating nucleic acids that originate from foreign  
genetic elements. Many different types of CRISPR-Cas systems have been identified to date and  
are categorized into two classes.

Within class II CRISPR systems, type II CRISPR-Cas systems are characterized by a  
20 single effector protein called Cas9, which forms a ribonucleoprotein (RNP) complex with  
CRISPR RNA (crRNA) and trans-activating RNA (tracrRNA) to target and cleave DNA. The  
crRNA contains a programmable guide sequence that can direct Cas9 to almost any DNA  
sequence in living organisms.

This programmability of Cas9 RNP complexes has been harnessed by many researchers  
25 for genome editing in eukaryotic systems. It has been used to edit the genomes of mammalian  
cells, human embryos, plants, rodents, and other living organisms. Cas9 RNPs have been used  
for precise (with donor template) and imprecise genome editing, both of which have found  
applications in gene therapy, agriculture, and elsewhere. In addition, the nuclease-dead versions  
of Cas9 orthologs are being used for transcription modulation, site-specific DNA labeling, and  
30 for proteome profiling at specific genomic loci. Several different Cas9s have been used for these  
applications. Central to the programmability of Cas9 and hence its applications is the ability to



introduce any guide sequence in the crRNA. The crRNA and tracrRNA can be fused together to form a single-guide RNA (sgRNA), which is more stable and provides enhanced genome editing.

What is needed in the art are improved Cas9s and sgRNA sequences that can provide specific and accurate editing of a wider range of target sites, especially when combined with reliable nucleic acid delivery platforms.

### Summary of The Invention

According to a first aspect, the present invention provides a single guide ribonucleic acid (sgRNA) sequence comprising a truncated repeat:antirepeat region and a truncated Stem 2 region.

According to a second aspect, the present invention provides an adeno-associated viral (AAV) plasmid comprising a single guide ribonucleic acid (sgRNA)-*Neisseria meningitidis* Cas9 nucleic acid vector, wherein said single guide ribonucleic acid comprises a truncated repeat:antirepeat region and a truncated Stem 2 region.

According to a third aspect, the present invention provides a method, comprising:

- a) providing;
  - i) a patient exhibiting at least one symptom of a medical condition, wherein said patient comprises a plurality of genes related to said medical condition;
  - ii) an adeno-associated viral (AAV) plasmid comprising a single guide ribonucleic acid (sgRNA)-*Neisseria meningitidis* Cas9 nucleic acid vector, wherein said sgRNA comprises:
    - a spacer region that is complementary to a portion of at least one of said plurality of genes;
    - a truncated repeat:antirepeat region; and
    - a truncated Stem 2 region; and

b) administering said AAV plasmid to said patient under conditions such that said at least one symptom of said medical condition is reduced.

According to a fourth aspect, the present invention provides use of an adeno-associated viral (AAV) plasmid comprising a single guide ribonucleic acid (sgRNA)-*Neisseria meningitidis* Cas9 nucleic acid vector in the manufacture of a medicament for reducing at least one symptom of a medical condition in a patient, wherein said patient

comprises a plurality of genes related to said medical condition, and wherein said sgRNA comprises:

- a spacer region that is complementary to a portion of at least one of said plurality of genes;
- a truncated repeat:antirepeat region; and
- a truncated Stem 2 region.

The present invention is related to compositions and methods for gene therapy. Several approaches described herein utilize *Neisseria meningitidis* Cas9 systems that provide hyperaccurate CRISPR gene editing platforms. Furthermore, the invention incorporates improvements of this Cas9 system: for example, truncating the single guide RNA sequences, and the packing of Nme1Cas9 or Nme2Cas9 with its guide RNA in an adeno-associated viral vector that is compatible for in vivo administration. Furthermore, Type II-C Cas9 orthologs have been identified that target protospacer adjacent motif sequences limited to between one – four required nucleotides.

In one embodiment, the present invention contemplates a single guide ribonucleic acid (sgRNA) sequence comprising a truncated repeat:anti-repeat region. In one embodiment, the sgRNA sequence further comprises a truncated Stem 2 region. In one embodiment, the sgRNA sequence further comprises a truncated spacer region. In one embodiment, said sgRNA sequence has a length of 121 nucleotides. In one embodiment, said sgRNA sequence length is selected from the group consisting of 111 nucleotides, 107 nucleotides, 105 nucleotides, 103 nucleotides, 102 nucleotides, 101 nucleotides, and 99 nucleotides. In one embodiment, said sgRNA sequence has a length of 100 nucleotides. In one embodiment, said sgRNA sequence is an Nme1Cas9 single guide ribonucleic acid sequence. In one embodiment, said sgRNA sequence is an Nme2Cas9 single guide ribonucleic acid sequence. In one embodiment, said sgRNA sequence is an Nme1Cas9 single guide ribonucleic acid sequence or an Nme2Cas9 single guide ribonucleic acid sequence.

In one embodiment, the present invention contemplates a single guide ribonucleic acid (sgRNA) sequence comprising a truncated Stem 2 region. In one embodiment, the sgRNA sequence further comprises a truncated repeat:anti-repeat region. In one embodiment, the sgRNA sequence further comprises a truncated spacer region. In one embodiment, said sgRNA

sequence has a length is selected from the group consisting of 111 nucleotides, 107 nucleotides, 105 nucleotides, 103 nucleotides, 102 nucleotides, 101 nucleotides, and 99 nucleotides. In one embodiment, said sgRNA sequence has a length of 100 nucleotides.

In one embodiment, the present invention contemplates an adeno-associated viral (AAV)  
5 vector comprising a single guide ribonucleic acid-*Neisseria meningitidis* Cas9 (sgRNA-Nme1Cas9 or sgRNA-Nme2Cas9) nucleic acid vector. In one embodiment, said single guide ribonucleic acid-*Neisseria meningitidis* Cas9 nucleic acid vector comprises at least one promoter. In one embodiment, said at least one promoter is selected from the group consisting of a U6 promoter and a U1a promoter. In one embodiment, said single guide ribonucleic acid-*Neisseria*  
10 *meningitidis* Cas9 nucleic acid vector comprises a Kozak sequence. In one embodiment, said sgRNA comprises a nucleic acid sequence that is complementary to a gene-of-interest sequence. In one embodiment, said gene-of-interest sequence is selected from the group consisting of a *PCSK9* sequence and a *ROSA26* sequence. In one embodiment, said sgRNA comprises an untruncated sequence that has a length of 145 nucleotides. In one embodiment, said sgRNA  
15 comprises a truncated repeat-antirepeat sequence. In one embodiment, said sgRNA further comprises a truncated Stem 2 region. In one embodiment, said sgRNA further comprises a truncated spacer region. In one embodiment, said sgRNA sequence has a length of 121 nucleotides. In one embodiment, said sgRNA sequence has a length selected from the group consisting of 111 nucleotides, 107 nucleotides, 105 nucleotides, 103 nucleotides, 102  
20 nucleotides, 101 nucleotides, and 99 nucleotides. In one embodiment, said sgRNA sequence has a length of 100 nucleotides. In one embodiment, said sgRNA comprises a truncated Stem 2 region. In one embodiment, said sgRNA further comprises a truncated repeat:antirepeat region. In one embodiment, said sgRNA further comprises a truncated spacer region. In one embodiment, said sgRNA sequence has a length selected from the group consisting of 111  
25 nucleotides, 107 nucleotides, 105 nucleotides, 103 nucleotides, 101 nucleotides, and 99 nucleotides. In one embodiment, said sgRNA sequence has a length of 100 nucleotides. In one embodiment, said sgRNA comprises an untruncated sequence has a length of 145 nucleotides.

In one embodiment, the present invention contemplates a method, comprising: a)  
providing; i) a patient exhibiting at least one symptom of a medical condition, wherein said  
30 patient comprises a plurality of genes related to said medical condition; ii) a delivery platform comprising a single guide ribonucleic acid-*Neisseria meningitidis* Cas9 (sgRNA-Nme1Cas9 or

sgRNA-Nme2Cas9) nucleic acid vector, wherein said sgRNA comprises a nucleic acid sequence that is complementary to a portion of at least one of said plurality of genes; and b) administering said AAV plasmid to said patient under conditions such that said at least one symptom of said medical condition is reduced. In one embodiment, the delivery platform comprises an adeno-associated viral (AAV) vector. In one embodiment, the delivery platform comprises a microparticle. In one embodiment, said medical condition comprises hypercholesterolemia. In one embodiment, said medical condition comprises tyrosinemia. In one embodiment, said at least one of said plurality of genes is a *PCSK9* gene. In one embodiment, said sgRNA nucleic acid is complementary to a portion of said *PCSK9* gene. In one embodiment, at least one of said plurality of genes is an *FAH* gene. In one embodiment, said sgRNA nucleic acid is complementary to a portion of said *FAH* gene. In one embodiment, said sgRNA comprises a truncated repeat-antirepeat sequence. In one embodiment, said sgRNA further comprises a truncated Stem 2 region. In one embodiment, said sgRNA further comprises a truncated spacer region. In one embodiment, said sgRNA sequence has a length of 121 nucleotides. In one embodiment, said sgRNA sequence has a length selected from the group consisting of 111 nucleotides, 107 nucleotides, 105 nucleotides, 103 nucleotides, 101 nucleotides, and 99 nucleotides. In one embodiment, said sgRNA sequence has a length of 100 nucleotides. In one embodiment, said sgRNA comprises a truncated Stem 2 region. In one embodiment, said sgRNA further comprises a truncated repeat-antirepeat region. In one embodiment, said sgRNA further comprises a truncated spacer region. In one embodiment, said sgRNA sequence has a length selected from the group consisting of 111 nucleotides, 107 nucleotides, 105 nucleotides, 103 nucleotides, 102 nucleotides, 101 nucleotides, and 99 nucleotides. In one embodiment, said sgRNA sequence has a length of 100 nucleotides. In one embodiment, said sgRNA comprises an untruncated sequence has a length of 145 nucleotides.

In one embodiment, the present invention contemplates an adeno-associated viral (AAV) plasmid encoding a Type II-C Cas9 nuclease protein wherein said protein comprises a protospacer adjacent motif recognition domain configured with a binding site to a protospacer adjacent motif sequence comprising between one to four required nucleotides. In one embodiment, said Type II-C Cas9 nuclease protein is selected from the group consisting of a *Neisseria meningitidis* strain De10444 Nme2Cas9 nuclease protein, a *Haemophilus parainfluenzae* HpaCas9 nuclease protein and a *Simonsiella muelleri* SmuCas9 nuclease protein.

In one embodiment, said protospacer adjacent motif sequence comprising one to four required nucleotides is selected from the group consisting of N<sub>4</sub>CN<sub>3</sub>, N<sub>4</sub>CT, N<sub>4</sub>CCN, N<sub>4</sub>CCA, and N<sub>4</sub>GNT<sub>3</sub>. In one embodiment, the one to four required nucleotides are selected from the group consisting of C, CT, CCN, CCA, CN<sub>3</sub> and GNT<sub>2</sub>. In one embodiment, said Type II-C Cas9  
 5 nuclease protein is bound to a truncated sgRNA. In one embodiment, the adeno-associated viral plasmid encodes two sgRNA sequences. In one embodiment, the adeno-associated viral plasmid encodes a poly-adenosine sequence. In one embodiment, the adeno-associated viral plasmid encodes a homology-directed repair donor nucleotide template. In one embodiment, the adeno-associated viral plasmid is an all-in-one adeno-associated viral plasmid.

10 In one embodiment, the present invention contemplates, a method, comprising: a) providing; i) a patient exhibiting at least one symptom of a medical condition, wherein said patient comprises a plurality of genes related to said medical condition, wherein said plurality of genes comprise a protospacer adjacent motif comprising between one – four required  
 15 Cas9 nuclease protein wherein said protein comprises a protospacer adjacent motif recognition domain configured with a binding site to said protospacer adjacent motif sequence comprising between two – four required nucleotides; and b) administering said delivery platform to said patient under conditions such that said at least one symptom of said medical condition is reduced. In one embodiment, said medical condition comprises hypercholesterolemia. In one  
 20 embodiment, said medical condition comprises tyrosinemia. In one embodiment, said at least one of said plurality of genes is a *PCSK9* gene. In one embodiment, said sgRNA nucleic acid is complementary to a portion of said *PCSK9* gene. In one embodiment, at least one of said plurality of genes is an *FAH* gene. In one embodiment, said sgRNA nucleic acid is complementary to a portion of said *FAH* gene. In one embodiment, said delivery platform  
 25 comprises an adeno-associated viral plasmid. In one embodiment, said delivery platform comprises a microparticle. In one embodiment, said Type II-C Cas9 nuclease protein is selected from the group consisting of a *Neisseria meningitidis strain De10444* Nme2Cas9 nuclease protein, a *Haemophilus parainfluenzae* HpaCas9 nuclease protein and a *Simonsiella muelleri* SmuCas9 nuclease protein. In one embodiment, said protospacer adjacent motif sequence  
 30 comprising one - four required nucleotides is selected from the group consisting of N<sub>4</sub>CN<sub>3</sub>, N<sub>4</sub>CT, N<sub>4</sub>CCN, N<sub>4</sub>CCA, and N<sub>4</sub>GNT<sub>3</sub>. In one embodiment, the one to four required nucleotides

are selected from the group consisting of C, CT, CCN, CCA, CN<sub>3</sub> and GNT<sub>2</sub>. In one embodiment, said Type II-C Cas9 nuclease protein is bound to a truncated sgRNA. In one embodiment, the adeno-associated viral plasmid encodes two sgRNA sequences. In one embodiment, the adeno-associated viral plasmid encodes a poly-adenosine sequence. In one embodiment, the adeno-associated viral plasmid encodes a homology-directed repair donor nucleotide template. In one embodiment, the adeno-associated viral plasmid is an all-in-one adeno-associated viral plasmid.

In one embodiment, the present invention contemplates an adeno-associated viral (AAV) plasmid encoding a Type II-C Cas9 nuclease protein wherein said protein comprises a protospacer adjacent motif recognition domain (e.g., a PAM-Interacting Domain; PID) configured to bind with a protospacer adjacent motif (PAM) sequence, said PAM sequence comprising an adjacent cytosine dinucleotide pair. In one embodiment the adjacent cytosine dinucleotide pair is at the PAM positions five (5) and six (6). In one embodiment, said Type II-C Cas9 nuclease protein is derived from a *Neisseria meningitidis* strain. In one embodiment, the *Neisseria meningitidis* strain is De10444. In one embodiment, the Type II-C Cas9 nuclease protein is an Nme2Cas9 nuclease protein. In one embodiment, the *Neisseria meningitidis* strain is 98002. In one embodiment, the Type II-C Cas9 nuclease protein is an Nme3Cas9 nuclease protein. In one embodiment, said PAM sequence is selected from the group consisting of N<sub>4</sub>CC, N<sub>4</sub>CCN<sub>3</sub>, N<sub>4</sub>CCA, N<sub>4</sub>CC(X), N<sub>4</sub>CA<sub>3</sub> and N<sub>10</sub>. In one embodiment, the PAM sequence is N<sub>3</sub>CC. In one embodiment, the Type II-C Cas9 nuclease protein further comprises an sgRNA sequence. In one embodiment, the sgRNA sequence comprises a spacer ranging in length between approximately seventeen (17) – twenty four (24) nucleotides.

In one embodiment, the present invention contemplates a method, comprising: a) providing; i) a patient exhibiting at least one symptom of a medical condition, wherein said patient comprises a plurality of genes related to said medical condition, wherein said plurality of genes comprise a protospacer adjacent motif comprising an adjacent cytosine dinucleotide pair; ii) a delivery platform comprising at least one nucleic acid encoding a Type II-C Cas9 nuclease protein wherein said protein comprises a protospacer adjacent motif recognition domain (e.g., a PAM Interacting Domain; PID) configured to bind with said protospacer adjacent motif sequence comprising an adjacent cytosine dinucleotide pair; and b) administering said delivery platform to said patient under conditions such that said at least one symptom of said medical

condition is reduced. In one embodiment, said delivery platform comprises an adeno-associated viral vector. In one embodiment, the adeno-associated viral vector is adeno-associated viral vector eight (AAV8). In one embodiment, said medical condition comprises hypercholesterolemia. In one embodiment, said medical condition comprises tyrosinemia. In one embodiment, the medical condition is x-linked chronic granulomatous disease. In one embodiment, the medical condition is aspartylglycosaminuria. In one embodiment, said at least one of said plurality of genes is a *PCSK9* gene. In one embodiment, said sgRNA nucleic acid is complementary to a portion of said *PCSK9* gene. In one embodiment, at least one of said plurality of genes is an *FAH* gene. In one embodiment, said sgRNA nucleic acid is complementary to a portion of said *FAH* gene. In one embodiment, the adeno-associated viral plasmid encodes at least one sgRNA sequence. In one embodiment, the adeno-associated viral plasmid encodes two sgRNA sequences. In one embodiment, the adeno-associated viral plasmid encodes a poly-adenosine sequence. In one embodiment, the adeno-associated viral plasmid encodes a homology-directed repair donor nucleotide template. In one embodiment, the adeno-associated viral plasmid is an all-in-one adeno-associated viral plasmid. In one embodiment, said delivery platform comprises a microparticle. In one embodiment the adjacent cytosine dinucleotide pair is at the PAM positions five (5) and six (6). In one embodiment, said Type II-C Cas9 nuclease protein is derived from a *Neisseria meningitidis* strain. In one embodiment, the *Neisseria meningitidis* strain is *De10444*. In one embodiment, the Type II-C Cas9 nuclease protein is an Nme2Cas9 nuclease protein. In one embodiment, the *Neisseria meningitidis* strain is 98002. In one embodiment, the Type II-C Cas9 nuclease protein is an Nme3Cas9 nuclease protein. In one embodiment, said PAM sequence is selected from the group consisting of N<sub>4</sub>CC, N<sub>4</sub>CCN<sub>3</sub>, N<sub>4</sub>CCA, N<sub>4</sub>CC(X), N<sub>4</sub>CA<sub>3</sub> and N<sub>10</sub>. In one embodiment, the PAM sequence is N<sub>3</sub>CC. In one embodiment, the Type II-C Cas9 nuclease protein further comprises an sgRNA sequence. In one embodiment, the sgRNA sequence comprises a spacer ranging in length between approximately seventeen (17) – twenty four (24) nucleotides.

## Definitions

To facilitate the understanding of this invention, a number of terms are defined below. Terms defined herein have meanings as commonly understood by a person of ordinary skill in the areas relevant to the present invention. Terms such as “a”, “an” and “the” are not intended to refer to only a singular entity but also plural entities and also includes the general class of which a specific example may be used for illustration. The terminology herein is used to describe specific embodiments of the invention, but their usage does not delimit the invention, except as outlined in the claims.

The term “about” or “approximately” as used herein, in the context of any of any assay measurements refers to +/- 5% of a given measurement.

As used herein the “*ROSA26* gene” or “*Rosa26* gene” refers to a human or mouse (respectively) locus that is widely used for achieving generalized expression in the mouse. Targeting to the *ROSA26* locus may be achieved by introducing a desired gene into the first intron of the locus, at a unique XbaI site approximately 248 bp upstream of the original gene trap line. A construct may be constructed using an adenovirus splice acceptor followed by a gene of interest and a polyadenylation site inserted at the unique XbaI site. A neomycin resistance cassette may also be included in the targeting vector.

As used herein the “*PCSK9* gene” or “*Pcsk9* gene” refers to a human or mouse (respectively) locus that encodes a PCSK9 protein. The *PCSK9* gene resides on chromosome 1 at the band 1p32.3 and includes 13 exons. This gene may produce at least two isoforms through alternative splicing.

The term “proprotein convertase subtilisin/kexin type 9” and “PCSK9” refers to a protein encoded by a gene that modulates low density lipoprotein levels. Proprotein convertase subtilisin/kexin type 9, also known as PCSK9, is an enzyme that in humans is encoded by the *PCSK9* gene. Seidah et al., “The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation” *Proc. Natl. Acad. Sci. U.S.A.* 100 (3): 928–933 (2003). Similar genes (orthologs) are found across many species. Many enzymes, including PSCK9, are inactive when they are first synthesized, because they have a section of peptide chains that blocks their activity; proprotein convertases remove that section to activate the enzyme. PSCK9 is believed to play a regulatory role in cholesterol



homeostasis. For example, PCSK9 can bind to the epidermal growth factor-like repeat A (EGF-A) domain of the low-density lipoprotein receptor (LDL-R) resulting in LDL-R internalization and degradation. Clearly, it would be expected that reduced LDL-R levels result in decreased metabolism of LDL-C, which could lead to hypercholesterolemia.

5           The term “hypercholesterolemia” as used herein, refers to any medical condition wherein blood cholesterol levels are elevated above the clinically recommended levels. For example, if cholesterol is measured using low density lipoproteins (LDLs), hypercholesterolemia may exist if the measured LDL levels are above, for example, approximately 70 mg/dl. Alternatively, if cholesterol is measured using free plasma cholesterol, hypercholesterolemia may exist if the  
10       measured free cholesterol levels are above, for example, approximately 200-220 mg/dl.

          As used herein, the term “CRISPRs” or “Clustered Regularly Interspaced Short Palindromic Repeats” refers to an acronym for DNA loci that contain multiple, short, direct repetitions of base sequences. Each repetition contains a series of bases followed by 30 or so base pairs known as “spacer” sequence. The spacers are short segments of DNA from a virus and  
15       may serve as a ‘memory’ of past exposures to facilitate an adaptive defense against future invasions. Doudna et al. Genome editing. The new frontier of genome engineering with CRISPR-Cas9” *Science* 346(6213):1258096 (2014).

          As used herein, the term “Cas” or “CRISPR-associated (*cas*)” refers to genes often associated with CRISPR repeat-spacer arrays.

20           As used herein, the term “Cas9” refers to a nuclease from type II CRISPR systems, an enzyme specialized for generating double-strand breaks in DNA, with two active cutting sites (the HNH and RuvC domains), one for each strand of the double helix. tracrRNA and spacer RNA may be combined into a “single-guide RNA” (sgRNA) molecule that, mixed with Cas9, could find and cleave DNA targets through Watson-Crick pairing between the guide sequence  
25       within the sgRNA and the target DNA sequence, Jinek et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity” *Science* 337(6096):816-821 (2012).

          As used herein, the term “catalytically active Cas9” refers to an unmodified Cas9 nuclease comprising full nuclease activity.

          The term “nickase” as used herein, refers to a nuclease that cleaves only a single DNA  
30       strand, either due to its natural function or because it has been engineered to cleave only a single DNA strand. Cas9 nickase variants that have either the RuvC or the HNH domain mutated

provide control over which DNA strand is cleaved and which remains intact. Jinek et al., “A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity” *Science* 337(6096):816-821 (2012) and Cong et al. Multiplex genome engineering using CRISPR/Cas systems” *Science* 339(6121):819-823 (2013).

5           The term, “trans-activating crRNA”, “tracrRNA” as used herein, refers to a small trans-encoded RNA. For example, CRISPR/Cas (clustered, regularly interspaced short palindromic repeats/CRISPR-associated proteins) constitutes an RNA-mediated defense system, which protects against viruses and plasmids. This defensive pathway has three steps. First a copy of the invading nucleic acid is integrated into the CRISPR locus. Next, CRISPR RNAs (crRNAs) are transcribed from this CRISPR locus. The crRNAs are then incorporated into effector complexes, where the crRNA guides the complex to the invading nucleic acid and the Cas proteins degrade this nucleic acid. There are several pathways of CRISPR activation, one of which requires a tracrRNA, which plays a role in the maturation of crRNA. TracrRNA is complementary to the repeat sequence of the pre-crRNA, forming an RNA duplex. This is cleaved by RNase III, an RNA-specific ribonuclease, to form a crRNA/tracrRNA hybrid. This hybrid acts as a guide for the endonuclease Cas9, which cleaves the invading nucleic acid.

10           The term “protospacer adjacent motif” (or PAM) as used herein, refers to a DNA sequence that may be required for a Cas9/sgRNA to form an R-loop to interrogate a specific DNA sequence through Watson-Crick pairing of its guide RNA with the genome. The PAM specificity may be a function of the DNA-binding specificity of the Cas9 protein (e.g., a “protospacer adjacent motif recognition domain” at the C-terminus of Cas9).

15           The terms “protospacer adjacent motif recognition domain”, “PAM Interacting Domain” or “PID” as used herein, refers to a Cas9 amino acid sequence that comprises a binding site to a DNA target PAM sequence.

20           The term “binding site” as used herein, refers to any molecular arrangement having a specific tertiary and/or quaternary structure that undergoes a physical attachment or close association with a binding component. For example, the molecular arrangement may comprise a sequence of amino acids. Alternatively, the molecular arrangement may comprise a sequence a nucleic acids. Furthermore, the molecular arrangement may comprise a lipid bilayer or other biological material.

As used herein, the term “sgRNA” refers to single guide RNA used in conjunction with CRISPR associated systems (Cas). sgRNAs are a fusion of crRNA and tracrRNA and contain nucleotides of sequence complementary to the desired target site. Jinek et al., “A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity” *Science* 337(6096):816-821 (2012) Watson-Crick pairing of the sgRNA with the target site permits R-loop formation, which in conjunction with a functional PAM permits DNA cleavage or in the case of nuclease-deficient Cas9 allows binds to the DNA at that locus.

As used herein, the term “orthogonal” refers to targets that are non-overlapping, uncorrelated, or independent. For example, if two orthogonal Cas9 isoforms were utilized, they would employ orthogonal sgRNAs that only program one of the Cas9 isoforms for DNA recognition and cleavage. Esvelt et al., “Orthogonal Cas9 proteins for RNA-guided gene regulation and editing” *Nat Methods* 10(11):1116-1121 (2013). For example, this would allow one Cas9 isoform (e.g. *S. pyogenes* Cas9 or SpyCas9) to function as a nuclease programmed by a sgRNA that may be specific to it, and another Cas9 isoform (e.g. *N. meningitidis* Cas9 or NmeCas9) to operate as a nuclease-dead Cas9 that provides DNA targeting to a binding site through its PAM specificity and orthogonal sgRNA. Other Cas9s include *S. aureus* Cas9 or SauCas9 and *A. naeshundii* Cas9 or AnaCas9.

The term “truncated” as used herein, when used in reference to either a polynucleotide sequence or an amino acid sequence means that at least a portion of the wild type sequence may be absent. In some cases, truncated guide sequences within the sgRNA or crRNA may improve the editing precision of Cas9. Fu, et al. “Improving CRISPR-Cas nuclease specificity using truncated guide RNAs” *Nat Biotechnol.* 2014 Mar;32(3):279-284 (2014).

The term “base pairs” as used herein, refer to specific nucleobases (also termed nitrogenous bases), that are the building blocks of nucleotide sequences that form a primary structure of both DNA and RNA. Double-stranded DNA may be characterized by specific hydrogen bonding patterns. Base pairs may include, but are not limited to, guanine-cytosine and adenine-thymine base pairs.

The term “specific genomic target” as used herein, refers to any pre-determined nucleotide sequence capable of binding to a Cas9 protein contemplated herein. The target may include, but may be not limited to, a nucleotide sequence complementary to a programmable DNA binding domain or an orthogonal Cas9 protein programmed with its own guide RNA, a

nucleotide sequence complementary to a single guide RNA, a protospacer adjacent motif recognition sequence, an on-target binding sequence and an off-target binding sequence.

The term “on-target binding sequence” as used herein, refers to a subsequence of a specific genomic target that may be completely complementary to a programmable DNA binding domain and/or a single guide RNA sequence.

The term “off-target binding sequence” as used herein, refers to a subsequence of a specific genomic target that may be partially complementary to a programmable DNA binding domain and/or a single guide RNA sequence.

The term “fails to bind” as used herein, refers to any nucleotide-nucleotide interaction or a nucleotide-amino acid interaction that exhibits partial complementarity, but has insufficient complementarity for recognition to trigger the cleavage of the target site by the Cas9 nuclease. Such binding failure may result in weak or partial binding of two molecules such that an expected biological function (e.g., nuclease activity) fails.

The term “cleavage” as used herein, may be defined as the generation of a break in the DNA. This could be either a single-stranded break or a double-stranded break depending on the type of nuclease that may be employed.

As used herein, the term “edit” “editing” or “edited” refers to a method of altering a nucleic acid sequence of a polynucleotide (e.g., for example, a wild type naturally occurring nucleic acid sequence or a mutated naturally occurring sequence) by selective deletion of a specific genomic target or the specific inclusion of new sequence through the use of an exogenously supplied DNA template. Such a specific genomic target includes, but may be not limited to, a chromosomal region, mitochondrial DNA, a gene, a promoter, an open reading frame or any nucleic acid sequence.

The term “delete”, “deleted”, “deleting” or “deletion” as used herein, may be defined as a change in either nucleotide or amino acid sequence in which one or more nucleotides or amino acid residues, respectively, are, or become, absent.

The term “gene of interest” as used herein, refers to any pre-determined gene for which deletion may be desired.

The term “allele” as used herein, refers to any one of a number of alternative forms of the same gene or same genetic locus.

The term “effective amount” as used herein, refers to a particular amount of a pharmaceutical composition comprising a therapeutic agent that achieves a clinically beneficial result (i.e., for example, a reduction of symptoms). Toxicity and therapeutic efficacy of such compositions can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD<sub>50</sub> (the dose lethal to 50% of the population) and the ED<sub>50</sub> (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index, and it can be expressed as the ratio LD<sub>50</sub>/ED<sub>50</sub>. Compounds that exhibit large therapeutic indices are preferred. The data obtained from these cell culture assays and additional animal studies can be used in formulating a range of dosage for human use. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED<sub>50</sub> with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.

The term “symptom”, as used herein, refers to any subjective or objective evidence of disease or physical disturbance observed by the patient. For example, subjective evidence is usually based upon patient self-reporting and may include, but is not limited to, pain, headache, visual disturbances, nausea and/or vomiting. Alternatively, objective evidence is usually a result of medical testing including, but not limited to, body temperature, complete blood count, lipid panels, thyroid panels, blood pressure, heart rate, electrocardiogram, tissue and/or body imaging scans.

The term “disease” or “medical condition”, as used herein, refers to any impairment of the normal state of the living animal or plant body or one of its parts that interrupts or modifies the performance of the vital functions. Typically manifested by distinguishing signs and symptoms, it is usually a response to: i) environmental factors (as malnutrition, industrial hazards, or climate); ii) specific infective agents (as worms, bacteria, or viruses); iii) inherent defects of the organism (as genetic anomalies); and/or iv) combinations of these factors.

The terms “reduce,” “inhibit,” “diminish,” “suppress,” “decrease,” “prevent” and grammatical equivalents (including “lower,” “smaller,” etc.) when in reference to the expression of any symptom in an untreated subject relative to a treated subject, mean that the quantity and/or magnitude of the symptoms in the treated subject is lower than in the untreated subject by any amount that is recognized as clinically relevant by any medically trained personnel. In one

embodiment, the quantity and/or magnitude of the symptoms in the treated subject is at least 10% lower than, at least 25% lower than, at least 50% lower than, at least 75% lower than, and/or at least 90% lower than the quantity and/or magnitude of the symptoms in the untreated subject.

5           The term "attached" as used herein, refers to any interaction between a medium (or carrier) and a drug. Attachment may be reversible or irreversible. Such attachment includes, but is not limited to, covalent bonding, ionic bonding, Van der Waals forces or friction, and the like. A drug is attached to a medium (or carrier) if it is impregnated, incorporated, coated, in suspension with, in solution with, mixed with, *etc.*

10           The term "drug" or "compound" as used herein, refers to any pharmacologically active substance capable of being administered which achieves a desired effect. Drugs or compounds can be synthetic or naturally occurring, non-peptide, proteins or peptides, oligonucleotides or nucleotides, polysaccharides or sugars.

15           The term "administered" or "administering", as used herein, refers to any method of providing a composition to a patient such that the composition has its intended effect on the patient. An exemplary method of administering is by a direct mechanism such as, local tissue administration (*i.e.*, for example, extravascular placement), oral ingestion, transdermal patch, topical, inhalation, suppository *etc.*

20           The term "patient" or "subject", as used herein, is a human or animal and need not be hospitalized. For example, out-patients, persons in nursing homes are "patients." A patient may comprise any age of a human or non-human animal and therefore includes both adult and juveniles (*i.e.*, children). It is not intended that the term "patient" connote a need for medical treatment, therefore, a patient may voluntarily or involuntarily be part of experimentation whether clinical or in support of basic science studies.

25           The term "affinity" as used herein, refers to any attractive force between substances or particles that causes them to enter into and remain in chemical combination. For example, an inhibitor compound that has a high affinity for a receptor will provide greater efficacy in preventing the receptor from interacting with its natural ligands, than an inhibitor with a low affinity.

The term "derived from" as used herein, refers to the source of a compound or sequence. In one respect, a compound or sequence may be derived from an organism or particular species. In another respect, a compound or sequence may be derived from a larger complex or sequence.

The term "protein" as used herein, refers to any of numerous naturally occurring  
5 extremely complex substances (as an enzyme or antibody) that consist of amino acid residues joined by peptide bonds, contain the elements carbon, hydrogen, nitrogen, oxygen, usually sulfur. In general, a protein comprises amino acids having an order of magnitude within the hundreds.

The term "peptide" as used herein, refers to any of various amides that are derived from  
10 two or more amino acids by combination of the amino group of one acid with the carboxyl group of another and are usually obtained by partial hydrolysis of proteins. In general, a peptide comprises amino acids having an order of magnitude with the tens.

The term "polypeptide", refers to any of various amides that are derived from two or more amino acids by combination of the amino group of one acid with the carboxyl group of  
15 another and are usually obtained by partial hydrolysis of proteins. In general, a peptide comprises amino acids having an order of magnitude with the tens or larger.

The term "pharmaceutically" or "pharmacologically acceptable", as used herein, refer to molecular entities and compositions that do not produce adverse, allergic, or other untoward reactions when administered to an animal or a human.

The term, "pharmaceutically acceptable carrier", as used herein, includes any and all  
20 solvents, or a dispersion medium including, but not limited to, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils, coatings, isotonic and absorption delaying agents, liposome, commercially available cleansers, and the like. Supplementary bioactive ingredients also can be  
25 incorporated into such carriers.

"Nucleic acid sequence" and "nucleotide sequence" as used herein refer to an oligonucleotide or polynucleotide, and fragments or portions thereof, and to DNA or RNA of genomic or synthetic origin which may be single- or double-stranded, and represent the sense or antisense strand.

The term "an isolated nucleic acid", as used herein, refers to any nucleic acid molecule that has been removed from its natural state (e.g., removed from a cell and is, in a preferred embodiment, free of other genomic nucleic acid).

5 The terms "amino acid sequence" and "polypeptide sequence" as used herein, are interchangeable and to refer to a sequence of amino acids.

As used herein the term "portion" when in reference to a protein (as in "a portion of a given protein") refers to fragments of that protein. The fragments may range in size from four amino acid residues to the entire amino acid sequence minus one amino acid.

10 The term "portion" when used in reference to a nucleotide sequence refers to fragments of that nucleotide sequence. The fragments may range in size from 5 nucleotide residues to the entire nucleotide sequence minus one nucleic acid residue.

The term "biologically active" refers to any molecule having structural, regulatory or biochemical functions. For example, biological activity may be determined, for example, by restoration of wild-type growth in cells lacking protein activity. Cells lacking protein activity  
15 may be produced by many methods (i.e., for example, point mutation and frame-shift mutation). Complementation is achieved by transfecting cells which lack protein activity with an expression vector which expresses the protein, a derivative thereof, or a portion thereof.

As used herein, the terms "complementary" or "complementarity" are used in reference to "polynucleotides" and "oligonucleotides" (which are interchangeable terms that refer to a  
20 sequence of nucleotides) related by the base-pairing rules. For example, the sequence "C-A-G-T," is complementary to the sequence "G-T-C-A." Complementarity can be "partial" or "total." "Partial" complementarity is where one or more nucleic acid bases is not matched according to the base pairing rules. "Total" or "complete" complementarity between nucleic acids is where  
25 each and every nucleic acid base is matched with another base under the base pairing rules. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of hybridization between nucleic acid strands. This is of particular importance in amplification reactions, as well as detection methods which depend upon binding between nucleic acids.

As used herein, the term "hybridization" is used in reference to the pairing of  
30 complementary nucleic acids using any process by which a strand of nucleic acid joins with a complementary strand through base pairing to form a hybridization complex. Hybridization and



the strength of hybridization (i.e., the strength of the association between the nucleic acids) is impacted by such factors as the degree of complementarity between the nucleic acids, stringency of the conditions involved, the  $T_m$  of the formed hybrid, and the G:C ratio within the nucleic acids.

As used herein the term "hybridization complex" refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary G and C bases and between complementary A and T bases; these hydrogen bonds may be further stabilized by base stacking interactions. The two complementary nucleic acid sequences hydrogen bond in an antiparallel configuration. A hybridization complex may be formed in solution (e.g.,  $C_0$  t or  $R_0$  t analysis) or between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized to a solid support (e.g., a nylon membrane or a nitrocellulose filter as employed in Southern and Northern blotting, dot blotting or a glass slide as employed in in situ hybridization, including FISH (fluorescent in situ hybridization)).

Transcriptional control signals in eukaryotes comprise "promoter" and "enhancer" elements. Promoters and enhancers consist of short arrays of DNA sequences that interact specifically with cellular proteins involved in transcription. Maniatis, T. et al., *Science* 236:1237 (1987). Promoter and enhancer elements have been isolated from a variety of eukaryotic sources including genes in plant, yeast, insect and mammalian cells and viruses (analogous control elements, i.e., promoters, are also found in prokaryotes). The selection of a particular promoter and enhancer depends on what cell type is to be used to express the protein of interest.

The term "poly A site" or "poly A sequence" as used herein denotes a DNA sequence which directs both the termination and polyadenylation of the nascent RNA transcript. Efficient polyadenylation of the recombinant transcript is desirable as transcripts lacking a poly A tail are unstable and are rapidly degraded. The poly A signal utilized in an expression vector may be "heterologous" or "endogenous." An endogenous poly A signal is one that is found naturally at the 3' end of the coding region of a given gene in the genome. A heterologous poly A signal is one which is isolated from one gene and placed 3' of another gene. Efficient expression of recombinant DNA sequences in eukaryotic cells involves expression of signals directing the efficient termination and polyadenylation of the resulting transcript. Transcription termination signals are generally found downstream of the polyadenylation signal and are a few hundred nucleotides in length.

The term "transfection" or "transfected" refers to the introduction of foreign DNA into a cell.

As used herein, the terms "nucleic acid molecule encoding", "DNA sequence encoding," and "DNA encoding" refer to the order or sequence of deoxyribonucleotides along a strand of deoxyribonucleic acid. The order of these deoxyribonucleotides determines the order of amino acids along the polypeptide (protein) chain. The DNA sequence thus codes for the amino acid sequence.

As used herein, the term "coding region" when used in reference to a structural gene refers to the nucleotide sequences which encode the amino acids found in the nascent polypeptide as a result of translation of a mRNA molecule. The coding region is bounded, in eukaryotes, on the 5' side by the nucleotide triplet "ATG" which encodes the initiator methionine and on the 3' side by one of the three triplets which specify stop codons (i.e., TAA, TAG, TGA).

As used herein, the term "structural gene" refers to a DNA sequence coding for RNA or a protein. In contrast, "regulatory genes" are structural genes which encode products which control the expression of other genes (e.g., transcription factors).

As used herein, the term "gene" means the deoxyribonucleotide sequences comprising the coding region of a structural gene and including sequences located adjacent to the coding region on both the 5' and 3' ends for a distance of about 1 kb on either end such that the gene corresponds to the length of the full-length mRNA. The sequences which are located 5' of the coding region and which are present on the mRNA are referred to as 5' non-translated sequences. The sequences which are located 3' or downstream of the coding region and which are present on the mRNA are referred to as 3' non-translated sequences. The term "gene" encompasses both cDNA and genomic forms of a gene. A genomic form or clone of a gene contains the coding region interrupted with non-coding sequences termed "introns" or "intervening regions" or "intervening sequences." Introns are segments of a gene which are transcribed into heterogeneous nuclear RNA (hnRNA); introns may contain regulatory elements such as enhancers. Introns are removed or "spliced out" from the nuclear or primary transcript; introns therefore are absent in the messenger RNA (mRNA) transcript. The mRNA functions during translation to specify the sequence or order of amino acids in a nascent polypeptide.

In addition to containing introns, genomic forms of a gene may also include sequences located on both the 5' and 3' end of the sequences which are present on the RNA transcript.

These sequences are referred to as "flanking" sequences or regions (these flanking sequences are located 5' or 3' to the non-translated sequences present on the mRNA transcript). The 5' flanking region may contain regulatory sequences such as promoters and enhancers which control or influence the transcription of the gene. The 3' flanking region may contain sequences which  
5 direct the termination of transcription, posttranscriptional cleavage and polyadenylation.

The term "viral vector" encompasses any nucleic acid construct derived from a virus genome capable of incorporating heterologous nucleic acid sequences for expression in a host organism. For example, such viral vectors may include, but are not limited to, adeno-associated viral vectors, lentiviral vectors, SV40 viral vectors, retroviral vectors, adenoviral vectors.

10 Although viral vectors are occasionally created from pathogenic viruses, they may be modified in such a way as to minimize their overall health risk. This usually involves the deletion of a part of the viral genome involved with viral replication. Such a virus can efficiently infect cells but, once the infection has taken place, the virus may require a helper virus to provide the missing proteins for production of new virions. Preferably, viral vectors should have a minimal effect on  
15 the physiology of the cell it infects and exhibit genetically stable properties (e.g., do not undergo spontaneous genome rearrangement). Most viral vectors are engineered to infect as wide a range of cell types as possible. Even so, a viral receptor can be modified to target the virus to a specific kind of cell. Viruses modified in this manner are said to be pseudotyped. Viral vectors are often engineered to incorporate certain genes that help identify which cells took up the viral  
20 genes. These genes are called marker genes. For example, a common marker gene confers antibiotic resistance to a certain antibiotic.

### **Brief Description Of The Figures**

The file of this patent contains at least one drawing executed in color. Copies of this  
25 patent with color drawings will be provided by the Patent and Trademark Office upon request and payment of the necessary fee.

Figure 1 presents representative sequence of a conventional, full-length, 145 nt Nme1Cas9 and Nme2Cas9 sgRNA.

Figure 2 presents exemplary Nme1Cas9 sgRNA sequences and associated gene editing  
30 activity having a truncated repeat:anti-repeat region or a truncated Stem 2 region.

Deletion/truncation series of Nme1Cas9 sgRNAs. Top: aligned sequences, color-coded as in

Figure 1. Bottom: T7E1 assays of editing at Nme1Cas9 target site 7 (NTS7), using the indicated sgRNAs as guides.

Figure 3 presents exemplary Nme1Cas9 sgRNA sequences and associated gene editing activity having a truncated repeat:anti-repeat region or a truncated Stem 2 region. The shortest Nme1Cas9 sgRNAs (#10 - 101 nt; 24 nt guide sequence; and #11 - 100 nt; 23 nt guide sequence) efficiently edit three distinct target sites (NTS7, NTS27, and NTS55) in the human genome. Top: sequences of wild-type and minimized sgRNAs, using the same color scheme as in the previous figures. Bottom: T7E1 assays of editing efficiency at the three target sites in HEK293T cells.

Figure 4 presents exemplary sequences (as secondary structures) of Nme1Cas9 wt sgRNA, and truncated sgRNAs 11 and 12 and associated gene editing by RNP delivery of Nme1Cas9 and sgRNAs. Three genomic sites (N-TS72, N-TS55 and N-TS40), and one traffic light reporter site was targeted in the human genome using HEK293T cells. Top: sequences shown as secondary structures of wild-type and minimized sgRNAs. Bottom: Editing efficiencies measured by T7E1 assay or flow cytometry are depicted as bar graphs.

Figure 5 presents gene editing in PLB985 cells using minimized sgRNA 11, and in vitro transcribed wt sgRNA. Cells were transfected with RNP complexes of Nme1Cas9 and sgRNAs and gene editing at genomic site N-TS72 measured by TIDE.

Figure 6 presents a schematic of one embodiment of an AAV vector comprising a complete CRISPR/Cas9 gene editing complex. Representative sequences of the various AAV vector regions are color coded in Appendix 1.

Figure 7 presents one embodiment of a color-coded sequence of Nme single-guide RNA and a promoter as depicted in Figure 4, wherein the backbone is linearized using SapI to insert a 24-nt target spacer.

U6 promoter: Turquoise.  
Nme single guide RNA: Purple  
SapI restriction sites: Bold

Figure 8 presents one embodiment of a color-coded sequence of an Nme1Cas9 and promoter as depicted in Figure 4, wherein Start and Stop codons underlined in bold.

U1a promoter: Blue  
Kozak sequence: Grey

Humanized Nme1Cas9: Red  
 SV40 NLS: Green  
 Nucleoplasmin (NP) NLS: Yellow  
 HA Tags (3X): Bold Orange  
 Synthetic NLS: Turquoise  
 Beta-globin polyadenylation signal: Teal

Figure 9 presents exemplary data showing editing efficiency of various target sites using AAV plasmids with sgRNA-Nme1Cas9 constructs guided to either the *Pcsk9* gene or the *Rosa26* gene (control).

Figure 10 presents one embodiment of color-coded target site sequences for sgRNA-Nme1Cas9 constructs guided to either a *Pcsk9* gene or a *Rosa26* gene (control).

24-nt Nme1Cas9 target spacer, blue bold  
 Nme1Cas9 PAM underlined [NNNNGATT)  
 T7E1 primers binding sites: green italics  
 TIDE primers binding sites: purple italics

Figure 11 presents exemplary data showing gene editing efficiency following in vivo hydrodynamic injection by mouse tail vein of 30 µg of endotoxin-free sgRNA-Nme1Cas9-AAV plasmid targeting *Pcsk9*.

Figure 12A presents exemplary data showing gene editing efficiency in the liver at the *Pcsk9* gene and the *Rosa26* gene by Nme1-Cas9 vector packaged in hepatocyte-specific AAV8 serotype, at a dose of  $4 \times 10^{11}$  genomic copies (gc) per mouse 14 days post vector administration. Figure 12B presents exemplary data showing gene editing efficiency in the liver at a *Pcsk9* gene and a *Rosa26* gene by an Nme1-Cas9 vector packaged in hepatocyte-specific AAV8 serotype, at a dose of  $4 \times 10^{11}$  genomic copies (gc) per mouse 50 days post vector administration.

Figure 13 presents exemplary data showing reduction in mouse cholesterol levels following injection of sgRNA-Cas9-AAV vectors targeting a *Pcsk9* gene, a *Rosa26* gene and a PBS control group at 0, 25 and 50 days.

Figures 14A and 14B present exemplary data showing a genome-wide unbiased identification of double strand breaks (DSBs) enabled by sequencing (e.g., GUIDE-Seq) assay that searched for off-target editing sites for both the *Pcsk9*-sgRNA-Cas9-AAV (A) and the *Rosa26*-sgRNA-Cas9-AAV (B).

Figure 15 presents exemplary data showing a targeted TIDE analyses in mice 14 days post-injection of both the *Pcsk9*-sgRNA-Cas9-AAV and the *Rosa26*-sgRNA-Cas9-AAV that revealed minimal cleavage. OnT, on-target site; OT1, OT2 etc.: off-target sites.

Figure 16 presents exemplary data showing a hematoxylin and eosin stain assay in the liver sections of mice sacrificed at day 14 subsequent to injection of vectors targeting a *Pcsk9* gene and a *Rosa26* gene. No evidence for a host immune response is observed.

Figure 17 illustrates one embodiment of an in vitro PAM library identification workflow. NGS, next-generation sequencing.

Figure 18 presents putative sequence from an in vitro PAM discovery assay depicted in Figure 17. Recombinantly purified Cas9 from each bacterium was incubated with an sgRNA and a target with randomized PAM. Nme1Cas9 was used as a control.

Figure 19 presents exemplary data showing percent genome editing at a single site (top panel) in the human genome in HEK293T cells. Percentages show estimated indel formation using a T7E1 endonuclease assay (Nme2Cas9, HpaCas9) or a fluorescent assay (for SmuCas9) based on the “traffic light” reporter integrated into the genome of HEK293T cells.

Figure 20 presents exemplary data showing genome editing in HEK293T cells of an integrated traffic light reporter with Nme2Cas9 targeting various protospacers with various PAMs (X-axis). The results suggest a preferred NNNNCC PAM for Nme2Cas9 in human cells.

Figure 21 presents exemplary data showing genome editing in HEK293T cells in the presence of various anti-CRISPR (Acr) proteins. T7E1 digestion shows genome editing following plasmid transfection (to express Nme2Cas9 and its sgRNA) or RNA/protein delivery (HpaCas9 and its sgRNA). Nme2Cas9 is robustly inhibited by two Acr proteins (AcrIIC3<sub>Nme</sub> and AcrIIC4<sub>Hpa</sub>), while HpaCas9 is inhibited by four of the previously reported type II-C Acrs. These results show that these two Cas9 proteins are subject to off-switch control by anti-CRISPRs.

Figure 22 presents exemplary data of traffic light reporter (TLR) gene editing using the Nme2Cas9-sgRNA complex on “CC” dinucleotide PAMs. Figure 22A. Blue bars are the % of cells that exhibit fluorescence, whereas red bars indicate % editing more accurately based on sequencing (“TIDE analysis”).

Figure 23 presents exemplary data of gene editing by Nme2Cas9 using T7E1 assays at the *AAVS1*, Chromosome 14 NTS4, *VEGF* and *CFTR* loci.

Figure 24 presents one embodiment for a wild type Nme2Cas9 bacterial open reading frame DNA sequence.

Figure 25 presents one embodiment of a wild type Nme2Cas9 bacterial protein sequence.

Figure 26 presents one embodiment of an Nme2Cas9 human-codon-optimized open reading frame DNA sequence. Yellow - SV40 NLS; Green - 3X-HA-Tag; Blue: cMyc-like NLS.

Figure 27 presents one embodiment of an Nme2Cas9 humanized protein sequence. Yellow - SV40 NLS; Green - 3X-HA-Tag; Blue: cMyc-like NLS.

Figure 28 presents one embodiment of an HpaCas9 bacterial protein sequence.

Figure 29 presents one embodiment of an SmuCas9 native bacterial open reading frame DNA sequence.

Figure 30 presents one embodiment of an SmuCas9 bacterial protein sequence.

Figure 31 presents one embodiment of an SmuCas9 Human-codon-optimized open reading frame DNA sequence. Yellow - SV40 NLS; Green - 3X-HA-Tag; Blue: cMyc-like NLS.

Figure 32 presents one embodiment of an SmuCas9 humanized protein sequence. Yellow - SV40 NLS; Green - 3X-HA-Tag; Blue: cMyc-like NLS.

Figure 33 presents exemplary Type-II C Cas9 ortholog single guide RNA sequences compatible with short C-rich PAMs. Yellow - crRNA; Gray – Linker; Purple – tracrRNA.

Figure 34 illustrates three closely related *Neisseria meningitidis* Cas9 orthologs that have distinct PAMs.

Figure 34A: Schematic showing mutated residues (orange spheres) between Nme2Cas9 (left) and Nme3Cas9 (right) mapped onto the predicted structure of Nme1Cas9, revealing the cluster of mutations in the PID (black).

Figure 34B: Experimental workflow of the *in vitro* PAM discovery assay with a 10 nt randomized PAM sequence downstream of a protospacer. Adapters were ligated to cleaved product and sequenced.

Figure 34C: Sequence logos of the *in vitro* PAM discovery assay demonstrating an N<sub>4</sub>GATT PAM for Nme1Cas9, as shown previously in cells.

Figure 34D: Sequence logos showing Nme1Cas9 with its PID swapped with those of Nme2Cas9 (left) and Nme3Cas9 (right) recognize a C at position

5. The remaining nucleotides were determined with lower confidence due to the modest cleavage efficiency of the protein chimeras (Figure 35C).

Figure 34E: Sequence logo illustrating that full-length Nme2Cas9 recognizes an N<sub>4</sub>CC PAM based on the PAM discovery assay with a fixed C at position 5, and PAM nts 1-4 and 6-8 randomized.

Figure 35 shows a characterization of *Neisseria meningitidis* Cas9 orthologs with rapidly-evolving PIDs in accordance with Figure 34.

Figure 35A: Unrooted phylogenetic tree of NmeCas9 orthologs that are >80% identical to Nme1Cas9. Three distinct branches emerged, with the majority of mutations clustered in the PID. Group 1 (blue) PIDs with >98% identity to Nme1Cas9, group 2 (orange) with PIDs ~52% identical to Nme1Cas9, and group 3 (green) with PIDs ~86% identical to Nme1Cas9. Three representative Cas9 orthologs from each group (Nme1Cas9, Nme2Cas9 and Nme3Cas9) are marked.

Figure 35B: Schematic showing the CRISPR loci of the strains encoding the three Cas9 orthologs (Nme1Cas9, Nme2Cas9, and Nme3Cas9) from (A). Percent identities of each CRISPR-Cas component to *N. meningitidis* 8013 (encoding Nme1Cas9) are shown.

Figure 35C: Number of reads from cleaved DNAs from the *in vitro* assays for intact Nme1Cas9, and for chimeras with Nme1Cas9's PID swapped with those of Nme2Cas9 and Nme3Cas9. The reduced read counts indicate lower cleavage efficiencies in the chimeras.

Figure 35D: Sequence logos from the *in vitro* PAM discovery assay on an NNNNCNNN randomized PAM by Nme1Cas9 with its PID swapped with those of Nme2Cas9 (left) or Nme3Cas9 (right).

Figure 36 shows that the Nme2Cas9 uses a 22-24 nucleotide spacer to recognize and edit sites adjacent to an N<sub>4</sub>CC PAM. All experiments were done in triplicate, and error bars represent standard error of mean (s.e.m.).

Figure 36A: Schematic showing the transient transfection workflow on HEK293T TLR2.0 cells. Nme2Cas9 and sgRNA plasmids were transfected and mCherry+ cells were detected 72 hours after transfection.



Figure 36B: Using Nme2Cas9 to target an array of PAMs in TLR2.0. All sites with N<sub>4</sub>CC PAMs were targeted with varying degrees of efficiency, while no Nme2Cas9 targeting observed at an N<sub>4</sub>GATT PAM or in the absence of sgRNA. SpyCas9 (targeting NGG) and Nme1Cas9 (targeting N<sub>4</sub>GATT) were used as positive controls.

Figure 36C: The effect of spacer length on the efficiency of Nme2Cas9 editing. An sgRNA targeting a TLR2.0 site (with an N<sub>4</sub>CCA PAM) with spacer lengths varying from 24 to 20 nts (including a 5'-terminal G), showing highest editing efficiencies with 22-24 nucleotide spacers.

Figure 36D: Nme2Cas9 nickases (HNH nickase = Nme2Cas9<sup>D16A</sup>; RuvC nickase = Nme2Cas9<sup>H588A</sup>) can be used in tandem to generate indels in TLR2.0. Targets with cleavage sites 32 base pairs and 64 base pairs apart were targeted using either nickase to generate indels. The HNH nickase shows efficient editing, particularly when the cleavage sites were close (32 bp). Wildtype Nme2Cas9 was used as a control. Green is GFP (HDR) and red is mCherry (NHEJ).

Figure 37 presents exemplary data regarding PAM, spacer, and seed elements for Nme2Cas9 targeting in mammalian cells, in accordance with Figure 36. All experiments were done in triplicate and error bars represent s.e.m.

Figure 37A: Nme2Cas9 targeting at N<sub>4</sub>CD sites in TLR2.0. Four sites for each non-C nucleotide at the tested position (N<sub>4</sub>CA, N<sub>4</sub>CT and N<sub>4</sub>CG) were examined, and an N<sub>4</sub>CC site was used as a positive control.

Figure 37B: Nme2Cas9 targeting at N<sub>4</sub>DC sites in TLR2.0 [similar to (A)].

Figure 37C: Guide truncations on another TLR2.0 site, revealing similar length requirements as those observed in Figure 36C.

Figure 37D: Nme2Cas9 targeting efficiency is differentially sensitive to single-nucleotide mismatches in the seed sequence. Data show the effects of walking single-nucleotide mismatches in the sgRNA along the 23-nt spacer in a TLR target site.

Figure 38 presents exemplary data showing Nme2Cas9 genome editing efficiency at genomic loci in mammalian cells via multiple delivery methods. All results represent 3 independent biological replicates, and error bars represent s.e.m.

Figure 38A: Nme2Cas9 genome editing using transient transfections with

sgRNAs targeting loci throughout the human genome in HEK293T cells.

14 sites were selected based the initial screening of 38 sites to demonstrate the range of indels (as detected by TIDE) at different loci induced by Nme2Cas9. An Nme1Cas9 target site (with an N<sub>4</sub>GATT PAM) was used as a negative control.

Figure 38B: Left panel: Transient transfection of an all-in-one plasmid

(Nme2Cas9 + sgRNA) targeting the *Pcsk9* and *Rosa26* loci in Hepa1-6 mouse cells, as detected by TIDE. Right panel: Electroporation of sgRNA plasmids into K562 cells stably expressing Nme2Cas9 from a lentivector results in efficient indel formation at the intended loci.

Figure 38C: Nme2Cas9 can be electroporated as an RNP complex for efficient genome editing. 40 picomoles Cas9 along with 50 picomoles of *in vitro* transcribed sgRNAs targeting three different loci were electroporated into HEK293T cells. Indels were measured using TIDE after 72h.

Figure 39 presents exemplary data showing dose dependence and block deletions by Nme2Cas9, in accordance with Figure 38.

Figure 39A: Increasing the dose of electroporated Nme2Cas9 plasmid (500 ng, vs. 200 ng in Fig. 3A) improves editing efficiency at two sites (TS16 and TS6).

Figure 39B: Nme2Cas9 can be used to create block deletions. Two TLR2.0 targets with cleavage sites 32 bp apart were targeted simultaneously with Nme2Cas9. The majority of lesions created were exactly 32 bp deletions (green).

Figure 40 presents exemplary data showing that Type II-C Anti-CRISPR proteins can be used to inhibit Nme2Cas9 gene editing activity (e.g., as an off-switch) *in vitro* and *in vivo*. All experiments were done in triplicate and error bars represent s.e.m.

Figure 40A: *In vitro* cleavage assay of Nme1Cas9 and Nme2Cas9 in the presence of five previously characterized anti-CRISPR proteins (10:1 ratio of Acr:Cas9). Top: Nme1Cas9 efficiently cleaves a fragment containing a protospacer with an N<sub>4</sub>GATT PAM in the absence of an Acr or in the presence of a control Acr (AcrE2). All other previously characterized Acrs inhibited Nme1Cas9, as expected. Bottom: Nme2Cas9 efficiently cleaves a target containing a protospacer with an N<sub>4</sub>CC PAM in the presence of AcrE2 and AcrIIC5<sub>Smu</sub>, suggesting that AcrIIC5<sub>Smu</sub> is unable to inhibit Nme2Cas9 at a 10:1 molar ratio.

Figure 40B: Genome editing in the presence of the five previously described anti-CRISPR proteins. Plasmids expressing Nme2Cas9, sgRNA and each respective Acr (200 ng Cas9, 100 ng sgRNA, 200 ng Acr) were co-transfected into HEK293T cells, and genome editing was measured using TIDE 72 hr post transfection. Except for AcrE2 and AcrIIC5<sub>Smu</sub>, all other Acrs inhibited genome editing, albeit at different efficiencies.

Figure 40C: Acr inhibition of Nme2Cas9 is dose-dependent with distinct apparent potencies. AcrIIC1<sub>Nme</sub> and AcrIIC4<sub>Hpa</sub> inhibit Nme2Cas9 completely at 2:1 and 1:1 ratios of cotransfected plasmids, respectively.

Figure 41 presents exemplary data showing that a Nme2Cas9 PID swap renders Nme1Cas9 insensitive to AcrIIC5<sub>Smu</sub> inhibition, in accordance with Figure 40. *In vitro* cleavage by the Nme1Cas9-Nme2Cas9PID chimera was performed in the presence of previously characterized Acr proteins (10 uM Cas9-sgRNA + 100 uM Acr).

Figure 42 presents exemplary data showing that Nme2Cas9 has no detectable off-targets in mammalian cells.

Figure 42A: Schematic showing the dual sites (DS) targetable by both SpyCas9 and Nme2Cas9 by virtue of their non-overlapping PAMs. The Nme2Cas9 PAM (orange) and SpyCas9 PAM (blue) are highlighted.

Figure 42B: Nme2Cas9 and SpyCas9 induce indels at dual sites. Six dual sites in *VEGFA* with GN<sub>3</sub>GN<sub>19</sub>NGGNCC sequences were selected for direct comparisons between the two orthologs. Plasmids expressing each Cas9 (with same promoter and NLSs) were transfected along with each

ortholog's cognate guide in HEK293T cells. Indel rates were determined by TIDE 72 hrs post transfection. Nme2Cas9 editing was detectable at all six sites and was more efficient than SpyCas9 on two sites (DS2 and 6). SpyCas9 edited four out of six sites (DS1, 2, 4 and 6), with two sites showing significantly higher editing rates than Nme2Cas9 (DS1 and 4). DS2, 4 and 6 were selected for GUIDE-Seq analysis as Nme2Cas9 was equally efficient, less efficient and more efficient than SpyCas9 at these sites, respectively.

Figure 42C: Nme2Cas9 has a clean off-target profile in human cells.

Numbers of off-target sites detected by GUIDE-Seq for each nuclease at individual target sites are shown. SpyCas9 off-target numbers are shown in black. In addition to dual sites, TS6 (because of its high efficiency and potential for off-targets) and two mouse sites (to test accuracy in another cell type) also showed zero or one off-target site per guide.

Figure 42D: Targeted deep sequencing confirms the high Nme2Cas9 accuracy indicated by GUIDE-seq. Top off-target loci detected by GUIDE-seq were amplified and deep-sequenced. SpyCas9 showed off-targeting at most loci, while for Nme2Cas9, only one (the *Rosa26* site) showed editing at the off-target locus at relatively low levels (~40% on-target vs ~1% off-target). Note the log scale on the y axis.

Figure 42E: Nme2Cas9 and SpyCas9 efficiencies vary based on the locus and target site. Sites throughout the genome (with GN<sub>3</sub>GN<sub>19</sub>NGGNCC sequences) were selected for direct comparisons of editing by the two orthologs. Plasmids expressing each Cas9 (with the same promoter, linkers, tags and NLSs) and its cognate guide were transfected into HEK293T cells. Indel efficiencies were determined by TIDE 72 hrs post-transfection. Box-and-whisker plots indicate editing efficiencies at twenty-eight (28) dual sites by Nme2Cas9 and SpyCas9 (left). The sites that showed no editing were excluded from the analysis. Relative efficiencies of Nme2Cas9 and SpyCas9 show that Nme2Cas9 is less efficient than SpyCas9 (right), on average. Editing efficiencies by both

Cas9 orthologs at all twenty-eight (28) sites were included in the analysis of relative efficiencies in the right panel.

Figure 42F presents nucleic acids sequences for the validated off-target site of the *Rosa26* guide, showing the PAM region (underlined), the consensus CC PAM dinucleotide (bold), and three mismatches in the PAM-distal portion of the spacer (red).

Figure 43 presents exemplary data showing the orthogonality and relative accuracy of Nme2Cas9 and SpyCas9 at dual target sites, in accordance with Figure 42.

Figure 43A: Nme2Cas9 and SpyCas9 guides are orthogonal. TIDE results show the frequencies of indels created by both nucleases targeting DS12 with either their cognate sgRNAs, or with the sgRNAs of the other ortholog.

Figure 43B: Nme2Cas9 and SpyCas9 exhibit comparable on-target editing efficiencies during GUIDE-seq. Bars indicate on-target read counts from GUIDE-Seq at the three dual sites targeted by each ortholog. Orange bars represent Nme2Cas9 and black bars represent SpyCas9.

Figure 43C: SpyCas9's on-target vs. off-target reads for each site. Orange bars represent the on-target reads while black bars represent off-targets.

Figure 43D: Nme2Cas9's on-target vs off-target reads for each site.

Figure 43E: Bar graphs showing TIDE at expected off-target sites based on CRISPRseek, detecting no indels at off-target loci.

Figure 44 presents exemplary data showing Nme2Cas9 genome editing *in vivo* via all-in-one AAV delivery.

Figure 44A: Workflow for delivery of AAV8.Nme2Cas9+sgRNA to lower cholesterol levels in mice by targeting *Pcsk9*. Top: schematic of the all-in-one AAV vector expressing Nme2Cas9 and the sgRNA. Bottom: Timeline for AAV8.Nme2Cas9+sgRNA tail-vein injections, followed by cholesterol measurements at day 14 and indel, histology and cholesterol analyses at day 28.

Figure 44B: Deep sequencing analysis to measure indels in DNA extracted from livers of mice injected with AAV8.Nme2Cas9+sgRNA targeting *Pcsk9* and *Rosa26* (control) loci.

Figure 44C: Reduced serum cholesterol levels in mice injected with the *Pcsk9*-targeting guide compared to the *Rosa26*-targeting controls. *P* values are calculated by unpaired T-test.

Figure 44D: H&E staining from livers of mice injected with AAV8.Nme2Cas9+sgRosa26 (left) or AAV8.Nme2Cas9+sgPcsk9 (right) vectors. Scale bar, 25  $\mu$ m.

Figure 45 presents one embodiment of minimized AAV backbone and exemplary comparative TLR 2.0 data to the conventional sized AAV backbone.

Figure 46 presents a comparison of Nme2Cas9 structures of truncated sgRNA 11 with truncated sgRNA 12.

Figure 47 illustrates one embodiment of a minimized all-in-one AAV with a short polyA signal.

Figure 48 illustrates two embodiments of a minimized all-in-one AAV backbone. Dual sgRNAs in tandem (Top). Donor template for homology directed repair (Bottom).

Figure 49 presents a validation of an all-in-one AAV-sgRNA-hNme1Cas9 construct.

Figure 49A: Schematic representation of a single rAAV vector expressing human-codon optimized Nme1Cas9 and its sgRNA. The backbone is flanked by AAV inverted terminal repeats (ITR). The poly(a) signal is from rabbit beta-globin (BGH).

Figure 49B: Schematic diagram of the *Pcsk9* (top) and *Rosa26* (bottom) mouse genes. Red bars represent exons. Zoomed-in views show the protospacer sequence (red) whereas the Nme1Cas9 PAM sequence is highlighted in green. Double-stranded break location sites are denoted (black arrowheads).

Figure 49C: Stacked histogram showing a representative percentage distribution of insertions-deletions (indels) obtained by TIDE after AAV-sgRNA-hNme1Cas9 plasmid transfections in Hepa1-6 cells targeting *Pcsk9* (sgPcsk9) and *Rosa26* (sgRosa26) genes. Data are presented as mean values  $\pm$  SD from three biological replicates.

Figure 49D: Stacked histogram showing a representative percentage distribution of indels at *Pcsk9* in the liver of C57Bl/6 mice obtained by TIDE after hydrodynamic injection of AAV-sgRNA-hNme1Cas9 plasmid.

Figure 50 presents exemplary data showing that many N<sub>4</sub>GN<sub>3</sub> PAMs are inactive, and revealed no off-target sites with fewer than four mismatches in the mouse genome.

Figure 51 presents exemplary data showing that Nme1Cas9-mediated knockout of *Hpd* rescues the lethal phenotype in hereditary tyrosinemia Type I mice.

5                   Figure 51A: Schematic diagram of the *Hpd* mouse gene. Red bars represent exons. Zoomed-in views show the protospacer sequences (red) for targeting exon 8 (sgHpd1) and exon 11 (sgHpd2). Nme1Cas9 PAM sequences are in green and double-stranded break locations are indicated (black arrowheads).

10                   Figure 51B: Experimental design. Three groups of Hereditary Tyrosinemia Type I *Fah*<sup>-/-</sup> mice are injected with PBS or all-in-one AAV-sgRNA-hNme1Cas9 plasmids sgHpd1 or sgHpd2.

15                   Figure 51C: Weight of mice hydrodynamically injected with PBS (green), AAV-sgRNA-hNme1Cas9 plasmid sgHpd1 targeting *Hpd* exon 8 (red) or sgHpd2-targeting *Hpd* exon 11 (blue) were monitored after NTBC withdrawal. Error bars represent three mice for PBS and sgHpd1 groups and two mice for the sgHpd2 group. Data are presented as mean ± SD.

20                   Figure 51D: Stacked histogram showing a representative percentage distribution of indels at *Hpd* in liver of *Fah*<sup>-/-</sup> mice obtained by TIDE after hydrodynamic injection of PBS or sgHpd1 and sgHpd2 plasmids. Livers were harvested at the end of NTBC withdrawal (day 43).

Figure 52 presents exemplary data showing average indel efficiencies of the guides presented in Figure 51.

25                   Figure 53 presents exemplary histological photomicrographs showing that liver damage is substantially less severe in the sgHpd1- and sgHpd2-treated mice compared to *Fah*<sup>mut/mut</sup> mice injected with PBS, as indicated by the smaller numbers of multinucleated hepatocytes compared to PBS-injected mice.

Figure 54 presents AAV-delivery of Nme1Cas9 for in vivo genome editing.

30                   Figure 54A: Experimental outline of AAV8-sgRNA-hNme1Cas9 vector tail-vein injections to target *Pcsk9* (sgPcsk9) and *Rosa26* (sgRosa26) in C57Bl/6 mice. Mice were sacrificed at 4 (n = 1) or 50 days (n = 5) post injection and liver

tissues were harvested. Blood sera were collected at days 0, 25, and 50 post injection for cholesterol level measurement.

Figure 54B: Serum cholesterol levels. p values are calculated by unpaired t test.

Figure 54C: Stacked histogram showing a representative percentage distribution of indels at *Pcsk9* or *Rosa26* in livers of mice, as measured by targeted deep-sequencing analyses. Data are presented as mean  $\pm$  SD from five mice per cohort.

Figure 54D: A representative anti-PCSK9 western blot using total protein collected from day 50 mouse liver homogenates. A total of 2 ng of recombinant mouse PCSK9 (r-PCSK9) was included as a mobility standard. The asterisk indicates a cross-reacting protein that is larger than the control recombinant protein.

Figure 55 presents exemplary data showing that mice injected with AAV8-sgRNA-hNme1Cas9 generate anti-Nme1Cas9 antibodies.

Figure 56 presents exemplary data showing GUIDE-seq genome-wide specificities of Nme1Cas9. Data are presented as mean  $\pm$  SD.

Figure 56A: Number of GUIDE-seq reads for the on-target (OnT) and off-target (OT) sites.

Figure 56B: Targeted deep sequencing to measure the lesion rates at each of the OT sites in Hepa1-6 cells. The mismatches of each OT site with the OnT protospacers is highlighted (blue). Data are presented as mean  $\pm$  SD from three biological replicates.

Figure 56C: Targeted deep sequencing to measure the lesion rates at each of the OT sites using genomic DNA obtained from mice injected with all-in-one AAV8-sgRNA-hNme1Cas9 sgPcsk9 and sgRosa26 and sacrificed at day 14 (D14) or day 50 (D50) post injection.

Figure 57 presents exemplary data for *Tyrosinase* (*Tyr*) gene editing ex vivo by Nme2Cas9 in mouse zygotes, as related to Figure 58.

Figure 57A: Two sites in *Tyr* gene, each with N<sub>4</sub>CC PAMs, were tested for editing in Hepa1-6 cells. The sgTyr2 guide exhibited higher editing efficiency and was selected for further testing.



Figure 57B: Seven mice survived post-natal development, and each exhibited coat color phenotypes as well as on-target editing, as assayed by TIDE.

Figure 57C: Indel spectra from tail DNA of each mouse from Figure 57B, as well as an unedited C57BL/6NJ mouse, as indicated by TIDE analysis.

5 Efficiencies of insertions (positive) and deletions (negative) of various sizes are indicated.

Figure 58 presents exemplary data of ex vivo Nme2Cas9 genome editing using an all-in-one AAV delivery.

10 Figure 58A: Workflow for single-AAV Nme2Cas9 editing ex vivo to generate albino C57BL/6NJ mice by targeting the *Tyr* gene. Zygotes are cultured in KSOM containing AAV6.Nme2Cas9:sgTyr for 5-6 hours, rinsed in M2, and cultured for a day before being transferred to the oviduct of pseudo-pregnant recipients.

15 Figure 58B: Albino (left) and chinchilla or variegated (middle) mice generated by  $3 \times 10^9$  GCs, and chinchilla or variegated mice (right) generated by  $3 \times 10^8$  GCs of zygotes with AAV6.Nme2Cas9:sgTyr.

Figure 58C: Summary of Nme2Cas9.sgTyr single-AAV ex vivo *Tyr* editing experiments at two AAV doses.

Figure 59 shows an alignment of Nme1Cas9 and Nme2Cas9 nucleotide sequences.

20 Legend: Non-PID aa differences (turquoise shading); PID aa differences (yellow shading); active site residues (red letters).

Figure 60 shows an alignment of Nme1Cas9 and Nme3Cas9 nucleotide sequences.

Legend: Non-PID aa differences (turquoise shading); PID aa differences (yellow shading); active site residues (red letters).

25 Figure 61 shows one embodiment of an Nme2Cas9 amino acid sequence. Legend: SV40 NLS (yellow shading); 3X-HA-Tag (green shading); cMyc-like NLS (turquoise shading); Linker (purple shading).

Figure 62 shows one embodiment of an Nme2Cas9 amino acid sequence. Legend: SV40 NLS (yellow shading); 3X-HA-Tag (green shading); Nucleoplasmin-like NLS (red shading); c-  
30 myc NLS (turquoise shading); Linker (purple shading).

Figure 63 shows one embodiment of a recombinant Nme2Cas9 (rNme2Cas9) amino acid sequence. Legend: SV40 NLS (yellow shading); Nucleoplasmin-like NLS (red shading); Linker (purple shading).

Figure 64 shows one embodiment of a all-in-one AAV-sgRNA-hNmeCas9 plasmid Nucleotide sequence. Legend: sgRNA scaffold (brown letters); GUIDE sequence (black letters); *U6 promoter* (blue letters); *Ula promoter* (purple letters); NLS NLS (green letters); hNmeCas9 (red letters); NLS 3X-HA and NLS BGH-pA (alternating green/black letters).

### Detailed Description Of The Invention

The present invention is related to compositions and methods for gene therapy. Several approaches described herein utilize the *Neisseria meningitidis* Cas9 system that provides a hyperaccurate CRISPR gene editing platform. Furthermore, the invention incorporates improvements of this Cas9 system: for example, truncating the single guide RNA sequences, and the packing of -Nme1Cas9 or Nme2Cas9 with its guide RNA in an adeno-associated viral vector that is compatible for *in vivo* administration. Furthermore, Type II-C Cas9 orthologs have been identified that target protospacer adjacent motif sequences limited to between one – four required nucleotides.

#### I. *Neisseria meningitidis* Cas9 (Nme1Cas9)/CRISPR Gene Editing Accuracy

Previously, a hyper-accurate version of type II-C CRISPR-Cas9 systems called *Neisseria meningitidis* Cas9 (Nme1Cas9) was reported. In addition to being hyper-accurate, Nme1Cas9 is also smaller than the widely used *Streptococcus pyogenes* Cas9 (SpyCas9), allowing Nme1Cas9 to be delivered more readily via viral and messenger RNA (mRNA)-based methods. Genome editing with Nme1Cas9 typically has been accomplished using plasmid transfections. Zhang et al., “Processing-independent CRISPR RNAs limit natural transformation in *Neisseria meningitidis*” *Mol Cell* 50:488-503 (2013); Hou et al., “Efficient genome engineering in human pluripotent stem cells using Cas9 from *Neisseria meningitidis*” *Proc Natl Acad Sci U.S.A.* 110:15644-15649 (2013); Esvelt et al., “Orthogonal Cas9 proteins for RNA-guided gene regulation and editing” *Nature Methods* 10:1116-1121 (2013); Zhang et al., “DNase H activity of *Neisseria meningitidis* Cas9” *Mol Cell* 60:242-255 (2015); Lee et al., “The *Neisseria meningitidis* CRISPR-Cas9 system enables specific genome editing in mammalian cells”

*Molecular Therapy* 24:645-654 (2016); Pawluk et al., “Naturally occurring off-switches for CRISPR-Cas9” *Cell* 167:1829-1838 (2016); and Amrani et al., “Nme1Cas9 is an intrinsically high-fidelity genome editing platform” *bioRxiv.org/content/early/2017/08/04/172650* (2017).

However, Nme1Cas9 viral, RNA- and ribonucleoproteins (RNP)-based delivery has not  
5 been extensively explored. RNA- and RNP-based delivery of Cas9 orthologs for genome engineering holds several advantages over other delivery methods. They not only result in faster editing since they bypass the expression issues related to DNA-based delivery of Cas9 and its sgRNA, but they also reduce off-target effects associated with Cas9-based editing. Reduced off-target activity results from finer control of the Cas9 RNA and RNP concentrations, and from  
10 relatively rapid Cas9 RNA and RNP degradation in cells. Prolonged presence of active Cas9 within the cell has been shown to be associated with higher off-target effects. Since Cas9 RNAs and RNPs are more rapidly degraded within cells, Cas9 delivered as RNA or RNP does not persist for long periods of time and consequently have reduced off-target effects.

Conventionally used full-length 145 nt Nme1Cas9 sgRNA includes a 48 nucleotide (nt)  
15 crRNA, a 4 nt linker, and a 93 nt tracrRNA. The crRNA region of the sgRNA is composed of a first 24 nt spacer sequence, and a second 24 nt repeat sequence that pairs with a 24 nt tracrRNA anti-repeat 5' region thereby forming a repeat:anti-repeat region. The remaining 69 nt tracrRNA region includes the Stem 1 region and Stem 2 region. Figure 1.

This full-length Nme1Cas9 sgRNA has been successfully used for genome editing using  
20 plasmid-based methods. Furthermore, *in vitro* transcribed Nme1Cas9 sgRNA can be complexed with purified Nme1Cas9 and used for genome editing in human cells. While genome editing of human cells has been successful with *in vitro* transcribed sgRNAs, the editing efficiency of an Nme1Cas9 RNP is reduced in harder-to-transfect human cell lines such as PLB985.

It has previously been shown that the editing efficiency of Cas9 RNPs is proportional to  
25 the chemical stability their sgRNAs. Although it is not necessary to understand the mechanism of an invention, it is believed that several cellular mechanisms are employed to rapidly degrade RNAs. For this reason, Cas9 sgRNAs are routinely modified by chemical means. Some of the chemical modifications that confer increased stability to sgRNA include, but are not limited to, ribose 2'-O-methylation and/or phosphorothioate linkages. While chemically modified RNAs  
30 are options for improved genome editing by Cas9 RNPs, their effectiveness is limited by the fact that chemical synthesis of RNAs becomes increasingly difficult and expensive as the length of

RNA increases. At 145 nt, Nme1Cas9 sgRNA synthesis is out of reach for routine genome editing applications that employ chemically synthesized sgRNAs.

## II. Truncated Nme1Cas9 sgRNA Sequences

Due to the above identified limitation that a full-length 145 nt Nme1Cas9 sgRNA is too large for routine chemical synthesis of sgRNAs for genome editing, one embodiment of the present invention contemplates a truncated Nme1Cas9 sgRNA. Although it is not necessary to understand the mechanism of an invention, it is believed that a truncated Nme1Cas-sgRNA does not compromise the function of an Nme1Cas9 RNP. Furthermore, sgRNAs for Nme1Cas9 and Nme2Cas9 are identical and interchangeable (Figure 35B), so sgRNA truncations are equally applicable to both Nme1Cas9 and Nme2Cas9. Exemplary sequences of truncated sgRNAs and associated target sites are disclosed below, where variable sgRNA nts in guide regions are given as "N" residues. In the target sequences, the 24 nts recognized by the sgRNA guide region are underlined, and the protospacer adjacent motif (PAM) region is given in bold. Table 1.

Table 1: Exemplary Truncated sgRNA Sequences And Associated Genomic Targets

[illegible]

As contemplated herein, a truncated Nme1Cas9 sgRNA would not only allow synthesis at a reasonable cost, but also facilitates use in virus-based delivery methods (e.g., for example adeno-associated viral delivery platforms) where the allowed length of DNA is limited. In one embodiment, the truncated sgRNA reduces off-target Nme1Cas9 editing effect. In one

embodiment, the truncated Nme1Cas9 sgRNA comprises at least one chemical modification that increases Nme1Cas9 editing efficiency.

As discussed above, the full length 145 nt sgRNA of Nme1Cas9 includes a guide region, a repeat:anti-repeat duplex region, a Stem 1 region and a Stem 2 region. Figure 1. However, because the length of the sgRNA is problematic for routine genomic editing, and it was highly desirable to develop a truncated sgRNA for Nme1Cas9. Currently, commercially available RNA synthesis methods require that RNA end product be not more than ~100 nt.

In one embodiment, the present invention contemplates an Nme1Cas9 sgRNA comprising a truncated repeat:anti-repeat duplex. In one embodiment, the present invention contemplates an Nme1Cas9 sgRNA comprising a truncated stem 2. Figure 2. Furthermore, it has previously been shown that a 5' variable guide crRNA region (e.g., spacer region) of Nme1Cas9 can also be truncated by a few nucleotides without loss of function. Amrani et al., "Nme1Cas9 is an intrinsically high-fidelity genome editing platform" *bioRxiv.org/content/early/2017/08/04/172650* (2017); and Lee et al., "The *Neisseria meningitidis* CRISPR-Cas9 system enables specific genome editing in mammalian cells" *Molecular Therapy* 24:645-654 (2016).

In one embodiment, the present invention contemplates a 100 nt Nme1Cas9-truncated sgRNA. Figure 3, Construct #11. This 100 nt Nme1Cas9 truncated-sgRNA Construct #11 was tested on three different human genomic sites by transient transfections in HEK293T cells, and at all three sites they support Nme1Cas9 function at the same level as, if not better than, the full-length Nme1Cas9 sgRNA. Figure 3, Bottom Panel. Moreover, sgRNA 11 and sgRNA 13 were also tested at several genomic target sites using RNP delivery and editing efficiency was similar or higher than the wt sgRNA. Figure 4. The synthetic version of construct #11 was also tested in PLB985 cells resulting in higher editing efficiency relative to in vitro transcribed wt sgRNA. Figure 5.

### III. Associated-Adenovirus CRISPR Delivery Platforms

Compared to transcription activator-like effector nucleases (TALENs) and Zinc-finger nucleases (ZFNs), Cas9s are distinguished by their flexibility and versatility. Komor et al., "CRISPR-based technologies for the manipulation of eukaryotic genomes" *Cell* 2017;168:20–36. Such characteristics make them ideal for driving the field of genome engineering forward. Over the past few years, CRISPR-Cas9 has been used to enhance products in agriculture, food,

and industry, in addition to the promising applications in gene therapy and personalized medicine. Barrangou et al., “Applications of CRISPR technologies in research and beyond” *Nat Biotechnol.* 2016;34:933–41. Despite the diversity of Class 2 CRISPR systems that have been described, only a handful of them have been developed and validated for genome editing in vivo. As shown herein, NmeCas9 is a compact, high-fidelity Cas9 that can be considered for future in vivo genome editing applications using all-in-one rAAV. NmeCas9’s unique PAM enables editing at additional targets that are inaccessible to the other two compact, all-in-one rAAV-validated orthologs (SauCas9 and CjeCas9).

Genome editing using a bacterial CRISPR system has opened a new avenue for human gene therapy. Named for Clustered Regularly Interspaced Short Palindromic Repeats that capture snippets of invasive nucleic acids in bacteria, the CRISPR complex comprises a guide RNA (e.g., sgRNA) that directs a nuclease Cas9 (CRISPR-associated protein 9) to cleave complementary double-stranded DNA. Non-homologous repair of a Cas9-induced DNA break leads to small insertions or deletions (indels) that inactivate target genes, but breaks can also be repaired by homologous DNA templates resulting in gene replacement. Nelson et al., “In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy” *Science* 351: 403-407 (2016); and Ran et al., “In vivo genome editing using *Staphylococcus aureus* Cas9” *Nature* 520:186-191 (2015); and Yin et al., “Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype” *Nature Biotechnology* 32:551-553 (2014).

The current and widely-used Type II-A *Streptococcus pyogenes* (Spy) Cas9 as a flexible genome-editing tool demonstrates several disadvantages: i) inefficient delivery; ii) off-target cleavage; and iii) unregulated activity. These disadvantages strictly limit SpyCas9 as a potential gene therapy tool. As discussed herein a highly accurate and precise Nme1Cas9 or Nme2Cas9 complex can overcome these SpyCas9 limitations.

Nme1Cas9 and Nme2Cas9 have been shown herein to be an efficient genome-editing platform in mammalian cells and, as a smaller protein than SpyCas9, it is easier to engineer viral vectors for in vivo delivery. Furthermore, Nme1Cas9 and Nme2Cas9 have significantly lower off-target editing than SpyCas9 and anti-CRISPR proteins have been identified that allow control of Nme1Cas9 and Nme2Cas9 activity. Esvelt et al., “Orthogonal Cas9 proteins for RNA-guided gene regulation and editing” *Nature Methods* 10:1116-1121 (2013); Amrani et al., “Nme1Cas9 is an intrinsically high-fidelity genome editing platform” *bioRxiv.org/content/early/2017/08/04/*

172650 (2017); Lee et al., "The *Neisseria meningitidis* CRISPR-Cas9 System Enables Specific Genome Editing in Mammalian Cells" *Molecular Therapy* 24:645-654 (2016); Hou et al., "Efficient genome engineering in human pluripotent stem cells using Cas9 from *Neisseria meningitidis*" *Proc Natl Acad Sci USA* 110:15644-15649 (2013); and Pawluk et al., "Naturally  
 5 Occurring Off-Switches for CRISPR-Cas9" *Cell* 167:1829-38 e9 (2016); and Figure 21.

Adeno-Associated Virus (AAV) has been demonstrated as a delivery shuttle with minimal pathogenicity in pre-clinical and clinical settings, but it has a limited packaging capacity. Nme1Cas9, encoded by a ~3.3kb open reading frame, and its guide RNAs are within the packaging limit of AAV. Nme2Cas9 has similar advantages. Unlike SpyCas9, which  
 10 requires delivery by separate vectors for the sgRNA and Cas9, Nme1Cas9, Nme2Cas9 and their sgRNA are small enough to be delivered with a single AAV vector.

Other Cas9 orthologs have been successfully delivered in vivo by AAV, such as *Campylobacter jejuni* Cas9 (CjeCas9) and *Staphylococcus aureus* (SauCas9). Kim et al., "In vivo genome editing with a small Cas9 orthologue derived from *Campylobacter jejuni*" *Nat  
 15 Commun* 8:14500 (2017); and Ran et al., "In vivo genome editing using *Staphylococcus aureus* Cas9" *Nature* 520:186-191 (2015). Nme1Cas9 is usually associated with an N<sub>4</sub>GATT PAM, which is unlike the CjeCas9 PAM (e.g., N<sub>4</sub>RYAC), or the SauCas9 PAM (e.g., NNGRRT) (R = purine (A or G), Y = pyrimidine (C or T)).

Nme1Cas9 has been successfully delivered as a ribonucleoprotein (RNP) complex in  
 20 human cells. Figure 2 and Figure 3. Further, the data presented herein show that an Nme1Cas9 nucleic acid sequence can be expressed in vivo in mice to target genes using an all-in-one sgRNA-Nme1Cas9-AAV vector subsequent to a tail vein injection.

The data presented herein demonstrates a targeting of a mouse Proprotein Convertase Subtilisin/Kexin type 9 (*Pcsk9*) gene. PCSK9 functions as an antagonist to the low-density  
 25 lipoprotein (LDL) receptor and limits LDL cholesterol uptake. Detection of reduced cholesterol levels in the serum can thereby provide a direct functional readout of efficient Nme1Cas9 editing using a *PCSK9* - directed Cas9 platform.

In one embodiment, the present invention contemplates an adeno-associated viral vector comprising an Nme1Cas9-sgRNA complex or an Nme2Cas9-sgRNA complex. Although it is  
 30 not necessary to understand the mechanism of an invention, it is believed that an



AAV/Nme1Cas9-sgRNA complex or an AAV/Nme2Cas9-sgRNA complex are compatible with an in vivo delivery route in order to provide gene editing.

In one embodiment, the present invention contemplates an sgRNA-Nme1Cas9-AAV vector comprising an sgRNA sequence, an RNA Polymerase III U6 promoter sequence, a human  
5 codon-optimized Nme1Cas9 sequence, and an RNA Polymerase II U1a promoter sequence.

Figure 6. U1a is a ubiquitous promoter allowing versatile expression of Cas9 in various tissues of interest. Specific genes to be edited can be targeted by inserting a spacer sequence matching a target gene into an sgRNA cassette using conventional restriction sites (e.g., SapI).

Representative sequences of the various elements of the sgRNA-Nme1Cas9-AAV are shown by  
10 colored annotations. Figures 7 and 8.

Editing efficiencies of several target sites using a *Pcsk9*-sgRNA-Nme1Cas9-AAV plasmid and a *Rosa26*-sgRNA-Nme1Cas9-AAV plasmid were estimated by an T7E1 assay following transient transfection into mouse Hepa1-6 hepatoma cells. Figure 9. Representative target site sequences within a *Pcsk9* gene and a *Rosa26* gene complementary with a *Pcsk9*-  
15 sgRNA-Nme1Cas9-AAV plasmid and a *Rosa26*-sgRNA-Nme1Cas9-AAV plasmid are shown by colored annotations. Figure 10.

The plasmid design was validated in vivo with mice by hydrodynamic injection of 30 µg of endotoxin-free sgRNA-Nme1Cas9-AAV plasmid targeting *Pcsk9* via tail-vein. Significant gene editing was detected in mouse liver 10 days after injection as measured by Tracking of  
20 Indels by DEcomposition (TIDE), a sequencing-based method of evaluating indel efficiencies. Figure 11.

The plasmid backbones targeting a *Pcsk9* gene and a *Rosa26* gene were packaged in hepatocyte-specific AAV8 serotype, and a dose of  $4 \times 10^{10}$  genomic copies (gc) per mouse was injected via tail-vein. Preliminary data show indel values from mice sacrificed at 14 days post-  
25 injection at a significant indel level in liver *Pcsk9* and *Rosa26* genes. Figure 12A. Deep-sequencing data has also been collected at day 50 post-injection.

The three mice groups were sacrificed at day 50 post-injection, and liver gDNA was used to measure the indel values at *Pcsk9* and *Rosa26* using TIDE. Figure 12B. Deep-sequencing analyses has also been performed to record accurate measurements of indel values.

30 PCSK9 protein “knock-down” may lead to significant lowering of cholesterol levels in mice. Serum cholesterol level was measured by Infinity™ colorimetric endpoint assay (Thermo-

Scientific) in 3 mice groups injected with vectors targeting a *Pcsk9* gene, a *Rosa26* gene and a PBS control group. Results suggest that Nme1Cas9-induced indel formation has led to the interruption of the normal reading frame of the *Pcsk9* gene, as showed by significantly reduced values of serum cholesterol at 25 and 50 days post-injection. Figure 13. Western blot assay has also been performed to measure the level of PCSK9 protein in mice liver at day 50.

A genome-wide unbiased identification of double strand breaks (DSBs) enabled by a sequencing assay (e.g., GUIDE-Seq<sup>®</sup>, Illumina) searched for off-target editing sites subsequent to injection of vectors targeting a *Pcsk9* gene and a *Rosa26* gene. The data revealed four (4) potential off-target sites for *Pcsk9* and six (6) potential off-target sites for *Rosa26*. Figures 14A and 14B.

A targeted TIDE analyses revealed on-target genome editing in cells and in the mice at day 14 subsequent to injection of AAV vectors targeting a *Pcsk9* gene and a *Rosa26* gene. Figure 15. Deep-sequencing analyses for off-target cleavage at these sites has also been performed at 50 days post-injection.

A hematoxylin and eosin stain assay did not show signs of massive immune cell infiltration in the liver sections of mice sacrificed at day 14 subsequent to injection of vectors targeting a *Pcsk9* gene and a *Rosa26* gene. Figure 16. Specific immune-response assays will be performed at 50 day post-injection.

In one embodiment, the present invention contemplates a method for therapeutic *in vivo* genome editing by all-in-one AAV delivery of an Nme2Cas9. Although it is not necessary to understand the mechanism of an invention it is believed that the compactness, small PAM and high fidelity make Nme2Cas9 an ideal tool for *in vivo* genome editing using AAV. To this end, Nme2Cas9 was cloned with its cognate sgRNA and their respective promoters into a single AAV vector backbone. Figure 44A; top.. This all-in-one AAV.sgRNA.Nme2Cas9 was packaged in a hepatocyte-selective AAV8 capsid. Two genes were targeted: i) *Rosa26*, a commonly used locus as a negative control; and ii) the *Proprotein convertase subtilisin/kexin type 9* (*Pcsk9*), a major regulator of circulating cholesterol homeostasis. Studies have shown that knocking out *Pcsk9* using Cas9 results in reduced cholesterol levels (Ran et al).

Two groups of mice ( $n=5$ ) were injected with packaged AAV8.sgNA.Nme2Cas9 targeting either *Pcsk9* or *Rosa26*. Serum was collected at 0, 14 and 28 days post vector injection for cholesterol level measurement. Mice were sacrificed at 28 days post-injection

and liver tissues were harvested. (Figure 44A, bottom. A deep sequencing analysis showed significantly high level of indels at *Pcsk9* and *Rosa26*. Figure 44B.. These indel values were accompanied by significant reduction in blood cholesterol level in mice injected with *sgPcsk9* after 14 and 28 days; where mice injected with *sgRosa26* maintained normal level of  
5 cholesterol throughout the study. Figure 44C. An H&E analyses showed no signs of toxicity or tissue damage at both groups after Nme2Cas9 expression. Figure 44D.. These data validate that Nme2Cas9 is highly functional *in vivo*, and it can be readily delivered by the favorable all-in-one AAV platform.

In one embodiment, the present invention contemplates a minimized AAV.hNmeCas9  
10 construct. See, Figure 44A. As discussed above, the present invention contemplates an engineered all-in-one AAV.sgRNA.hNme1Cas9 construct, which is packaged in AAV8 virions that successfully edited *Pcsk9* and *Rosa26* genes in mice liver.

In one embodiment, the present invention contemplates an AAV8 backbone comprising an Nme2Cas9 cassette. Similar to Nme1Cas9, Nme2Cas9 also showed robust editing at *Pcsk9*  
15 and *Rosa26* in mice (*infra*). The data presented herein shows that *in vivo* administration of AAV8-NmeCas9 to mice is accompanied by significant reduction in level of circulating cholesterol after 28 days post vector injection.

In order to increase the utility of this all-in-one AAV platform, various truncations were introduced to minimize the size of the cargo to make a space for additional features in the AAV  
20 capsid, such as dual sgRNAs or donor DNA segment.

In order to minimize the cargo of the all-in-one AAV backbone, the extra features (3x HA tags and 2x NLS sequences) were systematically removed without compromising the nuclease activity of the Cas9. Nme1Cas9, using the traffic light reporter (TLR) system, show that this minimized all-in-one AAV.sgRNA.hNme1Cas9 (4.468 kb) is as potent as the previous  
25 longer version with 4 NLS sequences. See, Figure 45. Truncated sgRNAs were constructed to free more space using a new sgRNA12, which is similar to an sgRNA11 version, but with UA added at the 3' end. See, Figure 46..

Previously, it has been reported that a short polyA sequence may be useful for Cas9 constructs. Platt *et. al.* (2015). In one embodiment, the present invention contemplates an AAV-  
30 Nme2Cas9 construct comprising a BGH polyA. See, Figure 47. Although it is not necessary to

understand the mechanism of an invention, it is believed that this polyA sequence further reduces the size of the all-in-one AAV backbone.

It is further believed that this minimized (4.4 kb) all-in-one AAV backbone increases the utility of Nme1Cas9 and Nme2Cas9 by including another sgRNA for dual genes knockout or DNA fragment excision. See, Figure 48, top. This configuration also provides free space in the AAV capsid to include a donor template (~ 600 base pairs) for homology-directed repair application. See, Figure 48, bottom. In some embodiments, dual sgRNA AAV constructs are packaged within a single AAV vector.

The relatively compact Nme1Cas9 is active in genome editing in a range of cell types. To exploit the small size of this Cas9 ortholog, an all-in-one AAV construct was generated with human-codon-optimized Nme1Cas9 under the expression of the mouse U1a promoter and with its sgRNA driven by the U6 promoter. See, Figure 49A. Two sites in the mouse genome were selected initially to test the nuclease activity of Nme1Cas9 in vivo: the *Rosa26* “safe-harbor” gene (targeted by sgRosa26); and the proprotein convertase subtilisin/kexin type 9 (*Pcsk9*) gene (targeted by sgPcsk9), a common therapeutic target for lowering circulating cholesterol and reducing the risk of cardiovascular disease. Figure 49B. Genome-wide off-target predictions for these guides were determined computationally using the Bioconductor package CRISPRseek 1.9.1 with N<sub>4</sub>GN<sub>3</sub> PAMs and up to six mismatches. Zhu et al., “CRISPRseek: a bioconductor package to identify target-specific guide RNAs for CRISPR-Cas9 genome editing systems” *PLoS One* 2014;9:e108424. Many N<sub>4</sub>GN<sub>3</sub> PAMS are inactive, so these search parameters are nearly certain to cast a wider net than the true off-target profile. Despite the expansive nature of the search, an analyses revealed no off-target sites with fewer than four mismatches in the mouse genome. See, Figure 50. On-target editing efficiencies at these target sites were evaluated in mouse Hepa1–6 hepatoma cells by plasmid transfections and indel quantification was performed by sequence trace decomposition using the Tracking of Indels by Decomposition (TIDE) web tool. Brinkman et al., “Easy quantitative assessment of genome editing by sequence trace decomposition” *Nucleic Acids Res.* 2014;42:e168. The data show > 25% indel values for the selected guides, the majority of which were deletions. See, Figure 49C.

To evaluate the preliminary efficacy of the constructed all-in-one AAV-sgRNA-hNme1Cas9 vector, endotoxin-free sgPcsk9 plasmid was hydrodynamically administered into the C57Bl/6 mice via tail-vein injection. This method can deliver plasmid DNA to ~ 40% of

hepatocytes for transient expression. Liu et al., “Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA” *Gene Ther.* 1999;6:1258–66. Indel analyses by TIDE using DNA extracted from liver tissues revealed 5–9% indels 10 days after vector administration, comparable to the editing efficiencies obtained with analogous tests of SpyCas9. See, Figure 49D; and Xue et al., “CRISPR-mediated direct mutation of cancer genes in the mouse liver” *Nature* 2014;514:380–4. These results suggest that Nme1Cas9 is capable of editing liver cells in vivo.

Hereditary Tyrosinemia type I (HT-I) is a fatal genetic disease caused by autosomal recessive mutations in the *Fah* gene, which codes for the fumarylacetoacetate hydroxylase (FAH) enzyme. Patients with diminished FAH have a disrupted tyrosine catabolic pathway, have a disrupted tyrosine catabolic pathway, leading to the accumulation of toxic fumarylacetoacetate and succinyl acetoacetate, causing liver and kidney damage. Grompe M., “The pathophysiology and treatment of hereditary tyrosinemia type 1” *Semin Liver Dis.* 2001;21:563–71. Over the past two decades, the disease has been controlled by 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), which inhibits 4-hydroxyphenylpyruvate dioxygenase upstream in the tyrosine degradation pathway, thus preventing the accumulation of the toxic metabolites. Lindstedt et al., “Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate Dioxygenase” *Lancet* 1992;340:813–7. However, this treatment requires lifelong management of diet and medication and may eventually require liver transplantation. Das, AM., “Clinical utility of nitisinone for the treatment of hereditary tyrosinemia type-1 (HT-1)” *Appl Clin Genet.* 2017;10:43–8.

Several gene therapy strategies have been tested to correct a defective *Fah* gene using site-directed mutagenesis or homology-directed repair by CRISPR-Cas9. Paulk et al., “Adenoassociated virus gene repair corrects a mouse model of hereditary tyrosinemia in vivo” *Hepatology* 2010;51:1200–8; Yin et al., “Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo” *Nat Biotechnol.* 2016;34:328–33; and Yin et al., “Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype” *Nat Biotechnol.* 2014;32:551–3. It has been reported that successful modification of only 1/10,000 of hepatocytes in the liver is sufficient to rescue the phenotypes of *Fah*<sup>mut/mut</sup> mice. Recently, a metabolic pathway reprogramming approach has been suggested in which the

function of the hydroxyphenylpyruvate dioxygenase (HPD) enzyme was disrupted by the deletion of exons 3 and 4 of the *Hpd* gene in the liver. Pankowicz et al., “Reprogramming metabolic pathways in vivo with CRISPR/Cas9 genome editing to treat hereditary tyrosinaemia” *Nat Commun.* 2016;7:12642. This provides a context in which to test the efficacy of Nme1Cas9 editing, for example, by targeting *Hpd* and assessing rescue of the disease phenotype in *Fah* mutant mice. Grompe et al., “Loss of fumarylacetoacetate hydrolase is responsible for the neonatal hepatic dysfunction phenotype of lethal albino mice” *Genes Dev.* 1993;7:2298–307. For this purpose, two target sites (one each in exon 8 [sgHpd1] and exon 11 [sgHpd2]) were screened and identified within the open reading frame of *Hpd*. See, Figure 51A. These guides (e.g., sgRNAs) facilitated Nme1Cas9-induced average indel efficiencies of 10.8% and 9.1%, respectively, by plasmid transfections in Hepal–6 cells. Figure 52.

Three groups of mice were treated by hydrodynamic injection with either phosphate-buffered saline (PBS) or with one of the two sgHpd1 and sgHpd2 all-in-one AAV-sgRNA-hNme1Cas9 plasmids. One mouse in the sgHpd1 group and two in the sgHpd2 group were excluded from the follow-up study due to failed tail-vein injections. Mice were taken off NTBC-containing water seven days after injections and their weight was monitored for 43 days post injection. See, Figure 51B. Mice injected with PBS suffered severe weight loss (a hallmark of HT-I) and were sacrificed after losing 20% of their body weight. Overall, all sgHpd1 and sgHpd2 mice successfully maintained their body weight for 43 days overall and for at least 21 days without NTBC. See, Figure 51C.

NTBC treatment had to be resumed for 2–3 days for two mice that received sgHpd1 and one that received sgHpd2 to allow them to regain body weight during the third week after plasmid injection, perhaps due to low initial editing efficiencies, liver injury due to hydrodynamic injection, or both. Conversely, all other sgHpd1 and sgHpd2 treated mice achieved indels with frequencies in the range of 35–60%. See, Figure 51D. This level of gene inactivation likely reflects not only the initial editing events but also the competitive expansion of edited cell lineages (after NTBC withdrawal) at the expense of their unedited counterparts. Liver histology revealed that liver damage is substantially less severe in the sgHpd1- and sgHpd2-treated mice compared to *Fah*<sup>mut/mut</sup> mice injected with PBS, as indicated by the smaller numbers of multinucleated hepatocytes compared to PBS-injected mice. See, Figure 53.

AAV vectors have recently been used for the generation of genome-edited mice, without the need for microinjection or electroporation, simply by soaking the zygotes in culture medium containing AAV vector(s), followed by reimplantation into pseudopregnant females. Editing was obtained previously with a dual-AAV system in which SpyCas9 and its sgRNA were delivered in separate vectors. Yoon et al., “Streamlined ex vivo and in vivo genome editing in mouse embryos using recombinant adeno-associated viruses” *Nat. Commun.* 9:412 (2018). To test whether Nme2Cas9 could enable accurate and efficient editing in mouse zygotes with an all-in-one AAV delivery system, the tyrosinase gene (*Tyr*) was targeted, where a bi-allelic inactivation of which disrupts melanin production, resulting in albino pups. Yokoyama et al., “Conserved cysteine to serine mutation in tyrosinase is responsible for the classical albino mutation in laboratory mice” *Nucleic Acids Res.* 18:7293-7298 (1990).

An efficient *Tyr* sgRNA (which cleaves the *Tyr* locus only 17 bp from the site of the classic albino mutation) was validated in Hepa1-6 cells by transient transfections. See, Figure 57. Next, C57BL/6NJ zygotes were incubated for 5-6 hours in culture medium containing  $3 \times 10^9$  or  $3 \times 10^8$  GCs of an all-in-one AAV6 vector expressing Nme2Cas9 along with the *Tyr* sgRNA. After overnight culture in fresh media, those zygotes that advanced to the two-cell stage were transferred to the oviduct of pseudopregnant recipients and allowed to develop to term. See, Figure 58A. Coat color analysis of pups revealed mice that were albino, light grey (suggesting a hypomorphic allele of *Tyr*), or that had variegated coat color composed of albino and light grey spots but lacking black pigmentation. See, Figures 58B & 58C. These results suggest a high frequency of biallelic mutations since the presence of a single wild-type *Tyr* allele should render black pigmentation. A total of five pups (10%) were born from the  $3 \times 10^9$  GCs experiment. All of them carried indels; phenotypically, two were albino, one was light grey, and two had variegated pigmentation, indicating mosaicism. From the  $3 \times 10^8$  GCs experiment, four (4) pups (14%) were obtained, two of which died at birth, preventing coat color or genome analysis. Coat color analysis of the remaining two pups revealed one light grey and one mosaic pup. These results indicate that single-AAV delivery of Nme2Cas9 and its sgRNA can be used to generate mutations in mouse zygotes without microinjection or electroporation.

To measure on-target indel formation in the *Tyr* gene, DNA was isolated from the tails of each mouse, the locus was amplified and a TIDE analysis was performed. The data showed that all mice had high levels of on-target editing by Nme2Cas9, varying from 84% to 100%. See,

Figures 57B and 5C. Most lesions in albino mouse 9-1 were either a 1- or a 4-bp deletion, suggesting either mosaicism or trans-heterozygosity. Albino mouse 9-2 exhibited a uniform 2-bp deletion. See, Figure 58C. Analysis of tail DNA from light grey mice revealed the presence of in-frame mutations that are potentially a cause of the light grey coat color. The limited  
 5 mutational complexity suggests that editing occurred early during embryonic development in these mice. One female (mouse 9-2) was mated with a classical albino male, and all six of the resulting pups were albino, demonstrating that mutations generated by zygotic all-in-one AAV delivery of Nme2Cas9 + sgRNA can be transmitted through the germline. These results provide a streamlined route toward mammalian mutagenesis through the application of a single AAV  
 10 vector, in this case delivering both Nme2Cas9 and its sgRNA.

Patients with mutations in the *Hpd* gene are considered to have Type III Tyrosinemia and exhibit high level of tyrosine in blood, but otherwise appear to be largely asymptomatic.

Szymanska et al., "Tyrosinemia type III in an asymptomatic girl. *Mol Genet*

*Metab Rep.* 2015;5:48–50; and Nakamura et al., "Animal models of tyrosinemia" *J Nutr.*

15 2007;137:1556S–60S. HPD acts upstream of FAH in the tyrosine catabolism pathway and *Hpd* disruption ameliorates HT-I symptoms by preventing the toxic metabolite build-up that results from loss of FAH. Structural analyses of HPD reveal that the catalytic domain of the HPD enzyme is located at the C-terminus of the enzyme and is encoded by exon 13 and 14. Huang et al., "The different catalytic roles of the metal-binding ligands in human 4-

20 hydroxyphenylpyruvate dioxygenase" *Biochem J.* 2016;473:1179–89. Thus, frameshift-inducing indels upstream of exon 13 should render the enzyme inactive. This context was used to demonstrate that *Hpd* inactivation by hydrodynamic injection of Nme1Cas9 plasmid is a viable approach to rescue HT-I mice. Nme1Cas9 can edit sites carrying several different PAMs (N<sub>4</sub>GATT [consensus], N<sub>4</sub>GCTT, N<sub>4</sub>GTTT, N<sub>4</sub>GACT, N<sub>4</sub>GATA, N<sub>4</sub>GTCT, and N<sub>4</sub>GACA).

25 *Hpd* editing experiments confirmed one of the variant PAMs in vivo with the sgHpd2 guide, which targets a site with a N<sub>4</sub>GACT PAM.

Although plasmid hydrodynamic injections can generate indels, therapeutic development may require less invasive delivery strategies, such as by using an rAAV. To this end, all-in-one AAV-sgRNA-hNme1Cas9 plasmids were packaged in hepatocyte-tropic AAV8 capsids to target  
 30 *Pcsk9* (sgPcsk9) and *Rosa26* (sgRosa26). See, Figure 49B; Gao et al., "Novel adenoassociated



viruses from rhesus monkeys as vectors for human gene therapy” *Proc Natl Acad Sci U S A* 2002;99:11854–9; and Nakai et al., “Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice” *J Virol*. 2005;79:214–24. *Pcsk9* and *Rosa26* were used in part to enable Nme1Cas9 AAV delivery to be benchmarked with that of other Cas9 orthologs delivered similarly and targeted to the same loci. Ran et al., “In vivo genome editing using *Staphylococcus aureus* Cas9” *Nature* 2015;520:186–91. Vectors were administered into C57BL/6 mice via tail vein. See, Figure 54A. Cholesterol levels were monitored in the serum and measured PCSK9 protein and indel frequencies in the liver tissues 25 and 50 days post injection.

Using a colorimetric endpoint assay, it was determined that the circulating serum cholesterol level in the mice administered Nme1Cas9/sgPcsk9 decreased significantly ( $p < 0.001$ ) compared to the PBS and Nme1Cas9/sgRosa26 mice at 25 and 50 days post injection. See, Figure 54B. Targeted deep-sequencing analyses at *Pcsk9* and *Rosa26* target sites revealed very efficient indels of 35% and 55%, respectively, at 50 days post vector administration. Figure 54C. Additionally, one mouse of each group was euthanized at 14 days post injection and revealed on-target indel efficiencies of 37% and 46% at *Pcsk9* and *Rosa26*, respectively. As expected, PCSK9 protein levels in the livers of Nme1Cas9/sgPcsk9 treated mice were substantially reduced compared to the mice injected with PBS and Nme1Cas9/sgRosa26. See, Figure 54D. The efficient editing, PCSK9 reduction, and diminished serum cholesterol indicate the successful delivery and activity of Nme1Cas9 at the *Pcsk9* locus.

SpyCas9 delivered by viral vectors is known to elicit host immune responses. Chew et al., “A multifunctional AAV-CRISPR-Cas9 and its host response” *Nat Methods* 2016;13:868–74; and Wang et al., “Adenovirus-mediated somatic genome editing of *Pten* by CRISPR/Cas9 in mouse liver in spite of Cas9-specific immune responses” *Hum Gene Ther.* 2015;26:432–42. To investigate if the mice injected with AAV8-sgRNA-hNme1Cas9 generate anti-Nme1Cas9 antibodies, sera was used from the treated animals to perform IgG1 ELISA. These results show that Nme1Cas9 elicits a humoral response in these animals. See, Figure 55. Despite the presence of an immune response, Nme1Cas9 delivered by rAAV is highly functional in vivo, with no apparent signs of abnormalities or liver damage. See, Figure 16.

A significant concern in therapeutic CRISPR/Cas9 genome editing is the possibility of activity at off-target edits. For example, it has been found that wild-type Nme1Cas9 is a

naturally high-accuracy genome editing platform in cultured mammalian cells. Lee et al., “The *Neisseria meningitidis* CRISPR-Cas9 system enables specific genome editing in mammalian cells” *Mol Ther.* 2016;24:645–54. To determine if Nme1Cas9 maintains its minimal off-targeting profile in mouse cells and in vivo, off-target sites were screened in the mouse genome using genome-wide, unbiased identification of DSBs enabled by sequencing (GUIDE-seq). Tsai et al., “Defining and improving the genome-wide specificities of CRISPR-Cas9 nucleases” *Nat Rev Genet.* 2016;17:300–12. Hepa1–6 cells were transfected with sgPcsk9, sgRosa26, sgHpd1, and sgHpd2 all-in-one AAV-sgRNA-hNme1Cas9 plasmids and the resulting genomic DNA was subjected to GUIDE-seq analysis. Consistent with observations in human cells (data not shown), GUIDE-seq revealed very few off-target (OT) sites in the mouse genome. Four potential OT sites were identified for sgPcsk9 and another six for sgRosa26. Off-target edits with sgHpd1 and sgHpd2 were not detected. See, Figure 56A. These data further validate that Nme1Cas9 is intrinsically hyper-accurate.

Several of the putative OT sites for sgPcsk9 and sgRosa26 lack the Nme1Cas9 PAM preferences (i.e., N<sub>4</sub>GATT, N<sub>4</sub>GCTT, N<sub>4</sub>GTTT, N<sub>4</sub>GACT, N<sub>4</sub>GATA, N<sub>4</sub>GTCT, and N<sub>4</sub>GACA). See, Figure 56B. To validate these OT sites, targeted deep sequencing was performed using genomic DNA from Hepa1–6 cells. By this more sensitive readout, indels were undetectable above background at all these OT sites except OT1 of *Pcsk9*, which had an indel frequency < 2%. See, Figure 56B. To validate Nme1Cas9’s high fidelity in vivo, indel formation was measured at these OT sites in liver genomic DNA from the AAV8-Nme1Cas9-treated, sgPcsk9-targeted, and sgRosa26-targeted mice. Little or no detectable off-target editing was found in mice liver sacrificed at 14 days at all sites except sgPcsk9 OT1, which exhibited < 2% lesion efficiency. More importantly, this level of OT editing stayed below < 2% even after 50 days and also remained either undetectable or very low for all other candidate OT sites. These results suggested that extended (50 days) expression of Nme1Cas9 in vivo does not compromise its targeting fidelity. See, Figure 56C.

To achieve targeted delivery of Nme1Cas9 to various tissues in vivo, rAAV vectors are a promising delivery platform due to the compact size of Nme1Cas9 transgene, which allows the delivery of Nme1Cas9 and its guide in an all-in-one format. The data presented herein validates this approach for the targeting of *Pcsk9* and *Rosa26* genes in adult mice, with efficient editing observed even at 14 days post injection. Nme1Cas9 is intrinsically accurate, even without the

extensive engineering that was required to reduce off-targeting by SpyCas9. Lee et al., “The *Neisseria meningitidis* CRISPR-Cas9 system enables specific genome editing in mammalian cells” *Mol Ther.* 2016;24:645–54; Bolukbasi et al., “Creating and evaluating accurate CRISPRCas9 scalpels for genomic surgery” *Nat Methods* 2016;13:41–50; Tsai et al., “Defining  
5 and improving the genome-wide specificities of  
CRISPR-Cas9 nucleases” *Nat Rev Genet.* 2016;17:300–12; and Tycko et al., “Methods for optimizing CRISPR-Cas9 genome editing specificity” *Mol Cell.* 2016;63:355–70.

Side-by-side comparisons of Nme1Cas9 OT editing were performed in cultured cells and in vivo by targeted deep sequencing and found that off-targeting is minimal in both settings.

10 Editing at the sgPcsk9 OT1 site (within an unannotated locus) was the highest detectable at ~ 2%.

#### IV. Small Cas9 Orthologs With Cytosine-Rich PAMs

As noted above, CRISPR systems may be classified into at least six (6) different types.

15 Generally, Type II systems are categorized by the presence of a Cas9 nuclease protein. For example, a Cas9 nuclease protein is believed to be an RNA-guided nuclease that can be repurposed as a genome editing platform in almost all organisms, including humans. Reports have indicated that Cas9 genome editing has been used in medicine, agriculture, human gene therapy and many other applications.

20 Generally, targeting of a specific gene locus in the human genome may be accomplished by a Cas9 nuclease protein bound to a single guide RNA (sgRNA) that targets the locus via an interaction with a specific nucleic acid sequence (e.g., for example, a protospacer adjacent motif; PAM). sgRNA's usually comprise a 20-24 nucleotide segment that is complementary to a target nucleic acid sequence followed by a constant region that interacts (e.g., for example, binds) with  
25 the Cas9 protein. For the Cas9 nuclease protein to perform genome editing, the Cas9:sgRNA complex first recognizes a protospacer adjacent motif (PAM) sequence that is normally found downstream of the target site sequence. Although it is not necessary to understand the mechanism of an invention, it is believed that each Cas9 nuclease protein has affinity for a particular PAM (i.e., mediated by a protospacer adjacent motif recognition domain). In the  
30 absence of the PAM recognition domain binding to a downstream PAM target nucleic acid sequence double-stranded DNA (dsDNA) cannot be cleaved by the Cas9 nuclease.

Reports suggest that only a handful of Cas9 orthologs have been validated for human genome editing. Three of the reported CRISPR-Cas9 types include II-A, II-B and II-C. Type II-A Cas9 (e.g., *Streptococcus pyogenes* (SpyCas9)), is the most commonly used Cas9 to date. However, SpyCas9 (and most other type II-A orthologs) possesses several characteristics that may make it unsuitable for certain applications. First, SpyCas9 is relatively large, making this Cas9 unsuitable for efficient packaging into viral vectors. Second, SpyCas9 has a high rate of off-target activity (i.e. it cleaves DNA at unintended loci in the human genome), although higher-specificity variants have been engineered. Finally, SpyCas9's PAM (e.g., NGG) has limited use in some sites in the human genome, or for applications where a specific nucleotide is to be recognized during editing. To overcome these shortcomings, several groups have repurposed other Cas9 orthologs to function in humans and other organisms. As discussed above, type II-C Cas9 orthologs (e.g., Nme1Cas9) are small enough for all-in-one viral packaging (e.g., adeno-associated virus (AAV) vectors] that results in higher fidelity activity in mammalian cells. However, wild type Cas9 II-C PAMs are usually approximately four (4) nucleotides in length as opposed to an SpyCas9 PAM that is usually two (2) nucleotides in length. This additional PAM length can limit the number of loci that can be targeted by a wild type Cas9 II-C PAM. This creates a need in the art for the identification of more Cas9 orthologs for genome editing.

While there are thousands of Cas9 orthologs in the NCBI database to choose from, an empirical process is required to develop small type II-C Cas9 orthologs with less restrictive PAMs that provide improved functionality in mammalian cells. In one embodiment, the present invention contemplates an improved type II-C Cas9 ortholog that enables precise genome editing with a broader range of target sites. In one embodiment, the improved type II-C Cas9 ortholog has a compact size capable of efficient viral delivery. In one embodiment, the improved type II-C Cas9 ortholog includes, but is not limited to, *Haemophilus parainfluenzae* (HpaCas9), *Simonsiella muelleri* (SmuCas9) and *Neisseria meningitidis strain De10444* (Nme2Cas9).

#### **A. Short PAMs Associated With Type II-C Cas9 Orthologs**

The data presented herein shows the characterization of short PAM targets for several type II-C Cas9 orthologs. Figure 17. For example, type II-C Cas9 orthologs may interact with short PAMs comprising between one – four required nucleotides. Although it is not necessary to understand the mechanism of an invention, it is believed that these short C-rich PAMs provide

improved Cas9 genome editing of target sites previously not accessible even by the more compact Cas9 orthologs (e.g., Nme1Cas9). In one embodiment, an Nme2Cas9 PAM has a sequence of NNNNCc, wherein “c” is the only a partial preference. In one embodiment, an SmuCas9 PAM has a sequence of NNNNCT. Figure 18.

5 It is currently believed that no Cas9 orthologs with short C-rich PAMs have been validated for genome editing and that Nme2Cas9 is particularly compelling as a potential candidate for highly efficient gene editing activity in human cells. In one embodiment, the present invention contemplates an Nme2Cas9 nuclease bound to a wild type Nme1Cas9 sgRNA (e.g., *Neisseria meningitidis* 8013 Cas9; previously referred to as NmeCas9). Nme1Cas9 has  
10 been previously described. Sontheimer et al., “RNA-Directed DNA Cleavage and Gene Editing by Cas9 Enzyme From *Neisseria Meningitidis*” United States Patent Application Publication Number 2014/0349,405 (herein incorporated by reference). Although Nme1Cas9 can be useful for genome editing, its main limitation is its relatively long PAM, which restricts the number of editable sites in any given genomic locus.

15 In some embodiments, the present invention contemplates shorter and less stringent PAMs for type II-C Cas9 orthologs including, but not limited to, Nme2Cas9. Although it is not necessary to understand the mechanism of an invention, it is believed that short and less stringent PAMs partially relieve target restriction limitations, while still leaving many, if not most, of the advantages of Nme1Cas9 including, but not limited to, small size (e.g., compactness) for  
20 efficient all-in-one AAV delivery and improved target accuracy (e.g., reductions in off-target cleavages). In addition, minimized sgRNAs for Nme1Cas9 discussed above are also compatible with Nme2Cas9 constructs. Consequently, such truncated guide RNAs could likely be used for genome editing with Nme2Cas9 as well.

25 In one embodiment, the present invention contemplates an HpaCas9 PAM having a sequence of NNNNGNTTT. Despite the fact that the long PAM limits the number of targetable sites in the human genome it is believed that the HpaCas9 PAM may target sites with very high accuracy that is similar to the extreme accuracy Nme1Cas9 (*supra*).

The data presented herein demonstrates the ability of type II-C Cas9 nucleases targeted to short C-rich PAMs to perform genome editing in human (HEK293T) cells. Certo et al.,  
30 “Tracking genome engineering outcome at individual DNA breakpoints” *Nature Methods* 8:671-676 (2011). For example, HpaCas9 and Nme2Cas9, were shown to provide efficient genome

editing at specific loci demonstrating that they are active in mammalian cells. Figure 19 and Table 2.

Table 2: Representative Type II-C Cas9 Orthologs Target Sequences in The Human Genome

Cas9	Spacer sequence	PAM	Chromosome
Nme2	GAATATCAGGAGACTAGGAAGGAG	GAGGCCTA	19
Hpa	GGACAGGAGTCGCCAGAGGCCGGT	GGTGGATTT	4
Snu	GCACCTGCCTCGTGGAATACGGT	AAACCTAC	Traffic Light Reporter

5

These data show that both Nme2Cas9 and HpaCas9 performed genome editing at comparable levels to the previously validated Nme1Cas9 at the same genomic locus. For SnuCas9, the efficiency of editing is relatively low, though it is significant that the activity is not zero, and efficiency improvements are expected. Nme2Cas9 was then used to test fourteen (14) additional sites in the traffic light reporter (TLR) integrated into the genome of HEK293T cells. In these assays, each site conforms to a PAM template that a “C” is the fifth nucleotide of the PAM region (i.e., NNNNCNNN). Remarkably, all fourteen sites were edited by Nme2Cas9, indicating that this enzyme is consistently active with a variety of guides in mammalian cells. The most successful guide RNAs conform to the NNNNCNNN PAM consensus. Figure 20.

15

Type II-C Cas9 ortholog cleavage was tested for sensitivity to anti-CRISPR proteins. Anti-CRISPR proteins are naturally occurring proteins that can turn Cas9 off when Cas9 activity is no longer desired. The data show that all three Type II-C Cas9 orthologs are inhibited by certain anti-CRISPRs. Figure 21. The controllability of these Cas9 orthologs by anti-CRISPRs could increase their potential utility in genome editing.

20

## **B. Nme2Cas9 Gene Editing**

The data presented herein shows gene editing using the Nme2Cas9-sgRNA complex. The data employs the traffic light reporter (TLR) system to demonstrate that any CC dinucleotide in a gene target sequence can function as a PAM, within the context of an NNNNC sequence (supra). Figure 22. Blue bars are the % of cells that exhibit fluorescence, whereas red bars indicate % editing more accurately based on sequencing (“TIDE analysis”). These data confirm that a dinucleotide is sufficient for Nme2Cas9 PAM binding as opposed to a requirement for a trinucleotide sequence (e.g, the “X” in the sequence NNNNCX). Although it is not necessary

25

to understand the mechanism of an invention, it is believed that this means that Nme2Cas9 editable genomic target sites are at least as frequent as SpyCas9 editable sites, and more frequent than with SauCas9, Nme1Cas9 or CjeCas9 and other current alternatives.

Furthermore, T7E1 assays were employed to analyze editing of native genomic sites (e.g., not an integrated, artificial fluorescent reporter). These data suggest that, in some situations, the second “C” might not even be required. See, Figure 23. Note that target sites DeTS1 and DeTS4, both in the AAVS1 locus, enables editing at target sites with NNNNCA and NNNNCG candidate PAMs, respectively. Several of these Nme2Cas9 target sites are disclosed herein. See, Table 3.

Table 3: Representative PAM Target Sites For Nme2Cas9

Target site name	Target locus	Target Sequence (Spacer-PAM)
Nme2TS1	AAVS1	ATGTGGCTCTGGTCTGGGTACTTTTATCTGTCCCCCTCCACC CCACAGTGGG
Nme2TS4	AAVS1	CAGATAAGGAATCTGCCTAACAGGAGGTGGGGGTTAGACG AATATCAGGAGA
Nme2TS5	AAVS1	GGGGTTAGACGAATATCAGGAGACTAGGAAGGAGGAGGC CTAAGGATGGGGG
Nme2TS6	Chr. 14	CCCACCCGGCGGCGCCTCCTGCAGGGCTGCTCCCCAGCCC AAACCGCCGCG
Nme2TS10	AAVS1	TCCGAGAGCTCAGCTAGTCTTCTTCTCCTCCAACCCGGGCCCT ATGTCCACTTC
Nme2TS11	AAVS1	TGGGTACTTTTATCTGTCCCCCTCCACCCACAGTGGGGCCA CTAGGGACAGG
Nme2TS12	AAVS1	GTAGGGGAGCTGCCCCAAATGAAAGGAGTGAGAGGTGACC CGAATCCACAGGA
Nme2TS13	AAVS1	TAGCACCTCTCCATCCTCTTGCTTTCTTTGCCTGGACACCCC GTTCTCCTGT
Nme2TS14	AAVS1	GTCTCCCTTGCGTCCCGCCCTCCCCTTCTTGTAGGCCTGCATC ATCACCGTTT
Nme2TS15	AAVS1	CCTCACCCAAACCCCATGCCGTGTTCACTCGCTGGGTTCCTT TTTCCTTCTCCT
Nme2TS16	Chr. 14	GCGCAGGACAGGAGTCGCCAGAGGCCGGTGCTGGATTTC TCCCCGCATCTC
Nme2TS17	Chr. 14	CGCGGGGACGCCAGCGGCCGGATATCAGCTGCCACGCCC GCGTGGGCGGA
Nme2TS22	VEGF	GATTCCAATAGATCTGTGTGTCCCTCTCCCCACCCGTCCTT GTCCGGCTCTC
Nme2TS23	VEGF	TGACCCCTGGCCTTCTCCCCGCTCCAACGCCCTCAACCCCA

		CACGCACACAC
Nme2TS24	VEGF	TCCCTCTCCCCACCCCGTCCCTGTCCGGCTCTCCGCCCTTCCCC TGCCCCCTTC
Nme2TS25	VEGF	ACACGCACACACTCACTCACCCACACAGACACACACGTCC TCACTCTCGAAG
Nme2TS26	Chr. 7 (CFTR)	TAAGCACAGTGGGAAGAATTTCATTCTGTCTCAGTTTTCCT GGATTATGCCT
Nme2TS27	Chr. 7 (CFTR)	TTCATTCTGTTCTCAGTTTTCCTGGATTATGCCTGGCACCAT TAAAGAAAAT

Although it is not necessary to understand the mechanism of an invention, it is believed that these data suggest that there may be candidate editing sites in a genome at every 4-8 base pairs, on average. These data also suggest that most Cas9 sgRNAs have some functionality,  
 5 consequently the need for sgRNA screening may be overemphasized in the art.

### C. Rapidly-Evolving PAM-Interacting Domains

*In vivo* applications of CRISPR-Cas9 have the potential to transform many areas of biotechnology and therapeutics. There are thousands of Cas9 orthologs in nature, only a handful  
 10 of which have been validated for *in vivo* genome editing. The Cas9 from *Streptococcus pyogenes* (SpyCas9) has been widely used due to its high efficiency and non-restrictive NGG protospacer adjacent motif (PAM). However, the relatively large size of SpyCas9 restricts its use in *in vivo* therapeutic applications using delivery shuttles with limited packaging capacity such as adeno-associated virus (AAV). Several smaller Cas9 orthologs are known to be active in mammalian  
 15 cells, but they possess more restrictive PAMs that limit target site density. The natural variation in the PAM Interacting Domains (PIDs) of closely related Cas9 orthologs may be taken advantage of to identify a genome editing enzyme that overcomes these limitations. In some embodiments, the present invention contemplates using an Nme2Cas9 complex which is compact, naturally hyper-accurate Cas9 with an N<sub>4</sub>CC PAM. The data presented herein show  
 20 that Nme2Cas9 is a high-fidelity mammalian genome editing platform that affords the same target site density as SpyCas9. Delivery of Nme2Cas9 with its guide RNA via an all-in-one AAV vector leads to efficient genome editing in adult mice, with *Pcsk9* gene targeting in the liver inducing serum cholesterol reduction with no significant off-targeting (*infra*). Nme2Cas9 also provides a unique combination of all-in-one AAV compatibility, natural hyper-accuracy,  
 25 and high target site density for *in vivo* genome editing in mammals.



In addition to target density, minimizing off-target activity (e.g., cleavage at undesired loci) of a Cas9 is highly desirable for its use as a safe therapeutic agent. Wild-type (wt) SpyCas9 possesses a high degree of off-target activity due to its unique hybridization kinetics. (Klein et al, 2018). In particular, questions remain regarding their on-target editing efficiency and these variants do not overcome the above discussed limitations regarding overall size. In contrast, it has been shown herein that embodiments of Nme1Cas9 and CjeCas9 comprise naturally accurate gene editing activity. Although it is not necessary to understand the mechanism of an invention, it is believed that no Cas9 ortholog has been previously reported that: i) is active in human cells; ii) exhibits the exceptionally high target-site density of SpyCas9; iii) is sufficiently compact for all-in-one AAV deliverability; and iv) is naturally hyper-accurate. In one embodiment, the present invention contemplates an Nme2Cas9 as a genome editing platform comprising all of the characteristics described above. For example, Nme2Cas9 comprises a binding site comprising a high affinity for an N<sub>4</sub>CC PAM, is hyper-accurate and functions efficiently in mammalian cells. In one embodiment, Nme2Cas9 is packaged in an all-in-one AAV delivery platform for therapeutic genome editing.

#### 1. Closely-Related Nme1Cas9 Orthologs With Rapidly-Evolving PIDs

It has previously been reported that Nme1Cas9 (from *Neisseria meningitidis* strain 8013) is a small, hyper-accurate Cas9 for *in vivo* genome editing (Amrani et al, 2018). However, Nme1Cas9 binds to a long PAM (N<sub>4</sub>GTTT) which limits its use in certain contexts where a small window can be targeted. PAM recognition by Cas9 occurs predominantly through protein-DNA interaction between the PAM-Interacting Domain (PID) of Cas9 and the nucleotides adjacent to the PAM. PIDs are subject to high selection pressure by phages and other mobile genetic elements (MGEs). For example, anti-CRISPR proteins have been shown to interact with PIDs to inhibit Cas9 (*infra*). This may result in closely-related Cas9 orthologs having PIDs that recognize drastically different PAMs.

Recently, this principle was highlighted using two species of *Geobacillus*. *G. sterothermophilus*'s was determined to comprise a PID specific for a N<sub>4</sub>CRAA PAM but when exchanged for a strain LC300 PID its affinity changed to a N<sub>4</sub>GMAA PAM (Harrington et al, 2017). It was hypothesized that given that *N. meningitidis* strains are highly sequenced, a closely related Cas9 ortholog could be found with rapidly-evolved PIDs that recognize different PAMs. Cas9 orthologs with high sequence identity (>80%) to NmeCas9 strain 8013 were

investigated because this Cas9 has been fully characterized for genome editing, is small and hyper-accurate. Several Cas9 orthologs were identified which differed in their PID amino acid sequences as compared with strain 8013. Figure 34A.

Three distinct groups of Cas9 orthologs were found with drastically different PIDs.

5 Figure 35A. One strain was selected from each PID group, for example, De11444 from group 2 and 98002 from group 3. These two CRISPR loci had intact Cas9 open reading frames and CRISPR arrays with several spacers, which suggest they are active loci. Interestingly, the crRNA and tracrRNA of these CRISPR loci were identical to that of 8013 and can utilize the same sgRNAs. Figure 35B.

10 To test whether these Cas9 orthologs indeed had PIDs with affinity for different PAMs, because of the high sequence identity in the remainder of the protein from these orthologs, the 8013 PID was interchanged with the 98002 PID and the De11444 PID. To identify the PAMs, these protein “chimeras” were recombinantly expressed, purified and used for *in vitro* PAM identification as described previously. Briefly, a DNA fragment comprising a protospacer and a  
15 ten (10) nucleotide randomized sequence downstream was cleaved *in vitro* using recombinant Cas9 and an sgRNA targeting the protospacer. Figure 34B. A G23 nucleotide spacer length was used for the sgRNA, consistent with Nme1Cas9 8013 and other type II-C systems studied. The PAM identification assay revealed that these different Cas9 chimeras had PIDs recognizing different PAMs. For example, by recognizing a C residue at position 5 instead of a G  
20 recognized by Nme1Cas9 8013 with its N<sub>4</sub>GATT PAM. Figure 34C.

However, the remaining nucleotides could not be confidently characterized due to the low cleavage efficiency of the chimeric proteins, which suggests that the few residues outside of the PID are likely involved for efficient activity. Figure 35C. To further resolve the PAMs, an *in vitro* assay was performed on a library with a 7-nucleotide randomized PAM, with a C at  
25 position 5 (e.g., NNNNCNNN). The results suggested that NmeCas9-De11444 and NmeCas9-98002 recognized NNNNCC(A) and NNNNCAAA PAMs, respectively. Figure 35D. NmeCas9-De11444 had a strong preference for the C at position 5, but less so for nucleotides 6 and 7. As used herein, the Cas9 De11444 ortholog is termed “Nme2Cas9”, and the Cas9 98002 ortholog is termed “Nme3Cas9”.

We also performed this assay using full-length (e.g., not PID-swapped) Nme2Cas9 and observed similar results. Figure 34E. These results suggest that Nme2Cas9 and Nme3Cas9 have PIDs recognizing drastically different PAMs than that of Nme1Cas9.

## 2. Nme2Cas9 In Human Cells

Because the Nme2Cas9 PID binds with a small PAM sequence, this ortholog is useful for human genome editing, especially when high-targeting density is involved. To characterize the Nme2Cas9, a full-length (not PID-swapped) humanized Nme2Cas9 was cloned into a CMV-driven plasmid along with NLSs for mammalian expression. For characterization in human cells, a Traffic Light Reporter system was used similar to the one described previously (Certo *et al.*, 2011)

Induction of +1 frameshift indels were created by imperfect repair via non-homologous end joining (NHEJ) in the TLR 2.0 locus. In the absence of a donor DNA an in-frame mCherry protein resulted, which can be quantified through flow cytometry. Figure 36A. As an initial test, a Nme2Cas9 plasmid was transfected along with fifteen (15) sgRNA plasmids with spacers targeting protospacers with N<sub>4</sub>CCX PAMs. As controls, SpyCas9 and Nme1Cas9 were used along with their cognate sgRNAs targeting NGG and N<sub>4</sub>GATT protospacers, respectively. Cells were harvested after seventy-two (72) hours and the number of mCherry positive cells was quantified for each target site. SpyCas9 and Nme1Cas9 showed efficient editing at their respective targets (~28% and 10% mCherry, respectively) Figure 36B. For Nme2Cas9, all fifteen (15) targets with N<sub>4</sub>CCX PAMs were functional to various degrees (ranging from 4% to 20% mCherry), while NmeCas9 treatments without accompanying sgRNA and/or N<sub>4</sub>GATT controls yielded no mCherry cells. Figure 36B. These data suggested that Nme2Cas9 recognizes an N<sub>4</sub>CC PAM in human cells.

To further resolve Nme2Cas9 PAMs, target sites were also tested with N<sub>5</sub>CX and N<sub>4</sub>CD (D = A, T, G) in TLR reporter cells. No detectable editing was observed at target sites with N<sub>5</sub>CX and N<sub>4</sub>CD PAMs, suggesting that both C nucleotides at positions 5 and 6 are required for Nme2Cas9's activity based on the TLR 2.0 reporter. Figures 37A and 37B. These results demonstrate that Nme2Cas9 comprises a PID that binds to an N<sub>4</sub>CC PAM and is consistently functional in mammalian cells at the TLR 2.0 locus.

The length of the spacer portion of the crRNA differs between different Cas9 orthologs. SpyCas9's optimal spacer length is twenty (20) nucleotides, however, truncations down to

seventeen (17) nucleotides are tolerated. Fu et al., Nature Biotechnology 32, 279 (2014). In contrast, Nme1Cas9 comprises sgRNAs with twenty-four (24) nucleotide spacers and tolerates truncations down to eighteen (18) nucleotides. (Amrani et al., 2018). To test the spacer length for Nme2Cas9, sgRNA plasmids were created that targeted the same locus, but with varying  
 5 spacer lengths. Figure 36C and Figure 37B. Comparable activities were observed when G23, G22 and G21 spacers were used, with a significant decrease in activity when the guide was truncated to G20 and G19. Figure 36C. These results suggest that Nme2Cas9's optimal spacer length is between 22-24 nucleotides, similar to that of Nme1Cas9, GeoCas9 and CjeCas9. Therefore, all experiments described below were performed with 23-24 nucleotide spacers.

10 Cas9 orthologs are believed to use their HNH and RuvC domains to induce a double stranded break in the complementary and non-complementary strands of the target DNA, respectively. Alternatively, Cas9 nickases have been used to improve genome editing specificity and homology-directed repair (HDR) by creating overhangs. (Ran et al, 2013). However, this approach has only been successful by use of SpyCas9 due to its high target density. To use  
 15 Nme2Cas9 as a nickase, Nme2Cas9<sup>D16A</sup> and Nme2Cas9<sup>H588A</sup> were created which provide mutations in the catalytic residues of the RuvC and HNH domains, respectively. Since TLR 2.0 can also be used to study the efficiency of HDR, where a repaired locus expresses GFP when a donor is provided, a donor DNA sequence was included to test HDR with these Nme2Cas9 nickases. Target sites were selected within the TLR 2.0 gene to test the functionality of each  
 20 nickase using guide RNAs that targeted cleavage sites spaced 32 bp and 64 bp apart. As a control, wild type Nme2Cas9 targeted to a single site showed efficient editing, accompanied by induction of both NHEJ and HDR repair pathways. For nickases, the cleavage sites spaced 32 bp and 64 bp apart showed editing using the Nme2Cas9<sup>D16A</sup> (HNH nickase), but neither target was nicked using Nme2Cas9<sup>H588A</sup>. Figure 36D.

25 Cas9 orthologs comprise a seed sequence that usually hybridizes to a target sequence between eight to twelve (8-12) nucleotides proximal to the PAM. Mismatches (e.g., non-complementarity) between the seed sequence and the PAM can reduce Cas9 nuclease activity. A series of transient transfections were performed that targeted the same locus in the TLR 2.0 gene by walking single nucleotide mismatches along a twenty-three (23) nucleotide spacer. Figure  
 30 37C. Similar to other Cas9 orthologs, the data suggest that Nme2Cas9 possesses a "seed sequence" in the first eight-to-nine (8-9) nucleotides that hybridize to a target sequence proximal

to the PAM, as deduced from the decrease in the number of mCherry positive cells. Even though tolerance to mismatches is highly dependent on the sequence and the target locus of an sgRNA, these results suggest that Nme2Cas9 has very low tolerance for mismatches particularly in its seed sequence.

### 3. Nme2Cas9 Genome Editing Efficiency

Nme2Cas9 was used to target forty (40) different target sites throughout the human genome in HEK293T cells using transient transfections. Table 4.

Table 4: Representative HEK293T Cell Nme2Cas9 Target Sites

Number	Site Name	Spacer Seq	PAM	Locus	Target Class	Target Primer	FW TIDE score	RV TIDE score
1	T51	GSTTCTGAGTACTTTATCTGTGG	CTTCACG	AAVS1	0.2	AAVS1_TIDE1	75.6CTTACGACTCTTTCAT	AGAACTAGGAGCACTTATTTCG
2	T54	GTCTGCTTACAGAGGCTGGGGGT	TAGACAAA	AAVS1	11	AAVS1_TIDE1	TGCTTACGACTCTTTCAT	AGAACTAGGAGCACTTATTTCG
3	T55	GAATATCAGGAGACTAGGAAGGAG	GAGGCTTA	AAVS1	15	AAVS1_TIDE1	TGCTTACGACTCTTTCAT	AGAACTAGGAGCACTTATTTCG
4	T58	GGCTGCTTGCAGGGCTGCTGCC	GAGGCTTA	LINE1588	20	LINE1588_TIDE	AGAGGAGGCTTGTGACTCTGAGGA	ATGACACACACAACACAGAGGGCA
5	T515	GAGCTAGTCTTCTTCTGCTGAAAGCC	GGGCTTAA	AAVS1	3.5	AAVS1_TIDE1	TGCTTACGACTCTTTCAT	AGAACTAGGAGCACTTATTTCG
6	T511	GATCTGCTCCCTGACCTCAGCT	GGGCTTAA	AAVS1	9	AAVS1_TIDE1	TGCTTACGACTCTTTCAT	AGAACTAGGAGCACTTATTTCG
7	T512	GCCGCAATGAAAGGAGTGAAGG	TGAGCTGA	AAVS1	10	AAVS1_TIDE1	TGCTTACGACTCTTTCAT	TAGGAAAGGAGGAGGCTTAAG
8	T513	GCATGCTCTTGTCTTCTTGTCTG	GACACCTG	AAVS1	2	AAVS1_TIDE1	TGCTTACGACTCTTTCAT	TAGGAAAGGAGGAGGCTTAAG
9	T518	GAGTGGCAGAGGCTGCTGCTGG	ATTTCCTG	LINE1588	26	LINE1588_TIDE	AGAGGAGGCTTGTGACTCTGAGGA	ATGACACACACAACACAGAGGGCA
10	T517	GGCAGGCGCGGATATGAGCTGC	CAGGCTTA	LINE1588	0.2	LINE1588_TIDE	AGAGGAGGCTTGTGACTCTGAGGA	ATGACACACACAACACAGAGGGCA
11	T519	GGAGGGGAGATATTACTATTTC	TTTCTGCT	CYBB	1	NT55_TIDE	TAGAGAACTGGGTATGTC	CCAAATTTCGATGGGATGG
12	T519	GTGAGTGGCTGCTATGAGCTAG	GTATCTGA	CYBB	5	NT55_TIDE	TAGAGAACTGGGTATGTC	CCAAATTTCGATGGGATGG
13	T525	GAGGAGGGAGATATTACTATTTC	CTTTCGCT	CYBB	11.2	NT55_TIDE	TAGAGAACTGGGTATGTC	CCAAATTTCGATGGGATGG
14	T521	GTGAATTCTGATGAGCTAAATTC	CAAGCTTT	CYBB	1	NT55_TIDE	TAGAGAACTGGGTATGTC	CCAAATTTCGATGGGATGG
15	T525	GCTGACTTACCCACACAGACATAC	ACGCTGCT	VEGF_A	15.8	VEGF_TIDE3	GTGATGAGGAGCTGAGTCTGCA	ATGAAATTTCGATGGGATGG
16	T528	GGAAGAAATTCATCTGCTGCTGAG	TTTCTGCT	CFTR	2	CFTR_TIDE1	TGCTTACGACTCTTTCAT	AGAACTAGGAGCACTTATTTCG
17	T527	GCTGATTTTCTGCTGATATGCT	GAGCTGAT	CFTR	4	CFTR_TIDE1	TGCTTACGACTCTTTCAT	AGAACTAGGAGCACTTATTTCG
18	T531	GGCTTGGAGGGGCTGAGAGGGGAG	GGGCTTAA	VEGFA	3	VEGF_TIDE3	GTGATGAGGAGCTGAGTCTGCA	ATGAAATTTCGATGGGATGG
19	T534	GGGCTGGGAGATAGCTGAGGAGG	GGGCTTAA	LINE1588	3	LINE1588_TIDE	AGAGGAGGCTTGTGACTCTGAGGA	ATGACACACACAACACAGAGGGCA
20	T535	GGCTACCGCGGGGCTGCTGCTGC	AGGGTGGG	LINE1588	3	LINE1588_TIDE	AGAGGAGGCTTGTGACTCTGAGGA	ATGACACACACAACACAGAGGGCA
21	T538	GGCTGGGAGCTGATATGCTGAGGCT	TGGGCTTA	LINE1588	3	LINE1588_TIDE	AGAGGAGGCTTGTGACTCTGAGGA	ATGACACACACAACACAGAGGGCA
22	T537	GGCTGGGAGCTGATATGCTGAGGCT	GGGCTTAA	LINE1588	0.5	LINE1588_TIDE	AGAGGAGGCTTGTGACTCTGAGGA	ATGACACACACAACACAGAGGGCA
23	T538	GCTGCTGGGAGGCTGAGGAGGCTGC	GGGCTTAA	LINE1588	2	LINE1588_TIDE	AGAGGAGGCTTGTGACTCTGAGGA	ATGACACACACAACACAGAGGGCA
24	T541	GTGATATTGCTTCTGCTGAGATTG	CTAGCTGA	AGA	3	AGA_TIDE1	GGCTTACGACTCTTTCAT	AGAACTAGGAGCACTTATTTCG
25	T544	GTGAGGTGAATGAGAGGAGGAGG	TCTTGGAG	VEGFA	3	VEGF_TIDE3	GTGATGAGGAGCTGAGTCTGCA	ATGAAATTTCGATGGGATGG
26	T545	GTGCTGAGAGTGAAGGCTGAGGCTTC	TGCGGCTT	VEGFA	7.4	VEGF_TIDE3	GTGATGAGGAGCTGAGTCTGCA	ATGAAATTTCGATGGGATGG
27	T545	GATGCTGAGAGTGAAGGCTGAGGCTTC	GTGCGGCT	VEGFA	3	VEGF_TIDE3	GTGATGAGGAGCTGAGTCTGCA	ATGAAATTTCGATGGGATGG
28	T547	GTGCTGCTGCTTCTGCTGAGGCTTC	GTGCTGCT	VEGFA	22.1	VEGF_TIDE3	GTGATGAGGAGCTGAGTCTGCA	ATGAAATTTCGATGGGATGG
29	T548	GTGAGAGGAGGAGGAGGAGGAGG	GTGCTGCT	VEGFA	3	VEGF_TIDE3	GTGATGAGGAGCTGAGTCTGCA	ATGAAATTTCGATGGGATGG
30	T548	GTGCTGAGAGTGAAGGCTGAGGCTTC	GTGCGGCT	VEGFA	4	VEGF_TIDE3	GTGATGAGGAGCTGAGTCTGCA	ATGAAATTTCGATGGGATGG
31	T550	GTGAGGCTGAGGATATTGCTGAGG	AATTGCTA	AGA	3	AGA_TIDE1	GGCTTACGACTCTTTCAT	AGAACTAGGAGCACTTATTTCG
32	T551	GATATTTTGGCTGGCAATTCTGAG	CAAGCTTA	AGA	4.5	AGA_TIDE1	GGCTTACGACTCTTTCAT	AGAACTAGGAGCACTTATTTCG
33	T552 (DS1)	GAGGAGGCTGAGGCTTCTGCTG	GGGCTTAA	VEGFA	5	VEGF_TIDE3	GTGATGAGGAGCTGAGTCTGCA	ATGAAATTTCGATGGGATGG
34	T552 (DS12)	GAGGAGGCTGAGGCTTCTGCTG	GGGCTTAA	VEGFA	11.5	VEGF_TIDE3	GTGATGAGGAGCTGAGTCTGCA	ATGAAATTTCGATGGGATGG
35	T552 (DS13)	GAGGAGGCTGAGGCTTCTGCTG	GGGCTTAA	VEGFA	3	VEGF_TIDE3	GTGATGAGGAGCTGAGTCTGCA	ATGAAATTTCGATGGGATGG
36	T551 (DS14)	GTGAGGAGGCTGAGGCTTCTGCTG	GGGCTTAA	VEGFA	3.5	VEGF_TIDE3	GTGATGAGGAGCTGAGTCTGCA	ATGAAATTTCGATGGGATGG
37	T562 (DS15)	GTGAGGAGGCTGAGGCTTCTGCTG	GGGCTTAA	VEGFA	3.4	VEGF_TIDE3	GTGATGAGGAGCTGAGTCTGCA	ATGAAATTTCGATGGGATGG
38	T563 (DS16)	GATGAGGAGGCTGAGGCTTCTGCTG	AGGCTTAA	VEGFA	16	VEGF_TIDE3	GTGATGAGGAGCTGAGTCTGCA	ATGAAATTTCGATGGGATGG
39	T564	GAGGAGGCTGAGGCTTCTGCTG	AGGCTTAA	FANCL	7	FANCL_TIDE1	GTGATGAGGAGCTGAGTCTGCA	ATGAAATTTCGATGGGATGG
40	T565	GAGGAGGCTGAGGCTTCTGCTG	AGGCTTAA	FANCL	5	FANCL_TIDE1	GTGATGAGGAGCTGAGTCTGCA	ATGAAATTTCGATGGGATGG

72-hours post transfection, cells were harvested followed by gDNA extraction and selective amplification of the targeted locus. A Tracking of Indels by Decomposition (TIDE) analysis was used to measure indel rates at each locus. Efficient editing by Nme2Cas9 was observed, even though indel rates varied significantly depending on the target sequence and the locus. Figure 38A. Moreover, Nme2Cas9's affinity for target sites near/at therapeutically-relevant loci such as *CYBB* (mutations cause x-linked chronic granulomatous disease) and *AGA* (mutations cause

aspartylglycosaminuria) suggests Nme2Cas9 has therapeutic potential. In addition, editing efficiency could be increased by increasing the quantity of the Nme2Cas9 plasmid. Figure 39A. Taken together, these results demonstrate that Nme2Cas9 can be constructed to selectively edit specific target genomic sites in HEK293T cells.

5 In addition to HEK293T cells, Nme2Cas9's gene editing efficiency was determined in several other mammalian cells, including human leukemia K562 cells, human osteosarcoma U2OS cells and mouse liver hepatoma Hepa1-6 cells. A lentiviral construct expressing Nme2Cas9 was created and transduced K562 cells to stably express Nme2Cas9 under the control of SFFV promoter. This stable cell line did not show any significant differences with respect to  
10 growth and morphology as compared to untreated cells, suggesting Nme2Cas9 is not toxic when stably expressed. These cells were transiently electroporated with plasmids expressing sgRNAs targeting several target sites and analyzed after seventy-two (72) hours for indel rates by TIDE. Efficient editing was observed at the three sites tested, demonstrating Nme2Cas9's ability to function in K562 cells. For Hepa1-6 cells, plasmids encoding Nme2Cas9 and sgRNA were co-  
15 transfected using techniques similar to HEK293T transduction described above. These data also show that Nme2Cas9 efficiently edited *Pcsk9* and *Rosa26* sites in this mouse cell line. Figure 38B.

Previous work suggests that ribonucleoprotein (RNP) delivery of Cas9s, instead of plasmid transfection, may be an alternative choice for some genome editing applications. For  
20 example, off-target effects of SpyCas9 may be significantly reduced with RNP electroporations compared to plasmid delivery. Kim et al., *Genome Research* 24:1012-1019 (2014). To test whether Nme2Cas9 is functional by RNP delivery, a His-tagged Nme2Cas9 was cloned along with three (3) nuclear localization signals (NLSs) and a purified recombinant protein into a bacterial expression construct. sgRNAs targeting several validated target sites were generated by  
25 T7 *in vitro* transcription. Electroporation of a Nme2Cas9:sgRNA complex induced successful editing at the target sites, as detected by TIDE. Figure 38C. These results suggest that Nme2Cas9 can be delivered as a plasmid, or as an RNP complex. Overall, these results demonstrate that Nme2Cas9 is functional in various cell types with different modes of delivery.

#### 4. Anti-CRISPR Protein Inhibition

30 Five (5) anti-CRISPR (Acr) protein families against Nme1Cas9 from diverse bacterial species have been reported to inhibit Nme1Cas9 *in vitro* and in human cells. (Pawluk et al. 2016,

Lee et al., *mBio*, in press). Considering the high sequence identity between Nme1Cas9 and Nme2Cas9, it seemed likely that at least some species within these Acr families might also inhibit Nme2Cas9. All five Acr families were recombinantly expressed, purified and Nme2Cas9's ability to cleave a target sequence *in vitro* was tested (10:1 Acr:Cas9 molar ratio).  
 5 As a negative control, an inhibitor for the type I-E CRISPR system in *E. coli* (AcrE2) was used. As expected, all Acr families inhibited Nme1Cas9, while AcrE2 failed to do so. In particular, Acrs IIC1<sub>Nme</sub>, -IIC2<sub>Nme</sub>, -IIC3<sub>Nme</sub> and -IIC4<sub>Hpa</sub> inhibited Nme2Cas9 gene editing activity. Figure 40A, top.

Strikingly, AcrIIC5<sub>Smu</sub> did not inhibit Nme2Cas9 *in vitro* even at 10-fold excess, suggesting that it likely inhibits Nme1Cas9 by interacting with a PID. To further confirm this,  
 10 the same *in vitro* cleavage assay was performed using a hybrid version of NmeCas9 (e.g., Nme1Cas9 with the PID of Nme2Cas9). Due to the reduced activity of this hybrid, higher concentration (~30X) of Cas9 was used to achieve similar cleavage profile while maintaining the 10:1 Cas9:Acr molar ratio. Consistent with the initial results, no inhibition by AcrIIC5<sub>Smu</sub> on  
 15 this protein chimera was observed. Figure 41.. The inability of AcrIIC5<sub>Smu</sub> to inhibit the hybrid protein further suggests that AcrIIC5<sub>Smu</sub> likely interacts with the PID of Nme1Cas9.

The above *in vitro* data, suggested that Acrs -IIC1<sub>Nme</sub>, -IIC2<sub>Nme</sub>, -IIC3<sub>Nme</sub> and -IIC4<sub>Hpa</sub> could be used as off-switches for Nme2Cas9 genome editing. To test this, transfections were performed as described above in the presence or absence of plasmids encoding Acrs driven by  
 20 mammalian promoters. Approximately 150 ng of each plasmid (e.g., having a 1:1:1 ratio of sgRNA:Cas9:Acr) was transfected, as most ACRs have been reported to inhibit Nme1Cas9 at those ratios. (Pawluk et al., 2016). As expected from the *in vitro* experiment, AcrIIC1<sub>Nme</sub>, -IIC2<sub>Nme</sub>, -IIC3<sub>Nme</sub> and -IIC4<sub>Hpa</sub> inhibited Nme2Cas9 genome editing, while AcrIIC5<sub>Smu</sub> failed to do so. (Figure 40B. Moreover, complete inhibition was observed to be below detection levels by  
 25 Acr3<sub>Nme</sub> and Acr4<sub>Hpa</sub>, suggesting their high potency as compared to AcrsIIC1<sub>Nme</sub> and AcrIIC2<sub>Nme</sub>. To further compare the potency of AcrIIC1<sub>Nme</sub> and AcrIIC4<sub>Hpa</sub>, experiments were performed at various ratios of Acr to Cas9. Figure 40C. Consequently, AcrIIC4<sub>Hpa</sub> is a highly potent inhibitor against Nme2Cas9, with concentrations as low as 25ng:100ng Acr:Cas9 inhibiting Nme2Cas9 by 4 fold. Together, these data suggest that Acr proteins can be used as  
 30 off-switches for Nme2Cas9-based applications.

## 5. Nme2Cas9 Hyper-Accuracy

Off-target effects could potentially confound therapeutic applications during *ex vivo* and *in vivo* human gene therapy by creating unintended mutations. Since wildtype SpyCas9 has a relatively high number of off-target sites in human cells, there have been several efforts to engineer high-fidelity SpyCas9 variants with variable success. In contrast, Nme1Cas9 is naturally hyper-accurate, demonstrating remarkable fidelity in cells and mouse models. Previous work shows that hybridization kinetics, which is not determined by the PAM, may determine the fidelity of a Cas9, therefore suggesting that Nme2Cas9 may also be hyper-accurate.

To empirically assess NmeCas9 off-target profiles, Genome-Wide, Unbiased Identification of double-stranded breaks Enabled by Sequencing (GUIDE-Seq) techniques were used to determine potential off-target sites in an unbiased fashion. GUIDE-Seq relies on the incorporation of double-stranded oligodeoxynucleotides (dsODNs) into DNA double-stranded break sites throughout the genome. These cleavage sites are detected by amplification and high-throughput sequencing.

As a benchmark for GUIDE-Seq, wildtype SpyCas9 was used. In particular, SpyCas9 and Nme2Cas9 were able to be cloned into identical backbones driven by the same promoter, and used to target the same sites because of their non-overlapping PAMs. This technique allows side-by-side comparison the two nucleases. Six (6) dual sites (DS) were targeted in *VEGFA* with a NGGNCCN sequence. Figure 42A. Seventy-two (72) hours after transfection, TIDE analysis was performed on the target sites. Nme2Cas9 induced indels at all six (6) sites, albeit at low efficiencies at two of them, while SpyCas9 induced indels at 4/6 sites. Figure 42B. On two of those 4 sites (DS1 and DS4), SpyCas9 induced ~7 fold more indels than Nme2Cas9, while Nme2Cas9 induced by ~3 folds increase in indels at DS6. For GUIDE-seq, targets DS2, DS4 and DS6 were selected to determine off-target cleavage at sites where Nme2Cas9 is as efficient, less efficient or more efficient than SpyCas9, respectively.

In addition to the three dual target sites, a TS6 target site with a 30-50% indel rate (depending on the cell type) along with the mouse *Pcsk9* and *Rosa26* genes were subjected to GUIDE-Seq analysis. It was considered that the off-target profiles would be more prominent because the TS6 target is known to undergo highly efficient gene editing. In addition, testing of the mouse *Pcsk9* and *Rosa26* sites would then reveal the fidelity of Nme2Cas9 in a different cell line, and candidate loci for *in vivo* genome editing. Consequently, transfections



were performed for each Cas9 along with their cognate sgRNAs and the dsODNs and GUIDE-Seq libraries were prepared. GUIDE-Seq analysis demonstrated efficient on-target editing with both Cas9 orthologs with similar patterns observed by TIDE. For off-target identification, the analysis revealed that while the three SpyCas9 sites had the expected high number of off-target sites (e.g., ranging between approximately between 10 - 1000). Nme2Cas9 had a strikingly clean off-target profile. Specifically, Nme2Cas9 targeting the same dual site showed, at most, one off-target site. See, Figure 42C.

To validate the off-target sites detected by GUIDE-seq, targeted deep sequencing was performed to measure indel formation at the top off-target loci following GUIDE-seq-independent editing (i.e. without co-transfection of the dsODN). While SpyCas9 showed considerable editing at most off-target sites tested (in some instances, more efficient than that at the corresponding on-target site), Nme2Cas9 exhibited no detectable indels at the lone DS2 and DS6 candidate off-target sites. With the Rosa26 sgRNA, Nme2Cas9 induced ~1% editing at the Rosa26-OT1 site in Hepa1-6 cells, compared to ~30% on-target editing. Figure 42D.

Next, to enable the use of SpyCas9 as a benchmark for GUIDE-seq, due to the fact that SpyCas9 and Nme2Cas9 have non-overlapping PAMs they can therefore potentially edit any dual site (DS) flanked by a 5'-NGGNCC-3' sequence, which simultaneously fulfills the PAM requirements of both Cas9's binding properties. This enables side-by-side comparisons of off-targeting with sgRNAs that bind the exact same on-target site. Using matched plasmids expressing each Cas9 and their respective sgRNAs, twenty-eight (28) DSs were targeted at multiple loci throughout the human genome. Seventy-two (72) hours after plasmid delivery, a TIDE analysis was performed on the sites targeted by each nuclease. Nme2Cas9 induced indels at nineteen (19) target sites, albeit at low efficiencies (<5%) at four of them, while SpyCas9 induced indels at twenty-three (23) of the target sites, in one case with <5% efficiency. Three dual target sites were recalcitrant to editing by both nucleases. While SpyCas9 is clearly more efficient overall, both enzymes have similar efficiencies at many of the sites, and at two of the seventeen sites that were edited by both nucleases, Nme2Cas9 was more efficient under these conditions. See, Figure 42E.

It is noteworthy that this off-target site has a consensus Nme2Cas9 PAM (ACTCCCT) with only 3 mismatches at the PAM-distal end of the guide-complementary region (i.e. outside of

the seed). See, Figure 42F. These data support and reinforce our GUIDE-seq results indicating a high degree of accuracy for Nme2Cas9 genome editing in mammalian cells.

On- vs. off-target on these sides were compared by targeted amplification of each locus followed by TIDE analysis. Figure 43A. Interestingly, no indels could be detected at those off-target sites for either sgRNA by TIDE, while efficient on-target editing was observed.

Furthermore, the read counts for these off-targets were negligible as compared to those observed in the case of SpyCas9 suggesting Nme2Cas9 is highly specific. (Figure 43C, left versus right, respectively). To further corroborate these GUIDE-Seq results, CRISPRseek was used to computationally predict potential off-target sites for two of the most active sgRNAs with highly similar sites in the genome. (Zhu et al., 2014). These were performed with N<sub>4</sub>CX PAMs and 2-5 mismatches, mostly in the PAM-distal region. Figure 43D. Taken together, these data suggest that Nme2Cas9 is a high-fidelity nuclease in mammalian cells.

## 6. Clinical Applications

In one embodiment, the present invention contemplates an Nme2Cas9 complex as the first compact, hyper-accurate Cas9 with a small non-restrictive PAM for therapeutic genome editing by AAV delivery. Although small, previously reported hyper-accurate Cas9 orthologs have longer PAMs than those disclosed herein, thereby restricting their therapeutic use due to limited target sites in a given gene (and off-target profile in the case of SauCas9). This disadvantage is exacerbated in loci where only a specific window can be targeted, or a precise block deletion is required.

The all-in-one AAV delivery platform established herein can be used to target any gene in any tissue. Moreover, Nme2Cas9's hyper-accuracy enables precise editing of the target genes, therefore ameliorating safety concerns raised due to off-target activities previously observed. To this end, Nme2Cas9 has the potential to not only complement existing tools, but to become a preferred choice for therapeutic genome editing by viral delivery.

Furthermore, inhibition of Nme2Cas9 by various Acrs suggest a possible evolutionary pressure imposed on Cas9 to rapidly evolve a particular domain. Specifically, the lack of inhibition of Nme2Cas9 by AcrIIC5<sub>S<sub>mu</sub></sub> raises the possibility that its mechanism of inhibition is through a PID. Considering that AcrIIC5<sub>S<sub>mu</sub></sub> is the most potent inhibitor of Nme1Cas9 to date, it is contemplated herein where AcrIIC5<sub>S<sub>mu</sub></sub> can be used to robustly turn off Nme1Cas9 but not

Nme2Cas9. This is of particular interest in cellular contexts where multiplexing would be enhanced by the ability to control a specific ortholog.

Finally, while there are thousands of Cas9 orthologs in the public database, only a handful of which have been characterized. Some embodiments contemplated herein take advantage of the natural variation in closely-related Cas9 orthologs to create two novel Cas9 nucleases, namely Nme2Cas9 and Nme3Cas9, with N4CC and N4CAA PAMs, respectively. The data presented herein demonstrate that even closely related orthologs can have vastly different properties. For example, these orthologs use the exact same sgRNA as Nme1Cas9, which circumvent the difficulties in the prediction of tracrRNAs and determining the right spacer length for each ortholog. Furthermore, it is likely that shorter and more stable sgRNAs (such as chemical modifications) can be engineered to expand to all three nucleases. These characteristics may ease genome editing efforts and reduce the costs associated with protein and RNA engineering.

It should be apparent to one of skill in the art that the embodiments described herein are not restricted to Cas9s and can be applied to other Cas proteins such as Cas12 and Cas13. It should also be appreciated that Cas9's hyper-variability is not restricted to PIDs. It is considered herein that strains exist which share high degree of homology with a given Cas9 but differ in other domains due to other types of selective pressure. Taken together, Nme2Cas9 is a novel nuclease which improves the current CRISPR platforms for therapeutic genome editing.

## **V. Nucleotide Delivery Platforms**

Aside from the above described AAV nucleotide delivery systems, the present invention contemplates several delivery systems compatible with nucleic acids that provide for roughly uniform distribution and have controllable rates of release. Some embodiments of the present invention contemplate nucleic acid delivery systems encoding Type II-C Cas9-sgRNA complexes as described herein.

A variety of different media are described below that are useful in creating nucleic acid delivery systems. It is not intended that any one medium or carrier is limiting to the present invention. Note that any medium or carrier may be combined with another medium or carrier; for example, in one embodiment a polymer microparticle carrier attached to a compound may be combined with a gel medium.

Carriers or mediums contemplated by this invention comprise a material selected from the group comprising gelatin, collagen, cellulose esters, dextran sulfate, pentosan polysulfate, chitin, saccharides, albumin, fibrin sealants, synthetic polyvinyl pyrrolidone, polyethylene oxide, polypropylene oxide, block polymers of polyethylene oxide and polypropylene oxide, polyethylene glycol, acrylates, acrylamides, methacrylates including, but not limited to, 2-hydroxyethyl methacrylate, poly(ortho esters), cyanoacrylates, gelatin-resorcin-aldehyde type bioadhesives, polyacrylic acid and copolymers and block copolymers thereof.

#### Microparticles

One embodiment of the present invention contemplates a nucleic acid delivery system comprising a microparticle. Preferably, microparticles comprise liposomes, nanoparticles, microspheres, nanospheres, microcapsules, and nanocapsules. Preferably, some microparticles contemplated by the present invention comprise poly(lactide-co-glycolide), aliphatic polyesters including, but not limited to, poly-glycolic acid and poly-lactic acid, hyaluronic acid, modified polysaccharides, chitosan, cellulose, dextran, polyurethanes, polyacrylic acids, pseudo-poly(amino acids), polyhydroxybutrate-related copolymers, polyanhydrides, polymethylmethacrylate, poly(ethylene oxide), lecithin and phospholipids.

#### Liposomes

One embodiment of the present invention contemplates liposomes capable of attaching and releasing nucleic acids as described herein. Liposomes are microscopic spherical lipid bilayers surrounding an aqueous core that are made from amphiphilic molecules such as phospholipids. For example, a liposome may trap a nucleic acid between the hydrophobic tails of the phospholipid micelle. Water soluble agents can be entrapped in the core and lipid-soluble agents can be dissolved in the shell-like bilayer. Liposomes have a special characteristic in that they enable water soluble and water insoluble chemicals to be used together in a medium without the use of surfactants or other emulsifiers. Liposomes can form spontaneously by forcefully mixing phospholipids in aqueous media. Water soluble compounds are dissolved in an aqueous solution capable of hydrating phospholipids. Upon formation of the liposomes, therefore, these compounds are trapped within the aqueous liposomal center. The liposome wall, being a phospholipid membrane, holds fat soluble materials such as oils. Liposomes provide controlled release of incorporated compounds. In addition, liposomes can be coated with water soluble

polymers, such as polyethylene glycol to increase the pharmacokinetic half-life. One embodiment of the present invention contemplates an ultra high-shear technology to refine liposome production, resulting in stable, unilamellar (single layer) liposomes having specifically designed structural characteristics. These unique properties of liposomes, allow the simultaneous storage of normally immiscible compounds and the capability of their controlled release.

In some embodiments, the present invention contemplates cationic and anionic liposomes, as well as liposomes having neutral lipids. Preferably, cationic liposomes comprise negatively-charged materials by mixing the materials and fatty acid liposomal components and allowing them to charge-associate. Clearly, the choice of a cationic or anionic liposome depends upon the desired pH of the final liposome mixture. Examples of cationic liposomes include lipofectin, lipofectamine, and lipofectace.

One embodiment of the present invention contemplates a nucleic acid delivery system comprising liposomes that provides controlled release of at least one nucleic acid. Preferably, liposomes that are capable of controlled release: i) are biodegradable and non-toxic; ii) carry both water and oil soluble compounds; iii) solubilize recalcitrant compounds; iv) prevent compound oxidation; v) promote protein stabilization; vi) control hydration; vii) control compound release by variations in bilayer composition such as, but not limited to, fatty acid chain length, fatty acid lipid composition, relative amounts of saturated and unsaturated fatty acids, and physical configuration; viii) have solvent dependency; iv) have pH-dependency and v) have temperature dependency.

The compositions of liposomes are broadly categorized into two classifications. Conventional liposomes are generally mixtures of stabilized natural lecithin (PC) that may comprise synthetic identical-chain phospholipids that may or may not contain glycolipids. Special liposomes may comprise: i) bipolar fatty acids; ii) the ability to attach antibodies for tissue-targeted therapies; iii) coated with materials such as, but not limited to lipoprotein and carbohydrate; iv) multiple encapsulation and v) emulsion compatibility.

Liposomes may be easily made in the laboratory by methods such as, but not limited to, sonication and vibration. Alternatively, compound-delivery liposomes are commercially available. For example, Collaborative Laboratories, Inc. are known to manufacture custom designed liposomes for specific delivery requirements.

### Microspheres, Microparticles And Microcapsules

Microspheres and microcapsules are useful due to their ability to maintain a generally uniform distribution, provide stable controlled compound release and are economical to produce and dispense. Preferably, an associated delivery gel or the compound-impregnated gel is clear or, alternatively, said gel is colored for easy visualization by medical personnel.

Microspheres are obtainable commercially (Prolease®, Alkerme's: Cambridge, Mass.). For example, a freeze dried medium comprising at least one therapeutic agent is homogenized in a suitable solvent and sprayed to manufacture microspheres in the range of 20 to 90 µm. Techniques are then followed that maintain sustained release integrity during phases of purification, encapsulation and storage. Scott et al., Improving Protein Therapeutics With Sustained Release Formulations, Nature Biotechnology, Volume 16:153-157 (1998).

Modification of the microsphere composition by the use of biodegradable polymers can provide an ability to control the rate of nucleic acid release. Miller et al., Degradation Rates of Oral Resorbable Implants {Polylactates and Polyglycolates: Rate Modification and Changes in PLA/PGA Copolymer Ratios, J. Biomed. Mater. Res., Vol. II:711-719 (1977).

Alternatively, a sustained or controlled release microsphere preparation is prepared using an in-water drying method, where an organic solvent solution of a biodegradable polymer metal salt is first prepared. Subsequently, a dissolved or dispersed medium of a nucleic acid is added to the biodegradable polymer metal salt solution. The weight ratio of a nucleic acid to the biodegradable polymer metal salt may for example be about 1:100000 to about 1:1, preferably about 1:20000 to about 1:500 and more preferably about 1:10000 to about 1:500. Next, the organic solvent solution containing the biodegradable polymer metal salt and nucleic acid is poured into an aqueous phase to prepare an oil/water emulsion. The solvent in the oil phase is then evaporated off to provide microspheres. Finally, these microspheres are then recovered, washed and lyophilized. Thereafter, the microspheres may be heated under reduced pressure to remove the residual water and organic solvent.

Other methods useful in producing microspheres that are compatible with a biodegradable polymer metal salt and nucleic acid mixture are: i) phase separation during a gradual addition of a coacervating agent; ii) an in-water drying method or phase separation method, where an antiflocculant is added to prevent particle agglomeration and iii) by a spray-drying method.

In one embodiment, the present invention contemplates a medium comprising a microsphere or microcapsule capable of delivering a controlled release of a nucleic acid for a duration of approximately between 1 day and 6 months. In one embodiment, the microsphere or microparticle may be colored to allow the medical practitioner the ability to see the medium  
5 clearly as it is dispensed. In another embodiment, the microsphere or microcapsule may be clear. In another embodiment, the microsphere or microparticle is impregnated with a radio-opaque fluoroscopic dye.

Controlled release microcapsules may be produced by using known encapsulation techniques such as centrifugal extrusion, pan coating and air suspension. Such microspheres  
10 and/or microcapsules can be engineered to achieve desired release rates. For example, Oliosphere<sup>®</sup> (Macromed) is a controlled release microsphere system. These particular microsphere's are available in uniform sizes ranging between 5 - 500  $\mu\text{m}$  and composed of biocompatible and biodegradable polymers. Specific polymer compositions of a microsphere can control the nucleic acid release rate such that custom-designed microspheres are possible,  
15 including effective management of the burst effect. ProMaxx<sup>®</sup> (Epic Therapeutics, Inc.) is a protein-matrix delivery system. The system is aqueous in nature and is adaptable to standard pharmaceutical delivery models. In particular, ProMaxx<sup>®</sup> are bioerodible protein microspheres that deliver both small and macromolecular drugs, and may be customized regarding both microsphere size and desired release characteristics.

In one embodiment, a microsphere or microparticle comprises a pH sensitive encapsulation material that is stable at a pH less than the pH of the internal mesentery. The  
20 typical range in the internal mesentery is pH 7.6 to pH 7.2. Consequently, the microcapsules should be maintained at a pH of less than 7. However, if pH variability is expected, the pH sensitive material can be selected based on the different pH criteria needed for the dissolution of  
25 the microcapsules. The encapsulated nucleic acid, therefore, will be selected for the pH environment in which dissolution is desired and stored in a pH preselected to maintain stability. Examples of pH sensitive material useful as encapsulants are Eudragit<sup>®</sup> L-100 or S-100 (Rohm GMBH), hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, polyvinyl acetate phthalate, cellulose acetate phthalate, and cellulose acetate  
30 trimellitate. In one embodiment, lipids comprise the inner coating of the microcapsules. In these compositions, these lipids may be, but are not limited to, partial esters of fatty acids and hexitol

anhydrides, and edible fats such as triglycerides. Lew C. W., Controlled-Release pH Sensitive Capsule And Adhesive System And Method. United States Patent No. 5,364,634 (herein incorporated by reference).

5 In one embodiment, the present invention contemplates a microparticle comprising a gelatin, or other polymeric cation having a similar charge density to gelatin (i.e., poly-L-lysine) and is used as a complex to form a primary microparticle. A primary microparticle is produced as a mixture of the following composition: i) Gelatin (60 bloom, type A from porcine skin), ii) chondroitin 4-sulfate (0.005% - 0.1%), iii) glutaraldehyde (25%, grade 1), and iv) 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC hydrochloride), and ultra-pure sucrose  
10 (Sigma Chemical Co., St. Louis, Mo.). The source of gelatin is not thought to be critical; it can be from bovine, porcine, human, or other animal source. Typically, the polymeric cation is between 19,000-30,000 daltons. Chondroitin sulfate is then added to the complex with sodium sulfate, or ethanol as a coacervation agent.

15 Following the formation of a microparticle, a nucleic acid is directly bound to the surface of the microparticle or is indirectly attached using a "bridge" or "spacer". The amino groups of the gelatin lysine groups are easily derivatized to provide sites for direct coupling of a compound. Alternatively, spacers (i.e., linking molecules and derivatizing moieties on targeting ligands) such as avidin-biotin are also useful to indirectly couple targeting ligands to the microparticles. Stability of the microparticle is controlled by the amount of glutaraldehyde-spacer crosslinking induced by the EDC hydrochloride. A controlled release medium is also  
20 empirically determined by the final density of glutaraldehyde-spacer crosslinks.

In one embodiment, the present invention contemplates microparticles formed by spray-drying a composition comprising fibrinogen or thrombin with a nucleic acid. Preferably, these microparticles are soluble and the selected protein (i.e., fibrinogen or thrombin) creates the walls  
25 of the microparticles. Consequently, the nucleic acids are incorporated within, and between, the protein walls of the microparticle. Heath et al., Microparticles And Their Use In Wound Therapy. United States Patent No. 6,113,948 (herein incorporated by reference). Following the application of the microparticles to living tissue, the subsequent reaction between the fibrinogen and thrombin creates a tissue sealant thereby releasing the incorporated compound into the  
30 immediate surrounding area.



One having skill in the art will understand that the shape of the microspheres need not be exactly spherical; only as very small particles capable of being sprayed or spread into or onto a surgical site (i.e., either open or closed). In one embodiment, microparticles are comprised of a biocompatible and/or biodegradable material selected from the group consisting of polylactide, polyglycolide and copolymers of lactide/glycolide (PLGA), hyaluronic acid, modified polysaccharides and any other well known material.

## Experimental

### Example I

#### Construction Of All-In-One sgRNA-Nme1Cas9-AAV Vector Plasmid

Bacterial Nme1Cas9 gene has been codon-optimized for expression in humans, and cloned into an AAV2 plasmid under U1a ubiquitous promoter. Guide RNA is under U6 promoter. The *cas9* gene contains four nuclear localization signals and three HA tag sequences in tandem. Spacer sequences were inserted into the crRNA cassette by digesting the plasmid with SapI restriction enzyme using annealed synthetic oligonucleotides to generate a duplex with overhangs compatible with those generated by SapI digested backbone.

The human-codon optimized Nme1Cas9 gene under the control of the U1a promoter and a sgRNA cassette driven by the U6 promoter were cloned into an AAV2 plasmid backbone. The NmeCas9 ORF was flanked by four nuclear localization signals – two on each terminus – in addition to a triple-HA epitope tag. This plasmid is available through Addgene (plasmid ID 112139). See, Figure 64. Oligonucleotides with spacer sequences targeting *Hpd*, *Pcsk9*, and *Rosa26* were inserted into the sgRNA cassette by ligation into a SapI cloning site.

AAV vector production was performed at the Horae Gene Therapy Center at the University of Massachusetts Medical School. Briefly, plasmids were packaged in AAV8 capsids by triple-plasmid transfection in HEK293 cells and purified by sedimentation as previously described. Gao et al., “Introducing genes into mammalian cells: viral vectors” In: Green MR, Sambrook J, editors. Molecular cloning: a laboratory manual. Volume 2. 4th ed. New York: Cold Spring Harbor Laboratory Press; 2012. p. 1209–13. The off-target profiles of these spacers were predicted computationally using the Bioconductor package CRISPRseek. Search parameters were adapted to Nme1Cas9 settings: gRNA.size = 24, PAM= “NNNNGATT,” PAM.- size = 8,

RNA.PAM.pattern = "NNNNGNNN\$", weights = c(0, 0, 0, 0, 0, 0, 0.014, 0, 0, 0.395, 0.317, 0, 0.389, 0.079, 0.445, 0.508, 0.613, 0.851, 0.732, 0.828, 0.615, 0.804, 0.685, 0.583),  
max.mismatch = 6, allowed.mismatch.PAM= 7, topN = 10,000, min.score = 0.

5

## Example II

### Cell Culture And Transfection

Mouse Hepa1-6 hepatoma cells were cultured in DMEM with 10% FBS and 1% Penicillin/Streptomycin (Gibco) in a 37°C incubator with 5% CO<sub>2</sub>. Human HEK293T cells and PLB985 cells were cultured in DMEM and RPMI media respectively. Both were supplemented with 10% FBS and 1% Penicillin/Streptomycin (Gibco). Transient transfections of Hepa 1-6 cells were performed using Lipofectamine LTX whereas Polyfect transfection reagent (Qiagen) was used for HEK293T cells. For transient transfection, approximately 1x10<sup>5</sup> cells per well were cultured in 24-well plate 24 hours before transfection. Each well was transfected with 500ng all-in-one sgRNA-Nme1Cas9-AAV plasmids, using Lipofectamine LTX with Plus Reagent (ThermoFisher) according to the manufacturer's protocol. HEK293T cells were transfected with 400 ng of all-in-one plasmid expressing Nme1Cas9 and sgRNA in 24-well plate according to manufacturer's guidelines (e.g., *Psck9* & *Rosa26*).

All cell lines were maintained in a 37°C incubator with 5% CO<sub>2</sub>. Mouse Hepa1-6 hepatoma and HEK293T cells were cultured in DMEM with 10% FBS and 1% Penicillin/Streptomycin (Gibco). K562 cells were grown in the same conditions but using IMDM. IMR-90 cells were cultured in EMEM and 10% FBS. Finally, HDFa cells were grown in DMEM and 20% FBS.

## Example III

25

### Expression And Purification Of Nme1Cas9

Nme1Cas9 was cloned into a pMCSG7 vector containing a T7 promoter followed by 6X His-tag and then a tobacco etch virus (TEV) protease cleavage site. This construct was transformed into Rosetta2 DE3 strain of *E. coli* and Nme1Cas9 was expressed. Briefly, bacterial culture was grown at 37 °C until OD600 of 0.6 was reached. At this point the temperature was lowered to 18 °C followed by addition of 1 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG). Cells were grown overnight, and then harvested for purification.

Purification of Nme1Cas9 was performed in three steps: Nickel affinity chromatography, cation exchange chromatography, and then size exclusion chromatography. The detailed protocols for these can be found in previous publications (Jinek *et al.*, *Science* 337, 816-821, 2012).

5

#### Example IV

##### Ribonucleoprotein (RNP) Delivery Of Nme1Cas9

RNP delivery of Nme1Cas9 was performed using the Neon transfection system (ThermoFisher). Approximately 20 picomoles of Nme1Cas9 and 25 picomoles of sgRNA were mixed in buffer R and incubated at room temperature for 20-30 minutes. This preassembled complex was then mixed with 50,000-100,000 cells, and electroporated using 10 µL Neon tips. After electroporation, cells were plated in 24-well plates containing the appropriate culture media without antibiotics.

15

#### Example V

##### DNA isolation from cells and tissue

Genomic DNA was isolated 72 hours post-transfection from cells via DNeasy<sup>®</sup> Blood and Tissue kit (Qiagen) according to the manufacturer's protocol. Mice were sacrificed and liver tissue was harvested 10 days post-hydrodynamic injection or 50 days post-tail vein vector administration, and genomic DNA was isolated with a DNeasy<sup>®</sup> Blood and Tissue kit (Qiagen) according to the manufacturer's protocol.

20

#### Example VI

##### Indel Analysis

50ng of genomic DNA was used for PCR amplification with genomic site-specific primers and High Fidelity<sup>®</sup> 2X PCR Master Mix (New England Biolabs). For TIDE analysis, 30µl of PCR product was purified using QIAquick<sup>®</sup> PCR Purification Kit (Qiagen), and subjected to Sanger sequencing. Indel values were obtained using the TIDE web tool ([tide-calculator.nki.nl/](http://tide-calculator.nki.nl/)) as described previously. Brinkman *et al.*, *Nucl. Acids Res.* (2014).

25

For the T7 Endonuclease I (T7EI) assay, 10µl of the PCR product was hybridized and treated with 0.5µl T7 Endonuclease I (New England Biolabs) in 1X NEB Buffer 2 for 1 hour.

30

The samples were run on a 2.5% agarose gel and quantified with ImageMaster-TotalLab<sup>®</sup> program. Indel percentages were calculated as previously described. Guschin *et al.*, Engineered Zinc Finger Proteins: Methods and Protocols (2010).

5

#### Example VII

##### GUIDE-Seq For Off-Target Analysis

GUIDE-seq analysis was performed as previously described. Tsai *et al.*, *Nature Biotechnology* (2014), Bolukbasi *et al.*, *Nature Methods* (2015a); Amrani *et al.*, [biorxiv.org/content/early/2017/08/04/172650](https://www.biorxiv.org/content/early/2017/08/04/172650) (2017).

10 Briefly, Hepa1-6 cells were transfected with 500ng of all-in-one sgRNA-Nme1Cas9-AAV plasmids and 7.5 pmol of annealed GUIDE-seq oligonucleotide using Lipofectamine LTX<sup>®</sup> with Plus<sup>®</sup> Reagent (ThermoFisher), for the two spacers targeting *Pcsk9* and *Rosa26* genes. Genomic DNA was extracted with a DNeasy<sup>®</sup> Blood and Tissue kit (Qiagen) at 72 hours after transfection following the manufacturer protocol. Library preparations, deep sequencing,  
15 and reads analysis were performed as previously described. Tsai *et al.*, *Nature Biotechnology* (2014), Bolukbasi *et al.*, *Nature Methods* (2015a); Amrani *et al.*, [biorxiv.org/content/early/2017/08/04/172650](https://www.biorxiv.org/content/early/2017/08/04/172650) (2017).

#### Example IX

20

##### AAV Vector Production

Plasmids were packaged in AAV8 by triple-plasmid transfection in HEK 293 cells and purified by sedimentation as previously described at the Horae Gene Therapy Center at the University of Massachusetts Medical School. Gao GP, Sena-Esteves M. Introducing Genes into Mammalian Cells: Viral Vectors. In: Green MR, Sambrook J, eds. *Molecular Cloning, Volume*  
25 *2: A Laboratory Manual*. New York: Cold Spring Harbor Laboratory Press; 2012:1209–1313.

#### Example X

##### Animals, AAV Vector Injections, And Liver Tissue Processing

All animal experiments were approved under the guidelines of the University of  
30 Massachusetts Medical School Institutional Animal Care and Use Committee. For hydrodynamic injections, 2.5mL of 30 µg of endotoxin-free sgRNA-Nme1Cas9-AAV plasmid targeting *Pcsk9*,

or PBS as a control, were injected via tail vein into 9-18 weeks old female C57BL/6 mice. For the AAV8 vector injections, 9-18 weeks old female C57BL/6 mice were injected with  $4 \times 10^{11}$  genome copies per mouse via tail vein. 8-week-old female C57BL/6NJ mice were used for genome editing experiments in vivo. For ex vivo experiments, embryos that were advanced to two-cell stage were transferred into the oviduct of E0.5 pseudo-pregnant female mice.

Mice were euthanized by CO<sub>2</sub> and liver was collected. Tissues were fixed in 4% paraformaldehyde overnight, and embedded in paraffin, sectioned and stained with hematoxylin and eosin (H&E).

#### Example XI

##### Serum Analysis

Blood (~ 200 µL) was drawn from the facial vein at 0, 25, and 50 days post vector administration. Serum was isolated using a serum separator (BD, Cat. No. 365967) and stored under -80 °C until assay. Serum cholesterol levels were measured by Infinity™ colorimetric endpoint assay (Thermo-Scientific) following the manufacturer's protocol. Briefly, serial dilutions of Data-Cal™ Chemistry Calibrator were prepared in PBS. In a 96-well plate, 2 µL of mice sera or calibrator dilution was mixed with 200 µL of Infinity™ cholesterol liquid reagent, then incubated at 37 °C for 5 min. The absorbance was measured at 500 nm using a BioTek Synergy® HT microplate reader.

#### Example XII

##### Discovery Of Cas9 Orthologs With Hyper-Evolved PIDs

Nme1Cas9 sequence was blasted to find all Cas9 orthologs in *Neisseria* species. Orthologs with >80% identity to Nme1Cas9 were selected for the remainder of this analysis. The PIDs of each was then aligned using ClustalW2 with that of Nme1Cas9 (from 820<sup>th</sup> amino acid to 1082<sup>nd</sup>) and those with clusters of mutations in the PID were selected.

Nme1Cas9 peptide sequence was used as a query in BLAST searches to find all Cas9 orthologs in *Neisseria meningitidis* strains. Orthologs with >80% identity to Nme1Cas9 were selected for study. The PIDs were then aligned with that of Nme1Cas9 (residues 820-1082) using ClustalW2® and those with clusters of mutations in the PID were selected for further

analysis. An unrooted phylogenetic tree of NmeCas9 orthologs was constructed using FigTree (tree.bio.ed.ac.uk/software/figtree).

### Example XIII

#### 5        Cloning And Purification Of Nme2 and Nme3 Cas9 And Acr Orthologs

The PIDs of Nme2Cas9 and Nme3Cas9 were ordered as gBlocks (IDT) to replace the PID of Nme1Cas9 using Gibson Assembly (NEB) in a bacterial expression plasmid pMSCG7 with 6X His-tag. The construct was transformed into *E. coli*, expressed and purified as previously described.

10       Briefly, Rosetta (DE3) cells containing the respective Cas9 plasmids were grown at 37°C to an optical density of 0.6 and protein expression was induced by 1mM IPTG for 16 hr at 18°C. Cells were harvested and lysed by sonication in lysis buffer (50 mM Tris pH 7.5, 500 mM NaCl, 5 mM imidazole, 1 mM DTT) supplemented with Lysozyme and protease inhibitor cocktail (Sigma).

15       The lysate was then run through a Ni-NTA agarose column (Qiagen), the bound protein was eluted with 300mM imidazole and dialyzed into storage buffer (20 mM HEPES pH 7.5, 250 mM NaCl, 1 mM DTT). For Acr proteins, 6x His tagged proteins were expressed in *E. coli* strain BL21 Rosetta (DE3). Cells were grown at 37° C to an optical density (OD<sub>600 nm</sub>) of 0.6 in a shaking incubator. The bacterial cultures were cooled to 18° C, and protein expression was  
20       induced by adding 1 mM IPTG for overnight expression. The next day, cells were harvested and resuspended in lysis buffer (50 mM Tris pH 7.5, 500 mM NaCl, 5 mM imidazole, 1 mM DTT) supplemented with 1 mg/mL Lysozyme and protease inhibitor cocktail (Sigma) and protein was purified using the same protocol as for Cas9. The 6X His tag was removed by incubation with Tobacco Etch Virus (TEV) protease overnight at 4 °C to isolate successfully cleaved, untagged  
25       Acrs.

### Example IVX

#### In vitro PAM Discovery Assay

A library of protospacers with randomized PAM sequences was generated using  
30       overlapping PCRs, with the forward primer containing the 10-nucleotide randomized PAM.

The library was gel purified and subjected to *in vitro* cleavage reaction by purified Cas9 along with *in vitro* transcribed sgRNAs. 300 nM Cas9:sgRNA complex was used to cleave 300 nM of the target fragment in 1X NE Buffer 3.1 (NEB) at 37 °C for 1 hr. The reaction was then treated with proteinase K at 50 °C for 10 minutes and run on a 4% agarose gel with 1X TAE.

5 The cleavage product was purified and subjected to library preparation. The library was sequenced using the Illumina NextSeq500<sup>®</sup> sequencing platform and analyzed. Sequence logos were generated using R.

#### Example XV

##### 10 Transfections And Mammalian Genome Editing

Humanized Nme2Cas9 was cloned into pCDEST2 plasmid previously used for Nme1Cas9 and SpyCas9 expression using Gibson Assembly. Transfection of HEK293T and HEK293T-TLR cells was performed as previously described (Amrani et al. 2018). For Hepa1-6 transfections, Lipofectamine LTX was used to transfect 500ng of all-in-one AAV.sgRNA.Nme2Cas9 plasmid  
15 in approximately  $1 \times 10^5$  cells per well that had been cultured in 24-well plates 24 hours before transfection. For K562 cells stably expressing Nme2Cas9, 50,000 – 150,000 cells were electroporated with 500 sgRNA plasmid using 10  $\mu$ L Neon tips.

To measure indels in all cells, 72 hr after transfections, cells were harvested, and genomic DNA was extracted using the DNeasy<sup>®</sup> Blood and Tissue kit (Qiagen). The targeted locus was  
20 amplified by PCR, Sanger sequenced (Genewiz<sup>®</sup>) and analyzed by TIDE (Brinkman et al. 2014).

#### Example XVI

##### Lentiviral transduction of K562 cells to stably express Nme2Cas9

K562 cells stably expressing Nme2Cas9 were generated as previously described. For  
25 lentivirus production, the lentiviral vector was co-transfected into HEK293T cells along with the packaging plasmids (Addgene 12260 & 12259) in 6-well plates using TransIT-LT1 transfection reagent (Mirus Bio) as recommended by the manufacturer. After 24 hours, the medium was aspirated from the transfected cells and replaced with fresh 1 mL of fresh DMEM media.

The next day, the supernatant containing the virus from the transfected cells was  
30 collected and filtered through 0.45  $\mu$ m filter. 10  $\mu$ L of the undiluted supernatant along with 2.5

µg of Polybrene was used to transduce ~ 1 million K562 cells in 6-well plates. The transduced cells were selected using 2.5 µg/mL of Puromycin containing media.

#### Example XVII

##### 5                    RNP Delivery For Mammalian Genome Editing

For RNP experiments, a Neon electroporation system was used. 40 picomoles of 3X NLS Nme2Cas9 along with 50 picomoles of *in vitro* transcribed sgRNA was assembled in buffer R, and electroporated using 10 µL Neon tips. After electroporation, cells were plated in pre-warmed 24-well plates containing the appropriate culture media without antibiotics.

10 Electroporation parameters (voltage, width, number of pulses) were 1150 v, 20 ms, 2 pulses for HEK293T cells; 1000 v, 50 ms, 1 pulse for K562 cells.

#### Example XVIII

##### GUIDE-Seq

15                    GUIDE-Seq experiments were performed as described previously with minor modifications (Amrani et al., 2018).

Briefly, HEK293T cells were transfected with 200 ng of Cas9, 200 ng of sgRNA, and 7.5 pmol of annealed GUIDE-seq oligonucleotide using Polyfect (Qiagen) for guides targeting dual sites with SpyCas9 or Nme2Cas9. Hepa1-6 cells were transfected as described above.

20                    Genomic DNA was extracted with a DNeasy® Blood and Tissue kit (Qiagen) 72 h after transfection according to the manufacturer protocol. Library preparation and sequencing were performed exactly as described previously.

For analysis, sites that matched a sequence with ten mismatches with the target site were considered potential off-target sites. Data were analyzed using the Bioconductor package

25                    GUIDEseq version 1.1.17 (Zhu et al., 2017).

#### Example XIX

##### Targeted Deep Sequencing And Analysis

Targeted deep sequencing was used to confirm the results of GUIDE-Seq and more  
30                    quantitatively measure indel rates. A two-step PCR amplification was used to produce DNA



fragments for each on- and off-target site. For SpyCas9, the top off-target locations were selected.

In the first step, locus-specific primers bearing universal overhangs with complementary ends to the adapters were mixed with 2X Phusion<sup>®</sup> PCR master mix (NEB) to generate fragments bearing the overhangs. In the second step, the purified PCR products were amplified with a universal forward primer and indexed reverse primers.

Full-size products (~250bp in length) were gel-extracted and sequenced using a paired-end MiSeq run. MiSeq data analysis was performed exactly as previously described (Amrani 2018).

#### Example XX

##### Off-Target Analysis Using CRISPRseek

Global off-target analyses for TS25 and TS47 were performed using the Bioconductor package CRISPRseek.

Minor changes were made to accommodate for characteristics of Nme2Cas9 not shared with SpyCas9. Specifically, the following changes were used: gRNA.size = 24, PAM = "NNNNCC", PAM.size = 6, RNA.PAM.pattern = "NNNNCN", off-target sites with less than 6 mismatches were collected. The top potential off-target sites based on the number and position of mismatches were selected. gDNA from cells targeted by each respective sgRNA was used to amplify each off-target locus and analyzed by TIDE.

#### Example XXI

##### In vivo AAV8.Nme2Cas9 Delivery And Liver Tissue Processing

All animal procedures were reviewed and approved by The Institutional Animal Care and Use Committee (IACUC) at University of Massachusetts Medical School.

For the AAV8 vector injections, 8 weeks old female C57BL/6 mice were injected with  $4 \times 10^{11}$  genome copies per mouse via tail vein targeting *Pcsk9* or *Rosa26*. Mice were sacrificed 28 days after vector administration and liver tissues were collected for analysis. Liver tissues were fixed in 4% formalin overnight, and embedded in paraffin, sectioned and stained with hematoxylin and eosin (H&E). Blood was drawn from facial vein at 0, 14 and 28 days post injection, and serum was isolated using a serum separator (BD, Cat. No. 365967) and stored at -

80 °C until assay. Serum cholesterol level was measured using the Infinity™ colorimetric endpoint assay (Thermo-Scientific) following manufacturer's protocol and as previously described (Ibraheim et al, 2018).

5

## Example XXII

### Animals and liver tissue processing

For hydrodynamic injections, 2.5 mL of 30 µg of endotoxin-free AAV-sgRNA-hNme1Cas9 plasmid targeting *Pcsk9* or 2.5 mL PBS was injected by tail vein into 9- to 18-week-old female C57BL/6 mice. Mice were euthanized 10 days later and liver tissue was harvested.

10 For the AAV8 vector injections, 12- to 16-week-old female C57BL/6 mice were injected with  $4 \times 10^{11}$  genome copies per mouse via tail vein, using vectors targeting *Pcsk9* or *Rosa26*. Mice were sacrificed 14 and 50 days after vector administration and liver tissues were collected for analysis.

For *Hpd* targeting, 2 mL PBS or 2 mL of 30 µg of endotoxin-free AAV-sgRNA-hNme1Cas9 plasmid was administered into 15- to 21-week-old Type 1 Tyrosinemia *Fah* knockout mice (Fahneo) via tail vein. The encoded sgRNAs targeted sites in exon 8 (sgHpd1) or exon 11 (sgHpd2). The HT1 mice were fed with 10 mg/L NTBC (2-(2-nitro-4--trifluoromethylbenzoyl)-1,3-cyclohexanedione) (Sigma-Aldrich, Cat. No. PHR1731-1G) in drinking water when indicated. Both sexes were used in these experiments. Mice were  
15 maintained on NTBC water for seven days post injection and then switched to normal water. Body weight was monitored every 1–3 days. The PBS-injected control mice were sacrificed when they became moribund after losing 20% of their body weight after removal from NTBC treatment.

25 Mice were euthanized according to our protocol and liver tissue was sliced and fragments stored at – 80 °C. Some liver tissues were fixed in 4% formalin overnight, embedded in paraffin, sectioned and stained with hematoxylin and eosin (H&E).

## XXIII

### Western Blot

30 Liver tissue fractions were ground and resuspended in 150 µL of RIPA lysis buffer. Total protein content was estimated by Pierce™ BCA Protein Assay Kit (Thermo-- Scientific)

following the manufacturer's protocol. A total of 20 µg of protein from tissue or 2 ng of Recombinant Mouse Proprotein Convertase 9/PCSK9 Protein (R&D Systems, 9258-SE-020) were loaded onto a 4–20% Mini-- Rotean<sup>®</sup> TGX<sup>™</sup> Precast Gel (Bio-Rad). The separated bands were transferred onto PVDF membrane and blocked with 5% Blocking-Grade Blocker solution (Bio-Rad) for 2 h at room temperature. Membranes were incubated with rabbit anti-GAPDH (Abcam ab9485, 1:2000) or goat anti-PCSK9 (R&D Systems AF3985, 1:400) antibodies overnight at 4 °C. Membranes were washed five times in TBST and incubated with horseradish peroxidase (HRP)-conjugated goat anti-rabbit (Bio-Rad 1,706,515, 1:4000) and donkey anti-goat (R&D Systems HAF109, 1:2000) secondary antibodies for 2 h at room temperature. The membranes were washed five times in TBST and visualized with Clarity<sup>™</sup> western ECL substrate (Bio-Rad) using an M35A X-OMAT Processor (Kodak).

#### Example XXIV

##### Humoral Immune Response

Humoral IgG1 immune response to Nme1Cas9 was measured by ELISA (Bethyl; Mouse IgG1 ELISA Kit, E99-- 105) following manufacturer's protocol with a few modifications. Briefly, expression and three-step purification of Nme1Cas9 and SpyCas9 was performed. A total of 0.5 µg of recombinant Nme1Cas9 or SpyCas9 proteins suspended in 1X coating buffer (Bethyl) were used to coat 96-well plates (Corning) and incubated for 12 h at 4 °C with shaking. The wells were washed three times while shaking for 5 min using 1X Wash Buffer. Plates were blocked with 1X BSA Blocking Solution (Bethyl) for 2 h at room temperature, then washed three times. Serum samples were diluted 1:40 using PBS and added to each well in duplicate. After incubating the samples at 4° C for 5 h, the plates were washed 3 times for 5 min and 100 µL of biotinylated anti-mouse IgG1 antibody (Bethyl; 1: 100,000 in 1 x BSA Blocking Solution) was added to each well. After incubating for 1 h at room temperature, the plates were washed four times and 100 µL of TMB Substrate was added to each well. The plates were allowed to develop in the dark for 20 min at room temperature and 100 µL of ELISA Stop Solution was then added per well. Following the development of the yellow solution, absorbance was recorded at 450 nm using a BioTek Synergy<sup>®</sup> HT microplate reader.

## Example XXV

Zygote Incubation And TransfectionMouse strains and embryo collection

5 All animal experiments were conducted under the guidance of the Institutional Animal Care and Use Committee (IACUC) of the University of Massachusetts Medical School. C57BL/6NJ (Stock No. 005304) mice were obtained from The Jackson Laboratory. All animals were maintained in a 12 h light cycle. The middle of the light cycle of the day when a mating plug was observed was considered embryonic day 0.5 (E0.5) of gestation. Zygotes were  
10 collected at E0.5 by tearing the ampulla with forceps and incubation in M2 medium containing hyaluronidase to remove cumulus cells.

In vivo AAV8 Nme2Cas9+sgRNA delivery and liver tissue processing

For the AAV8 vector injections, 8-week-old female C57BL/6NJ mice were injected with  
15  $4 \times 10^{11}$  genome copies per mouse via tail vein, with the sgRNA targeting a validated site in either *Pcsk9* or *Rosa26*. Mice were sacrificed 28 days after vector administration and liver tissues were collected for analysis. Liver tissues were fixed in 4% formalin overnight, embedded in paraffin, sectioned and stained with hematoxylin and eosin (H&E). Blood was drawn from the facial vein at 0, 14 and 28 days post injection, and serum was isolated using a serum separator  
20 (BD, Cat. No. 365967) and stored at -80°C until assay. Serum cholesterol level was measured using the Infinity™ colorimetric endpoint assay (Thermo-Scientific) following the manufacturer's protocol and as previously described. Ibraheim et al., "All-in-One Adeno-associated Virus Delivery and Genome Editing by Neisseria meningitidis Cas9 in vivo" *Genome Biology* 19:137 (2018).

25 For an anti-PCSK9 Western blot, 40 µg of protein from tissue or 2 ng of Recombinant Mouse PCSK9 Protein (R&D Systems, 9258-SE-020) were loaded onto a MiniProtean® TGX™ Precast Gel (Bio-Rad). The separated bands were transferred onto a PVDF membrane and blocked with 5% Blocking-Grade Blocker® solution (Bio-Rad) for 2 hours at room temperature. Next, the membrane was incubated with rabbit anti-GAPDH (Abcam ab9485, 1:2,000) or goat  
30 anti-PCSK9 (R&D Systems AF3985, 1:400) antibodies overnight. Membranes were washed in TBST and incubated with horseradish peroxidase (HRP)-conjugated goat anti-rabbit (Bio-Rad

1706515, 1:4,000), and donkey anti-goat (R&D Systems HAF109, 1:2,000) secondary antibodies for 2 hours at room temperature. The membranes were washed again in TBST and visualized using Clarity™ western ECL substrate (Bio-Rad) using an M35A XOMAT Processor (Kodak).

5 Ex vivo AAV6.Nme2Cas9 delivery in mouse zygotes

Zygotes were incubated in 15 µl drops of KSOM (Potassium-Supplemented Simplex Optimized Medium, Millipore, Cat. No. MR-106-D) containing  $3 \times 10^9$  or  $3 \times 10^8$  GCs of AAV6.Nme2Cas9.sgTyr vector for 5-6 h (4 zygotes in each drop). After incubation, zygotes were rinsed in M2 and transferred to fresh KSOM for overnight culture. The next day, the embryos that advanced to 2-cell stage were transferred into the oviduct of pseudopregnant recipients and allowed to develop to term.

Example XXVI

Quantification And Statistical Analyses

15 An analysis of in vitro PAM discovery data was performed using R. GraphPad Prism 6® for all statistical analyses. For mammalian cell experiments using Nme2Cas9, 3 independent replicates were performed and indel percentages were calculated using TIDE software, with error bars depicting s.e.m. The TIDE parameters were set to quantify indels <20 nucleotides for all figures. For side-by-side comparisons of Nme2Cas9 and SpyCas9, average indel percentages  
20 were calculated using Microsoft Excel. For in vivo experiments in mice, n = 5 for control and test subjects. P values were calculated by unpaired two-tailed t-test.

**CLAIMS:**

1. A single guide ribonucleic acid (sgRNA) sequence comprising a truncated repeat:antirepeat region and a truncated Stem 2 region.
2. The sgRNA sequence of Claim 1, further comprising a truncated spacer region.
3. The sgRNA sequence of Claim 1, wherein said sgRNA sequence is an Nme1Cas9 single guide ribonucleic acid sequence or an Nme2Cas9 single guide ribonucleic acid sequence.
4. An adeno-associated viral (AAV) plasmid comprising a single guide ribonucleic acid (sgRNA)-*Neisseria meningitidis* Cas9 nucleic acid vector, wherein said single guide ribonucleic acid comprises a truncated repeat:antirepeat region and a truncated Stem 2 region.
5. The AAV plasmid of Claim 4, wherein said single guide ribonucleic acid-*Neisseria meningitidis* Cas9 nucleic acid vector comprises at least one promoter.
6. The AAV plasmid of Claim 5, wherein said at least one promoter is selected from the group consisting of a U6 promoter and a U1a promoter.
7. The AAV plasmid of Claim 4, wherein said single guide ribonucleic acid-*Neisseria meningitidis* Cas9 nucleic acid vector comprises a Kozak sequence.
8. The AAV plasmid of Claim 4, wherein said sgRNA comprises a spacer region that is complementary to a gene-of-interest sequence.
9. The AAV plasmid of Claim 8, wherein said gene-of-interest sequence is selected from the group consisting of a *PCSK9* sequence and a *ROSA26* sequence.
10. The AAV plasmid of Claim 8, wherein said spacer region is a truncated spacer region.

11. A method, comprising:
  - a) providing;
    - i) a patient exhibiting at least one symptom of a medical condition, wherein said patient comprises a plurality of genes related to said medical condition;
    - ii) an adeno-associated viral (AAV) plasmid comprising a single guide ribonucleic acid (sgRNA)-*Neisseria meningitidis* Cas9 nucleic acid vector, wherein said sgRNA comprises:
      - a spacer region that is complementary to a portion of at least one of said plurality of genes:
      - a truncated repeat:antirepeat region; and
      - a truncated Stem 2 region; and
  - b) administering said AAV plasmid to said patient under conditions such that said at least one symptom of said medical condition is reduced.
12. Use of an adeno-associated viral (AAV) plasmid comprising a single guide ribonucleic acid (sgRNA)-*Neisseria meningitidis* Cas9 nucleic acid vector in the manufacture of a medicament for reducing at least one symptom of a medical condition in a patient, wherein said patient comprises a plurality of genes related to said medical condition, and wherein said sgRNA comprises:
  - a spacer region that is complementary to a portion of at least one of said plurality of genes:
  - a truncated repeat:antirepeat region; and
  - a truncated Stem 2 region.
13. The method of Claim 11 or the use of Claim 12, wherein said medical condition comprises hypercholesterolemia.
14. The method of Claim 11 or the use of Claim 12, wherein said at least one of said plurality of genes is a *PCSK9* gene.

15. The method or use of Claim 14, wherein said spacer region is complementary to a portion of said *PCSK9* gene.
16. The method of Claim 11 or the use of Claim 12, wherein said spacer region is a truncated spacer region.
17. The sgRNA sequence of Claim 1, the AAV plasmid of claim 4, the method of Claim 11, or the use of Claim 12, wherein said sgRNA sequence has a length of 121 nucleotides.
18. The sgRNA sequence of Claim 1, the AAV plasmid of claim 4, the method of Claim 11, or the use of Claim 12, wherein said sgRNA sequence has a length selected from the group consisting of 111 nucleotides, 107 nucleotides, 105 nucleotides, 103 nucleotides, 102 nucleotides, 101 nucleotides, and 99 nucleotides.
19. The sgRNA sequence of Claim 1, the AAV plasmid of claim 4, the method of Claim 11, or the use of Claim 12, wherein said sgRNA sequence has a length of 100 nucleotides.
20. The sgRNA of claim 1, AAV plasmid of claim 4, the method of claim 11, or the use of Claim 12, wherein the truncated repeat:antirepeat region comprises a 5'-UCCCGAAACGUU-3' sequence.
21. The sgRNA of claim 1, AAV plasmid of claim 4, or the method of claim 11, or the use of Claim 12, wherein the truncated Stem 2 region comprises a 3'-UUCU-5' sequence.

**University of Massachusetts**

**Patent Attorneys for the Applicant/Nominated Person**

**SPRUSON & FERGUSON**






Figure 1




Figure 2




Figure 3





Figure 4

C



D




Figure 4 (cont'd)

E




Figure 4 (cont'd)






Figure 5

A



B



C




Figure 6



ggcaggaagAGGGGCCTATTTCCCATGATTCCTTCATATTTGCATATACGATACAGGGCTGTTAGACAGAT  
AATTAGAATTAATTTGACTGTAAACACAAAGATATTAGTACAAAATACGTGACGTAGAAAGTAATAATTT  
CTTGGGTAGTTTGCAGTTTTAAAAATTATGTTTTAAATGGACTATCATATGCTTACCGTAACTTGAAAGT  
ATTTGATTTCTTGGCTTTATATATCTTGIGGAAAGGACGAAACACCggaagagcattccagctcttca  
TTGTAGTTTCTTTCTTATTTGGAAACGAATGAGATCTTTGCTACATAAGTGGCTGAAATAT  
TGGCGCAACGCTCTGGCTTTAAAGCTTCTGCTTTAAGGGCATCTTTATTTTTTTGTTTAAACtctag  
aggccgc

Figure 7

Figure 8




Figure 9

*Peak9*

TGGCGTGATCTCCCGGCCCCAGGCGTCCAGTACCCACRCCCCAAGGCTTCCACCTTCACGTGGACGC  
 GCAGGCTGCCGCTGGGCTCCCGTTCTCTCTCTCTTTCTGAGGCTAGAGGACTGAGCCAGTCCTTGGCTCC  
 CCAGAGACATCACGGCCCGCAGCCCCGAGCCRAGTGCCCCGAGTCCCAGGCGTCCATGTCTTCCCGAG  
 GCGCGCGCACCTCTCTCGCCCCGATGGGCACCCACTGCTCTGCGTGGCTGCGGTGGCCGCTGTTGCCG  
 CTGTTGCCGCGCTGCTGCTGCTGTTGCTGCTACTGTGCCCCACCGGCGCTGGTGCCCAAGACGAGGATG  
 GAGATTATGAAGAGCTGATGCTCGCCCTCCCGTCCCAGGAGGATGGCCTGGCTGATGAGGCCGCACATGT  
 GGCCACCGCCACCTTCCGCGCTTGCTCCAAGGTATGGGTGCCAGGCAACGGCGTTGCTTTGGGGTTGGGG  
 TGATGCTCTTCGGGGGTCTTCTCTGCTCATCTAGCCGTCTGGTGGTCTCTAAGTGCAGCCCTGAGGTGCG  
 GGAGGCGAGGGCAAGACTTAGTGCTCAGCTGCACCTTGTGGCACAGAGTGATGGGGGAGGCCACGTGCTA  
 AAGGCACTGCGGGGCTTGGTTCCAAAAGTGTGAGGCGGGGAGCGGGCTACCAGTGTGGTCATGCAGAAAA  
 CGTGTCTCTCCGAAGTAAAGTGGCATCGGGAGGCTGAGAACTCTAGTGGCACATCTTTCTCAACTGGTCAT  
 CCAGCAGTCATCTGGGTGCCCTGTTGGGGTTCTGTAGGCCTCGATTTAGCCGAAGGGTGTGAGGG

*Nowa26*

GGAAAGGGAAAATGCCAATGCTCTGTC TAGGGGTTGGATAAGCCAGTATAATAAATGAAAATGGGGCTAA  
 AATGAGTGTTCTAAAATACCTTTTGATAAGGCTGCAGAAGGAGCGGGAGAAAATGCATATGAAGTACTGGG  
 CTCTTTAAAAATGATTAAAATTCTGCTTACATAGTCTAACTCGCGACACTGTAATTTCACTAGTAA  
 GGATCTCAAGCAGGAGAGTATAAACTCGGGTGAGCATGTCTTAAATCTACCTCGATGGAAAAATACTCCG  
 AGGCGGATCACAAACAATAATAACCTTCTAGTTTTCTGCATAAAAACCCCAAGATGACTACCTATCCTCCCA  
 TTTTCCTTATTTGCCCCCTATTAAAAAACTTCCCGACAAAACCGAAAATCTGTGGGAAGTCTTGTCCCTCC  
 AATTTTACACCTGTTCAATTCCCCTGCAGGACAACGCCACACACCAGGTTAGCCTTTAAGCCTGCCAG  
 AAGACTCCCCCCATCTTCTAGAAAGACTGGAGTTGCAGATCACGAGGGAAGAGGGGGAAGGGATTCTCC  
 CAGGCCCAGGGCGGTCTCAGAAGCCAGGAGGCAGCAGAGAACTCCAGAAAGGTATTGCAACACTCCCC  
 TCCCCCTCCGGAGAAGGGTGCGGCCTTCTCCCCGCTACTCCACTGCAGCTCCCTTACTGATAACAACT  
 CAGAGCGACTTTGGGAGAGCAAGTGCTTCTGCTGCCAAAACAGCCCCAACTGAGCCCTCGCTCCTTCCCT  
 CCACTCCCCGGAGTGCGCGATGGAGGTCTGGCTCAGCACGCCCTCTTGAGGCAACTCAAGTCCGAAAAAG  
 TGGTTGCACCCGCCCGCAGCCG

Figure 10




Figure 11




Figure 12





Figure 13



A



B




Figure 14




Figure 15




Figure 16




Figure 17




Figure 18




Figure 19




Figure 20




Figure 21






Figure 22

## Genome editing with Nme2Cas9




Figure 23

ATGGCTGCCTTCAAACCTAATCCAATCAACTACATCCTCGGCCTCGATATCGGCATCGCATCCGTCGGC  
TGGGCGATGGTAGAAATTGACGAAGAAGAAAACCCCATCCGCCTGATTGATTTGGGCGTGCGCGTATT  
TGAGCGTGCCGAAGTACCGAAAACAGGCGACTCCCTTGCCATGGCAAGGCGTTTGGCGCGCAGTGTCC  
GCCGCCTGACCCGCCGTCGCGCCCATCGCCTGCTTCGGGCCCCGCCGCTATTGAAACGCGAAGGCGTA  
TTACAAGCCGCTGATTTTGACGAAAACGGCTTGATCAAATCCTTACCGAATACACCATGGCAACTTCG  
CGCAGCCGCATTAGACCGCAAACCTGACGCCTTTAGAGTGGTCGGCAGTCTTGTTCATTTAATCAAAC  
ACCGCGGTTATTTGTCGCAAAAGAAAAACGAGGGCGAAACTGCCGATAAAGAGCTTGGCGCTTTGCTT  
AAAGGCGTGGCCAACAATGCCCATGCCTTACAGACAGGCGATTTCGCGACACCGGCCGAATTGGCTTT  
AAATAAATTTGAGAAAGAAAGCGGCCATATCCGCAATCAGCGCGGCGATTATTCGCATACGTTTCAGCC  
GCAAAGATTTACAGGCGGAGCTGATTTTGCTGTTTGA AAAACAAAAAGAATTTGGCAATCCGCATGTT  
TCAGGCGGCCTTAAAGAAGGTATTGAAACCTACTGATGACGCAACGCCCTGCCCTGTCCGGCGATGC  
CGTTCAAAAAATGTTGGGGCATTGCACCTTCGAACCGGCAGAGCCGAAAGCCGCTAAAAACACCTAC  
ACAGCCGAACGTTTCATCTGGCTGACCAAGCTGAACAACCTGCGTATTTTAGAGCAAGGCAGCGAGCG  
GCCATTGACGATACCGAACGCGCCACGCTTATGGACGAGCCATACAGAAAAATCCAAACTGACTTACG  
CACAAGCCCGTAAGCTGCTGGGTTTAGAAGATACCGCCTTTTCAAAGGCTTGCGCTATGGTAAAG  
ACAATGCCGAAGCCTCAACATTGATGGAATGAAGGCCTACCATGCCATCAGCCGTGCACTGGAAAA  
AGAAGGATTGAAAGATAAAAAATCCCCATTAAACCTTTCTTCCGAATTACAAGATGAAATCGGCACGG  
CATTCTCCCTGTTCAAAACCGATGAAGACATTACAGGCCGTCTGAAAGACCGTGTTTCAGCCCGAAATC  
TTAGAAGCGCTGTTGAAACACATCAGCTTCGATAAGTTCGTCCAAATTTCTTGAAGCATTGCGCCG  
AATTGTGCCTCTAATGGAGCAAGGCAAACGTTACGATGAAGCCTGCGCCGAAATCTACGGAGACCATT  
ACGGCAAGAAAAATACGGAAGAAAAAATTTATCTGCCGCCCATCCCTGCCGACGAGATCCGCAACCC  
CGTCGCTTTCGCGCGCTTATCTCAAGCACGTAAGGTCATTAACGGCGTGGTACGCCGTTACGGCTCCCC  
AGCTCGTATCCATATTGAAACGGCAAGGGAAGTAGGTAAATCGTTTAAAGACCGCAAAGAAATCGAA  
AAACGCCAAGAAGAAAACCGCAAAGACCGGGAAAAAGCCGCCGCAAATTCGAGAGTATTTCCCCA  
ATTTTGTGCGCGAACCCAAATCAAAAGATATTCTGAAACTGCGCCTGTACGAGCAACAACACGGCAAA  
TGCCTGTATTCGGGCAAAGAAATCAACTTAGTCCGTCTGAACGAAAAAGGCTATGTGCAATCGACCA  
TGCCCTGCCGTTTTTCGCGCACATGGGACGACAGTTTCAACAATAAAGTGCTGGTATTGGGCAGCGAAA  
ACCAAAACAAAGGCAATCAAACCCCTTACGAATACTTCAACGGCAAAGACAACAGCCGCGAATGGCA  
GGAATTTAAAGCGCGTGTGCAAAACCAGCCGTTTCCCGCGCAGTAAAAACAACGGATTCTGCTGCAAA  
AATTCGATGAAGACGGCTTTAAAGAATGCAATCTGAACGACACGCGCTACGTCAACCGTTTTCTGTGC  
CAATTTGTTGCCGACCATATATTGCTGACAGGTAAGGGGAAAAGACGTGTCTTTGCCTCAAACGGACA  
AATTACCAATCTGTTGCGCGGCTTTTGGGGATTGCGCAAAGTGCGTGCGGAAAACGACCGCCATCACG  
CCTTGGACGCTGTAGTCGTTGCCCTGCTCGACCGTTGCCATGCAGCAGAAAAATTACCCGTTTTGTACGCT  
ATAAGAGATGAACGCGTTTGACGGTAAAACCATAGACAAAGAAACAGGAAAAGTGCTGCATCAAAA  
AACACACTTCCCACAACCTTGGGAATTTTCGCACAAGAAGTCATGATTCGCGTCTTCGGCAAACCGG  
ACGGCAAACCCGAATTCGAAGAAGCCGATACCCAGAAAAACTGCGCACGTTGCTTGCCGAAAAATT  
ATCATCTCGCCCCGAAGCCGTACACGAATACGTTACGCCACTGTTTGTTCACGCGCGCCCAATCGGA  
AGATGAGCGGTGCACATAAAGATACTTTGAGATCTGCTAAACGATTTGTTAAACATAATGAAAAAATT  
AGTGTTAAACGAGTATGGTTAACCGAAATCAAGTTGGCCGACCTTGAAAATATGGTTAATTATAAAAA  
TGGTAGAGAGATTGAATTATATGAGGCTCTTAAGGCGCGTTTAGAGGCATATGGAGGTAATGCTAAAC  
AAGCATTTGACCCTAAGGACAATCCGTTTTATAAAAAGGGAGGACAACCTGGTTAAAG  
CTGTGAGGGTCGAAAAAACCCAAGAGAGCGGAGTCTTATTAATAAAAAAATGCTTATACCATTGC  
AGATAATGGAGACATGGTACGTGTTGATGTGTTCTGTAAAGTAGATAAGAAAGGAAAAAATCAGTATT  
TTATTGTTCCCATCTATGCTTGGCAGGTTGCTGAAAACATTCTTCCCGATATTGATTGTAAGGGATACC  
GGATTGATGATAGCTATACATTCTGTTTTAGCTTGCATAAGTATGATCTGATTGCTTTTCAAAAAGATG  
AAAAATCTAAAGTAGAATTGCGCTACTATATCAACTGTGATAGCTCTAATGGACGATTCTATTTAGCTT  
GGCATGATAAAGGCTCTAAAGAACAGCAATTCCGTATTAGCACCCAAAATCTTGTATTGATACAAAAA  
TACCAAGTTAACGAACCTGGGCAAAGAAATCAGACCATGCCGTCTGAAAAAACGC  
CCACCTGTCCGTTAA

Figure 24

MAAFKPNPINYILGLDIGIASVGWAMVEIDEEENPIRLIDLGVRFERAEVPKTGDSLAM  
ARRLARSVRRLTRRRRAHRLLRARRLLKREGVLQAADFDENGLIKSLPNTPWQLRAAAL  
DRKLTPLEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGVANNAHALQTGDFRT  
PAELALNKFEKESGHIRNQRGDYSHTFSRKDLQAEILLFEKQKEFGNPHVSGGLKEGIE  
TLLMTQRPALSGDAVQKMLGHCTFEPAEPKAAKNTYTAERFIWLTCLNNLRILEQGSR  
PLTDTERATLMDEPYRKSKLTYAQARKLLGLEDTAFFKGLRYGKDNAEASTLMEMKA  
YHAISRALEKEGLKDKKSPLNLSSELQDEIGTAFSLFKTDEDITGRLKDRVQPEILEALLK  
HISFDKFVQISLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRN  
PVVLRALSQARKVINGVVRRYGSPARIHIETAREVGKSFKDRKEIEKRQEENRKDREKA  
AAKFREYFPNFVGEPKSKDILKLRLYEQQHGKCLYSGKEINLVRLNEKGYVEIDHALPFS  
RTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQ  
RILLQKFDEEDGFKECNLNDTRYVNRFLCQFVADHILLTGKGKRRVFASNGQITNLLRGF  
WGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGKVL  
HOKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTPEKLRTLLAEKLSSRPEAVHEYV  
TPLFVSRAPNRKMSGAHKDTLRSARFVKHNEKISVKRVWLTEIKLADLENMVNYKNG  
REIELYEALKARLEAYGGNAKQAFDPKDNPFYKKGQQLVKAVRVEKTQESGVLLNKK  
NAYTIADNGDMVRVDVFCKVDKKGKNQYFIVPIYAWQVAENILPDIDCKGYRIDDSYTF  
CFSLHKYDLIAFQKDEKSKVEFAYYINCDSSNGRFYLAWHDKGSKEQQFRISTQNLVLIQ  
KYQVNELGKEIRPCRLKKRPPVR

Figure 25

ATGCGCGCTTCAAGCCTAACCCAATCAATTACATCCTGGGACTGGACATCGGAATCGCATCCGTGGGATGGGCTATGGTGGAGATCGACGA  
 GGAGGAGAATCCTATCCGGCTGATCGATCTGGGCGTGAGAGTGTTTGAGAGGGCCGAGCTGCCAAAGACCGGCGATTCTCTGGCTATGGCCC  
 GGAGACTGGCACGGAGCGTGAGGCGCTGACACGGAGAAGGGCACACAGGCTGCTGAGGGCAOGCCGGCTGCTGAAGAGAGAGGGGCTGCT  
 GCAGGCAGCAGACTTCGATGAGAATGCCCTGATCAAGAGCCTGECAAACACCCCTGBCAGCTGAGAGCAOECGCCCTGGACAGGAAGCTG  
 ACACCACTGGAGTGGTCTGCCGTGCTGTCACCTGATCAAGCACCGCGGCTACCTGAGCCAGCGGAAGAAGAGGGGAGAGACAGCAGACA  
 AGGAGCTGGGCGCCCTGCTGAAGGGAGTGGCCAACAATGCCACCGCCCTGCAGACCGGCGATTTCAGGACACCTGCCAGCTGGCCCTGAAT  
 AAGTTTGAGAAGGAGTCCGGCCACATCAGAAACCAGAGGGGGGACTATAGCCACACCTTCTCCCGCAAGGATCTGCAGGCCGAGCTGATCCT  
 GCTGTTGAGAAGCAGAAGGACTTTGGCAATCCACAGCTGAGCGGAGGCTGAAGGAGGGAATCGAGACCTGCTGATGACACAGAGGCCCT  
 GCCCTGTCCGGCGACGCAGTGCAGAAGATGCTGGGACACTGCACCTTCGAGCCTGCAGAGCCAAAGGCCGCCAAGAACACCTACACAGCCGA  
 GCGGTTTATCTGCTGACAAAGCTGAACAATCTGAGAATCTGGAGCAGGGATCCGAGAGGCCACTGACCGACACAGAGAGGGCCACCCCTGA  
 TGGATGAGCCTTACCGGAAGTCTAAGCTGACATATGCCAGGCCAGAAAGCTGCTGGCCCTGGAGGACACCGCCTTCTTTAAGGCCCTGAGA  
 TACGGCAAGGATAATGCCGAGGCCCTCCACACTGATGGAGATGAAGGCCATATCAGGCCATCTCTCGCGCCCTGGAGAAGGAGGGCCCTGAAGGA  
 CAAGAAGTCCCCCTGAACCTGAGCTCCGAGCTGCAGGATGAGATCGGCACCGCCTTCTCTCTGTTAAGACCGAGGAGATATCAGAGGCC  
 GCCTGAAGGACAGGGTGCAGCTGAGATCTGGAGGCCCTGCTGAAGCACATCTCTTTGATAAGTTTGTGCAGATCAGCCTGAAGGCCCTG  
 AGAAGGATCGTGCACTGATGGAGCAGGCCAAGCGGTACGACGAGGCCCTCGCGCGAGATCTACGGCGATCACTATGGCAAGAAGAACACAG  
 AGGAGAAGATCTATCTGCCCCCTATCCCTGCCGACGAGATCAGAAATCTGTGGTCTGAGGGCCCTGTCCAGGCAAGAAAAGTATCAAC  
 GGAGTGGTGGCGCGGTACGGATCTCCAGCCCGGATCCACATCGAGACCGCCAGAGAAGTGGGCAAGAGCTTCAAGGACCGGAAGGAGATCG  
 AGAAGAGACAGGAGGAGAATCGCAAGGATCGGGAGAAGGCCGCCCGCAAGTTAGGGAGTACTTCCCTAATTTGTGGGCGAGCCAAAGTC  
 TAAAGACATCCTGAAGCTGCCCTGTACGAOCAGCAGCAGCGCAAGTGTCTGTATAGCGGCAAGGAGATCAATCTGGTGGCGCTGAACGAGA  
 AGGGCTATGTGGAGATCGATCAGCCCTGCCCTTCTCCAGAACCTGGGACGATTCTTTAACAATAAGGTGCTGGTGGCTGGGACGGAGAACC  
 AGAATAAGGGCAATCAGACACCATACGAGTATTTCAATGGCAAGGACAACCTCAAGGAGTGGCAGGAGTTCAAGGCCCGCTGGAGACCTC  
 TAGATTTCCAGGAGCAAGAAGCAGCGGATCCTGCTGCAGAAGTTGACAGGAGATGGCTTTAAGGAGTGAACCTGAATGACACCAGATAAG  
 TGAACCGGTTCTGTGCCAGTTTGTGGCGGATCACAATCTGCTGACCGGCAAGGGCAAGAGAAGGGTGTTCGCTCTAATGGCCAGATCACAA  
 ACCTGTGAGGGGATTTTGGGACTGAGGAAGGTGCGGGCAGAGAATGACAGACACCACGCACTGGATGCAGTGGTGGTGGATGCAGCAC  
 CGTGGCAATCAGCAGAAGATCACAAGATTCGTGAGGTATAAGGAGATGAACGCCCTTGACCGCAAGACCATCGATAAGGAGACAGGCAAG  
 GTGCTGCACCAGAAGACCACTTCCCCAGCCTTGGGAGTTCTTTGCCAGGAAGTGATGATCCGGGTGTTCGGCAAGCCAGACGGCAAGCCT  
 GAGTTTGAGGAGGCCGATACCCAGAGAAGCTGAGGACACTGCTGGCAGAGAAGCTGTCTAGCAGGCCAGAGGCAGTGCACGAGTACGTGA  
 CCCCACGTGTTCTGTCCAGGGCACCCAAATCGGAAGATGTCTGGGCGCCACAAGGACACACTGAGAAGCGCCAAGAGGTTTGTGAAGCACAA  
 GAGAAGATCTCGTGAAGAGAGTGTGGCTGACCGAGATCAAGCTGGCCGATCTGGAGAACATGGTGAATTACAAGAAGCGCAAGGAGATCG  
 AGCTGTATGAGGCCCTGAAGGCAAGGCTGGAGGCCCTACGGAGGAAATGCCAAGCAGGCCCTTCGACCCAAAGGATAAACCCTTTTATAAGAA  
 GGAGGACAGCTGGTGAAGGCCGTGCGGGTGGAGAAGACCCAGGAGAGCGGGGTGCTGCTGAATAAGAAGAAGCGCTACACAATCGCCGACA  
 ATGGCGATATGGTGAGAGTGGACGTGTTCTGTAAGGTGGATAAGAAGGGCAAGAATCAGTACTTTATCGTGCCTATCTATGCCCTGGCAGGTG  
 GCCGAGAACATCCTGCCAGACATCGATTGCAAGGGCTACAGAATCGACGATAGCTATACATTCTGTTTTCCCTGCACAAGTATGACCTGATC  
 GCCTTCAGAAGGATGAGAAGTCCAAGGTGGAATTTGCCCTACTATATCAATTGCGACTCCTCTAACGGCAGGTTCTACCTGGCCTGGCACGAT  
 AAGGGCAGCAAGGAGCAGCAGTTTCGATCTCCACCCAGAATCTGGTGTGATCCAGAAGTATCAGGTGAACGAGCTGGGCAAGGAGATCA  
 GGCCATGTGGCTGAAGAAGCGCCACCCGTGCGGGGCACCGCGGGCCCAAGAAGAAGAGGAAGGTA  
 GAGGCTATCTGATGAGCTTGGCAATCTAGGATCTATCAAGTTCAGATTACGCTGGATCCGCGCTCCGGCAOCTAAGAA  
 AAGAACTGAGTTTGAATCCGGATAA

Figure 26

MAAFKPNPNYLGLDIGIASVGWAMVEIDEEENPIRLIDLGRVVFERAEPVKTGDSLAMARRLARSVRRLTRRAHRLLLRARLLKREGVLQAADF  
DENGLEKSLPNTPWQLRAAALDRKLTPELWSAVLLHLIKHGRGYLSQRKNEGETADKELGALLKGVANNAHALQTGDFRTPAELALNKFEEKSGHR  
NQRGDYSHTSRKDLQAEILLFEKQKEFGPNPHVSGGLKEGIELTMTQRPALSGDAVQKMLGHCTFEPAEPKAAKNITYAERFIWLTKLNNLRILE  
QGSEPLTDTERATLMDEPYRKSCLTYAQARKLLGLEDTAFFKGLRYGKDNAEASTLMEKAYHAISRALEKGLDKKKSPLNLSSELQDEIGTAF  
SLFKTDDEITGRLKDRVQPEILLEALLKHISFDKFVQISLKALRRIVPLMEQGGKRYDEACAEIYGDHYGKKNTTEKIYLPPIPADEIRNPVVLRAISQAR  
KVINGVVRRYGSPARHIETAREVGKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPSKSDILKLRYEQQHGGKCLYSKGEINLVRLEKG  
YVEIDHALPFSRTWDDSFNNKVLVLGSENGKNGNQTPEYFNGKDNREWQEFKARVETSRFPRSKKQRIILLQXFDDEGFKECNLNDTRYVNRFLC  
QFVADHILLTGKGKRRVFAASNGQITNLLRGFWGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGKVLHQKTHF  
PQPWEFFAQEVMIRVFGKPDGKPEFEEDTPEKLRITLAEKLSRPEAVHEVYVTPLFVSRAPNRKMGAHKDITLRSKRFRVKHNEKISVRRVWLTEI  
KLADLENNMVNYKNGREIELYEALKARLEAYGGNAKQAFDPKDNPFYKKGGLVKAVRVEKTQESGVLLNKKNAYTIADNGDMVRVDVFCVKDK  
KGKNQYFIVPIYAWQVAENILPDIDCKGYRIDDSYTFCSLHKYDLIAFQKDEKSKVEFAYYTNCDSNGRFYLAWHDKGSKQQFRISTQNLVLQK  
YQVNLGKEIRPCRLKKRPPVRGTGGPKKKRKYVYEDPDPGTPDNDAGSTPDPDNGSAPAAKSKLDFESG\*

Figure 27

MENKNLNYILGLDLGIA SVGWAVVEIDEKENPLRLIDVGVRTFERAEVPKTGESLALSRR  
LARSARRLTQRRVARLKKAKRLLKSENILLSTDERLPHQVWQLRVEGLDHLKLERQEWA  
AVLLHLIKHRGYLSQRKNESKSENKELGALLSGVDNNHKLLQQATYRSPAELAVKKFE  
VEEGHIRNQQGAYTHTFSRLDLLAEMELLFSRQQHFGNPFASEKLLNLTALLMWQKPA  
LSGEAILKMLGKCTFEDEYKAAKNTYSAERFVWITKLNNLRIQENGLERALNDNERLAL  
MEQPYDKNRLFYSQVRSILKLSDEAIFKGLRYSGEDKKAIETKAVLMEMKAYHQIRKVL  
EGNNLKAEWAEELKANPTLLDEIGTAFSLYKTDEDISAYLAGKLSQPVLNALLNLSFDK  
FIQLSLKALYKLLPLMQQGLRYDEACREIYGDHYGKKTEENHHFLPQIPADEIRNPVVLRL  
TLTQARKVINGVVRLYGSPARIHIETGREVGKSYKDRRELEKRQEENRKQRENAIKEFKE  
YFPHFAGEPKAKDILKMRLYKQQNAKCLYSGKPIELHRLLEKGYVEVDHALPFSRTWD  
DSFNKVLVLANENQNKGNLTPFEWLDGKHNSERWRAFKALVETSAFPYAKKQRILSQ  
KLDEKGFIERNLNDTRYVARFLCNFIADNMHLTGEGKRKVFASNGQITALLRSRWGLAK  
SREDNDRHHALDAVVVACSTVAMQQKITRFVRFEAGDVFTGERIDRETGEIPLHFPTPW  
QFFKQEVIRIFSDNPKLELENRLPDRPQANHEFVQPLFVSRMPTRKMTGQGHMETVKS  
AKRLNEGISVIKMPLTKLKLKDLELMVNREREKDLYDTLTKARLEAFNDPAKAFAPFI  
KKGGAIKSVRVEQIQKSGVLVREGNGVADNASMVRVDVFTKGGKYFLVPIYTWQVA  
KGILPNKAATQYKDEEDWEVMDNSATFKFSLHPNDLVKLVTKKKTILGYFNGLNRATG  
NIDIKEHDLKSKGKQGIFEGVGIKLALSFEKYQVDELGKNIRLCKPSKRQPVR\*

Figure 28

ATGGAAAAATTTCACTATGTATTGGGTTTGGATTTGGGTATCGCCTCTGTGGGGTGGGCTGCCATTGAA  
ATTGACAAGGAAACCGAAACATCAATCGGTTTATTGGATTGCGGTGTCAGAACATTTGAACGTGCAGA  
AGTACCCAAAAACAGGCGATTCTCTTGCCAAAGCTCGCCGTGAAGCCAGAAGTACTCGCCGTTTAATTC  
GCAGACGTTTCGCATCGCTTATTACGTTTAAAACGTTTATTGAAAACGTGAAATTTTCAGGCAGCCTGAAA  
CGTTTAAAGACTTACCAATCAATGCTTGGCAATTGCGTGTTAAAGGCTTGGATAGTCGGTTGAATGAA  
TATGAATGGGCGGCCGTTTATTGCATTTGGTGAAGCATCGCGGTTATTTATCGCAACGCAAAAAGCGA  
AATGAGCGAAACAGACAGCAAATCTGAAATGGGCAGATTACTGGCAGGTGTGGCGGAAAATCACCAA  
CTTTTACAACAAGAACAATATCGTACACCAGCCGAATTAGCACTCAAAAAATTTGTGAAACATTTTCG  
CAATAAAGGTGGCGATTATGCACACACTTTCAACCGTTTGGATTTGCAAGCCGAATTGCATTTATTGTT  
TCAAAAACAACGTGAATTAGGCAATCCATTCACTTCACCAGAATTGGAACGGCAAGTTGATGATTTGT  
TGATGACGCAGCGCAGTGCTTTACAAGGTGATGCGATTTTGAAGATGTTGGGTCATTGTGGGTTTGAA  
CCTGAACAATTCAAAGCAGCGAAAAACACATTCACTGCCGAACGTTTATTTGGTTGACAAAACCTCAA  
TAATCTTCGCATTCAAGACCAAGGCAAAGAACGTGCGTTAACTGCCGATGAGCGTACCAAATTGTTGG  
ACGAGCCTTATAAAAAAAGTAAATTGACTTACGCACAAGTTCGCAAATTATTAAGCTTGCCTCAAACT  
GCTATTTTAAAGGTTTGCCTTATGATTTGGAACATGACAAAAAAGCAGAAAAACAGTACGTTGATGGA  
AATGAAATCCTATCACAACATCCGCCAAACATTGAAAAAATCAGGTTTGAAGACAGAATGGCAAAGT  
ATTGCCACGCAGCCTGAAATTTTAGATGCAATTGGCACGGCGTTTTCCATTTATAAAACCGATGAAGA  
TATTTTCGCATGAATTAACAAACGTGCAGGCTGCCTGAAAACGTATTGAATGAATTACTGAAAAACATCA  
ATTTTGATGGATTCAATTAATTCGTTGACTGCATTACGCAAAATTTTGCCCTTGATGGAACAAGGCT  
ACCGTTATGATGAAGCGTGTAACCAAATTTACGGTAATCATCATTACAGGCAGCTTGCAACAAGAATCA  
AAGCAATTTTGGCACATATTCCGATTGATGATGTCCGAAATCCTGTGGTGTTCGTAATTTGACCCAA  
GCAAGAAAAGTGGTGAATGCGATTATTCGTCGGTATGGTTCGCCAGCTCGTGTGCATATTGAGATGGC  
GCGTGAATTTGGGTAAGTCTAAATCAGACCGTGACCGAATTGAAAAACAACAACAAAAAATAAAAAA  
GAACGTGAAAACGCAGTCGCCAAATTCAAAGAAGATTTCCCTGATTTTGTGGGCGAACCCAGAGGGA  
AAGATATTTTGAAGATGCGTTTGTATGAACAACAACACGGCAAATGTTTGTATTTCGGGTCATGATATT  
GATATTAATCGATTGAATGAAAAAGGTTATGTTGAAATTGACCATGCCCTGCCATTTTCACGGACTTGG  
GATGATAGTCAAAATAATAAAGTTTTGGTACTTGGCAGCGAAAAACCAAATAAACGCAATCAAACGC  
CTGATGAATATTTGGACGGTGCAACAATAGCCAACGTTGGCTTGAATTTCAAGCGCGTGTACAACT  
TGTCATTTTTCTTACGGTAAAAACAACGCATTCAATTAGCCAAATTAGACGATGAAACCGAAAAAGG  
ATTTTTAGAACGCAATCTAAATGATACGCGGTATATTGCTCGTTTTATGTGTCAATTTGTCCAAGAAAA  
TTTATATTTGACAGGTAAAGGAAAACGTCTTGTTTTTGCATCAAACGGCGGAATGACCGCAACATTGA  
GAAATTTATGGGGTTTGAGAAAAGTCCGTGAAGACAACGACCGCCATCATGCTCTTGATGCGATTGTG  
GTGGCGTGTTCCTACTGCTTCTATGCAACAAAAAATAACCAAAGCATTTCAACGCCATGAAAGCATTGA  
ATATGTGGATACCGAAACGGGCGAAGTAAAATTTCTGATTCCACAGCCTTGGGATTTTTTCCGTCAGG  
AAGTGATGATTCTGTGTTCAGCGACCAACCGTGTGAAGATTTGGTAGAAAAATTGTGGGCTCGTCCC  
GAAGCTTTGCATGACAACGTAACGCCTTTATTTGTCTCGCGTGCACCAAATCGCAAAATGTGGGGCA  
AGGGCATTTGGAACCATCAAATCTGCAAAAAGGCTGTCTGAAGAAAAACAGTATGGTTAAAAAACCA  
TTAACCACATTGAAATTAAGATATTCCAGAAATCGTAGGCTACCCGAGTCGTGAACCTCAATTGTA  
TGCCGCATTGAAAACACGTTTAGAAAACGCATGATGATGACCCAATTAAGCCTTTGCCAAACCTTTTT  
ACAAACCAATAAAAAATGGTGAATTGGGGGCGTTGGTTCGATCGGTGCGTGTGAAAGGTGTACAAAA  
TACGGGTGTAATGGTTCATGATGGCAAAGGCATTGCCGATAATGCCACAATGGTTCGTGTTGATGTCT  
ATACCAAAGCGGGCAAAAATTACCTTGTCTGTGTATGTTTGGCAGGTGGCTCAAGGAATTTTGCCA  
AATCGGGCGGTTACTTCTGGCAAAAGTGAAGCAGATTGGGATTTAATTGATGAAAGTTTTGAATTTAA  
ATTTTCGCTGTCTCGTGGGGATTTAGTGGAATGATTAGCAATAAAGGAAGAATTTTGGTTATTACAA  
TGGGTTAGATCGTGCAAATGGAAGTATTGGGATTCGTGAACATGATTGGAAGTCCAAAGGAAAA  
GATGGTGTTCATCGTGTGGCGTGAAAACCGCCACCGCATTCAACAAATACCACGTTGACCCACTTGG  
TAAAGAAATTCATCGGTGTTTCATCTGAACCACGCCCCACATTAAAAATCAAATCCAAGAAATAA

Figure 29



MEKFHYVLGLDLGIASVGWAAIEIDKETETSIGLLDCGVRTFERAEVPKTGDSLAKARRE  
ARSTRRLIRRRSHRLLRLKRLKREIFRQPETFKDLPINAWQLRVKGLDSRLNEYEWAAV  
LLHLVKHRGYLSQRKSEMSETDSKSEMGRLLAGVAENHQLLQQEQYRTPAELALKKFV  
KHFRNKGGDYAHTFNRLDLQAEHLHLLFQKQRELGNPFTSPELERQVDDLLMTQRSALQ  
GDAILKMLGHCGFEPEQFKAANKNTFSAERFIWLTCLNRLRIQDQGKERALTADERTKLL  
DEPYKKSKLTYAQVRKLLSLPQTAIFKGLRYDLEHDKKAENSTLMEMKSYHNIRQTLEK  
SGLKTEWQSIATQPEILDAIGTAFSIYKTDEDISHELKTCRLPENVLNELLKNINFDFGIQL  
SLTALRKILPLMEQGYRYDEACTQIYGNHHSGLQQESKQFLPHIPIDVVRNPVVFRTLT  
QARKVVNAIIRRYGSPARVHIEMARELGKSKSDRDRIEKQQQKNKKERENAVAKFKED  
FPDFVGEPRGKDILKMRLYEQQHGKCLYSGHDIDINRLNEKGYVEIDHALPFSRTWDDS  
QNNKVLVLGSENQNKRNQTPDEYLDGANNSQRWLEFQARVQTCHFSYGKKQRIQLAK  
LDDETEKGFLERNLNDTRYIARFMCQFVQENLYLTGKGKRLVFASNGGMTATLRNLWG  
LRKVREDNDRHHALDAIVVACSTASMQQKITKAFQRHESIEYVDTETGEVKFRIPQPWD  
FFRQEV MIRVFSDQPCEDLVEKLSARPEALHDNVTPLFVSRAPNRKMSGQGHLETIKSA  
KRLSEENSMVKKPLTTLKLDIPEIVGYPSREPQLYAALKTRLETHDDDDPIKAFAKPFYK  
PNKNGELGALVRSVRVKGVQNTGVMVHDGKGIADNATMVRVDVYTKAGKNYLVPVY  
VWQVAQGILPNRAVTSGKSEADWDLIDESFEFKFSLSRGDLVEMISNKGRIFGYYNGLD  
RANGSIGIREHDLEKSKGKDGVHRVGVKTATAFNKYHVDPLGKEIHRCSSSEPRPTLKI  
KK\*

Figure 30

[illegible]

Figure 31

MEKFHYVLGLDLGASVGVAAIEIDKETETSIGLLDCGVRTFERAEVPKTGDSLAKARREARSTRRLIRRRSHRLLRLKRLKREIFRQPETFKDLPIN  
 AWQLRVKGLDSRLNEYEWAAVLLHLVKHRGYLSQRKSEMSETDSKSEMGRLLAGVAENHQLLQQEQYRTPAELALKKFVKHFRNKGGDYAHTF  
 NRDLQAEHLHLFQKQRELGNPFTSPELERQVDDLMTQRSALQGDAILKMLGHCGEPEQFKAANKTFSAEFIWLTCLNNLRIQDQGKERALTA  
 DERTKLLDEPYKSKLTYAQVRKLLSLPQTAIFKGLRYDLEHDKKAENSTLMEKSYHNRQTLEKSGLKTWQSIATQPEILDAIGTAFSIYKTD  
 ISHELKTCRLPENVLNELLKNINFDGFIQLSLTALRKILPLMEQGYRYDEACTQIYGNHHSGLQQESKQFLPHIPIDDVRNPVVFRTLTQARKVVNAII  
 RRYGSPARVHIEMARELGKSKSDRDRIKQQQKNKKERENAVAKFKEDFPDFVGEPRGKDILKMRLYEQQHGKCLYSGHDIDNRLNEKGYVEIDH  
 ALPFSRTWDDSQNNKVLVLGSENQNKRNQTPDEYLDGANNQRWLEFQARVQTCFHSYGGKKQRIQLAKLDDTEKGFLERNLNDTRYIARFMCQF  
 VQENLYLTGKGKRLVFASNGGMTATLNLWGLRKVREDNDRHHALDAIVVACSTASMQQKITKAFQRHESIEYVDTETGEVKFRIPQPWDFFRQE  
 VMIRVFSQPCEDLVEKLSARPEALHDNVTPLFVSRAPNRKMSGQGHLETIKSAKRLSEENSMVKKPLTTLKLDIPEIVGYPSREPQLYAALKTRLE  
 THDDPIKAFAPFYKPNKNGELGALVRSVRVKGVQNTGVMVHDGKGIADNATMVRVDVYTKAGKNYLVFVYVWQVAQGILPNRAVTSKGSEA  
 DWDLIDESFEFKFSLSRGDLVEMSNKGRIFGYNGLDRANGSIGREHDLEKSKGKDGVHRVGVTATAFNKYHVDPLGKEIHRCSSSEPRPTLKIKS  
 KKGTGGPKKKRKVTPIDNPDYAGTPIDPDYAGNPDYAGNPDYAGSAAPAAKKKKLDFESC\*

Figure 32

Nme2 sgRNA:

NNNNNNNNNNNNNNNNNNNGUUGAGCUCCUUUCUAULUCGAAA

NNNNNNNNNNNNNNNNNNNAAAAAAAAAAAAA

Hpa sgRNA:

[illegible]

Simu sgRNA:

NNNNNNNNNNNNNNNNNGLUAGGCUCCUCUUAUCUCGUAGUGGAAA

Figure 33





Figure 34




Figure 34 (cont'd)




Figure 34 (cont'd)




Figure 35






Figure 35 (cont'd)




Figure 35 ( cont'd)




Figure 36




Figure 36 (cont'd)




Figure 37





Figure 37 (cont'd)



**Figure 37 (cont'd)**




Figure 38






Figure 39




Figure 39 (cont'd)




Figure 40




Figure 40 (cont'd)




Figure 40 (cont'd)




Figure 41




Figure 42




Figure 42 (cont'd)






Figure 42 (cont'd)

Figure 42E




Figure 42F

Rosa26|On: TGAGGACCGCCCTGGGCCTGGGAGAATCCCT  
 Rosa26|OT1: GAAGGACCACCCTAGGCCTGGGAGACTCCCT

Figure 42 (cont'd)




Figure 43




Figure 43 (cont'd)




Figure 43 (cont'd)




Figure 43 (cont'd)





Figure 43 (cont'd)

Figure 44  
A



B




Figure 44







Figure 44 (cont'd)




Figure 45




Figure 46






Figure 47

A



B

C



D

Figure 48




Figure 48 (cont'd)




Figure 49




Figure 50






Figure 51




Figure 52




Figure 53





Figure 54

A



B




Figure 55




Figure 56




Figure 57




Figure 58



Nme1Cas9	MAAFKPNINYLGLDIGIASVGWAVEIDEEENPIALIDLGVVRVFERRAEVPKTDGLAM	60
Nme2Cas9	MAAFKPNINYLGLDIGIASVGWAVEIDEEENPIALIDLGVVRVFERRAEVPKTDGLAM	60
Nme1Cas9	ARRLARSVRRLTRRAHRLLEAPLLKREGVLQAAFDENGLIKSLPNTFWQLRAAALDR	120
Nme2Cas9	ARRLARSVRRLTRRAHRLLEAPLLKREGVLQAAFDENGLIKSLPNTFWQLRAAALDR	120
Nme1Cas9	KLTFLEWSAVLLHLIKHRYLSQPKNEGETADKELGALLKGVANAHALQTGDFRTPAEL	180
Nme2Cas9	KLTFLEWSAVLLHLIKHRYLSQPKNEGETADKELGALLKGVANAHALQTGDFRTPAEL	180
Nme1Cas9	ALNHFKEKSGHIRNQRYDVSHTFSRKDLQAEILILFEKQKEFGNPHVSGGLKEGIETLLM	240
Nme2Cas9	ALNHFKEKSGHIRNQRYDVSHTFSRKDLQAEILILFEKQKEFGNPHVSGGLKEGIETLLM	240
Nme1Cas9	TQRPALSGDAVQKMLGHCITFEPAEPKAAKNITYAERFIWLTMLNNLRILEQGSERPLTDT	300
Nme2Cas9	TQRPALSGDAVQKMLGHCITFEPAEPKAAKNITYAERFIWLTMLNNLRILEQGSERPLTDT	300
Nme1Cas9	ERATLMDEPYRKSCLTYAQARKLLGLEDTAFFNGLRVGNWAEASTLMEMKAYHAISRAL	360
Nme2Cas9	ERATLMDEPYRKSCLTYAQARKLLGLEDTAFFNGLRVGNWAEASTLMEMKAYHAISRAL	360
Nme1Cas9	EKEGLKDKKSPNLSELODEIGTAFSLFKTIDEDITGRKLDKQPEILEALLKHISFDKF	420
Nme2Cas9	EKEGLKDKKSPNLSELODEIGTAFSLFKTIDEDITGRKLDKQPEILEALLKHISFDKF	420
Nme1Cas9	VQISLKAALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEENKIYLPPIPADEIRNPFVFLRA	480
Nme2Cas9	VQISLKAALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEENKIYLPPIPADEIRNPFVFLRA	480
Nme1Cas9	LSQARKVINGVVRVYGSFARIHIETAREVGKSFDRKEIEKRQEEENRDRKAAAKFREY	540
Nme2Cas9	LSQARKVINGVVRVYGSFARIHIETAREVGKSFDRKEIEKRQEEENRDRKAAAKFREY	540
Nme1Cas9	FPNFVGEPSKNDILKRLRYEQQHGKCLYSGKEINLRLNEKGYVEIDNALPFSRTWDDSF	600
Nme2Cas9	FPNFVGEPSKNDILKRLRYEQQHGKCLYSGKEINLRLNEKGYVEIDNALPFSRTWDDSF	600
Nme1Cas9	NNKVLVLGSENGNNGNQTPEYFNGKDNSREWQEFKARVETSRFFRSKKQRIILQKFDE	660
Nme2Cas9	NNKVLVLGSENGNNGNQTPEYFNGKDNSREWQEFKARVETSRFFRSKKQRIILQKFDE	660
Nme1Cas9	GFKEINLNDTRYVNRFLCQFVADILTGNGKRVFASNGQITNLLRGFWGLPKVRAEND	720
Nme2Cas9	GFKEINLNDTRYVNRFLCQFVADILTGNGKRVFASNGQITNLLRGFWGLPKVRAEND	720
Nme1Cas9	RHHALDAVVACSTVANQOKITRFVRYKEMNAFDGKTIDKETGVHLQKTHFPQPEWFFA	780
Nme2Cas9	RHHALDAVVACSTVANQOKITRFVRYKEMNAFDGKTIDKETGVHLQKTHFPQPEWFFA	780
Nme1Cas9	QEVMIKRVFGKPDGKPEFEEADTEKLRITLLAEKLSRPEAVHEYVTPLFVSRAFNKMSG	840
Nme2Cas9	QEVMIKRVFGKPDGKPEFEEADTEKLRITLLAEKLSRPEAVHEYVTPLFVSRAFNKMSG	840
Nme1Cas9	QGHMETVNSAK---RLDEGVSVLRVPLTQLKLDLEKMWNR--EREKLYEALKARLEAH	900
Nme2Cas9	AKK-ETLSAKRFVYKHNEKISVVRVLTETIKLADLEKMWNYNGRETELYEALKARLEAY	900
Nme1Cas9	KDDPAKAFAE---PTKYDKAGNRTQGVKAVRVEQVQNTGVVVRNH--NGIADNATMVRV	960
Nme2Cas9	GGNANQAFDPKDNPFYKN---G---GQLVKAVRVEKQESGVLLNKKNAITADNGEMVRV	960
Nme1Cas9	DVFENG-----DHYLLVPIYSQVANGILPDRAVQCKDEEDWQLIDDSFNFFSLHEND	1000
Nme2Cas9	DVFCKYDKNGKNQYPIVPIYAWQVAENILPDIECKG-----YRIDDSVIFCFSLHXYD	1000
Nme1Cas9	LVEVIT--HARMFGYFASCHRESTGIMIRIHLDLMDKIGKNGILEGIGVKTALSFKKYQ	1060
Nme2Cas9	LIAFONDEKSKVEFAYYINCDSNGRFTLANHDKGSKVEQ---QFISTQNLVLICKYQV	1060
Nme1Cas9	DELGKEIRPCRLKKRPVR	1082
Nme2Cas9	NELGNEIRPCRLKKRPVR	1082

Figure 59

Nme1Cas9	1	MAAFKPNINYLGLNIGIASVGWAMVEIDEEENPIRLIDLGVRVFERAE	50
Nme3Cas9	1	MAAFKPNINYLGLNIGIASVGWAMVEIDEEENPIRLIDLGVRVFERAE	50
Nme1Cas9	51	VPKTGDSLAMARRLARSVRRLTRRAHRLLPRLLEKREGVLQAAAFDEN	100
Nme3Cas9	51	VPKTGDSLAMARRLARSVERLIRRAHRLLPRLLEKREGVLQAAAFDEN	100
Nme1Cas9	101	GLIKSLPNTFWQLRAAALDRKLYPLEWSAVILHLIHRGFLSQRRNEGET	150
Nme3Cas9	101	GLIKSLPNTFWQLRAAALDRKLYPLEWSAVILHLIHRGFLSQRRNEGET	150
Nme1Cas9	151	ADKELGALLNGVAGNAHALQIGDFRTPAELALNKFENEHRIHQRSQDYS	200
Nme3Cas9	151	ADKELGALLNGVAGNAHALQIGDFRTPAELALNKFENEHRIHQRSQDYS	200
Nme1Cas9	201	HTFSRKDLQAEILLFENQWFGNPHVSGGLKEGIEITLMTQRPALSGDA	250
Nme3Cas9	201	HTFSRKDLQAEILLFENQWFGNPHVSGGLKEGIEITLMTQRPALSGDA	250
Nme1Cas9	251	VQKMLGHCTFEPAEPKAAKNITYTAERFIWLTKLNNLRILEQGSERPLTDT	300
Nme3Cas9	251	VQKMLGHCTFEPAEPKAAKNITYTAERFIWLTKLNNLRILEQGSERPLTDT	300
Nme1Cas9	301	ERATLMDEPYRKSKLTYAQARKLLLEDIAFFNGLAYGKDAEASTLMEM	350
Nme3Cas9	301	ERATLMDEPYRKSKLTYAQARKLLLEDIAFFNGLAYGKDAEASTLMEM	350
Nme1Cas9	351	KAYHISRALEKEGLDKKNSPLNLSPELQDEIGTAFSLFNTLEDITGRLK	400
Nme3Cas9	351	KAYHISRALEKEGLDKKNSPLNLSPELQDEIGTAFSLFNTLEDITGRLK	400
Nme1Cas9	401	DRIQPEILEALLKHISFIMFVQISLHALPRIVPLMEQGHRYDEACAEIYG	450
Nme3Cas9	401	DRIQPEILEALLKHISFIMFVQISLHALPRIVPLMEQGHRYDEACAEIYG	450
Nme1Cas9	451	DHYGKNTTEEKIYLPPIPADEIRNPVVLRAALSQARKVINGVVRVYGPAP	500
Nme3Cas9	451	DHYGKNTTEEKIYLPPIPADEIRNPVVLRAALSQARKVINGVVRVYGPAP	500
Nme1Cas9	501	IHIETAREVGNSEFKDRAEIEKQZENNDRKDAKAAKFRYFFNFVGEPKS	550
Nme3Cas9	501	IHIETAREVGNSEFKDRAEIEKQZENNDRKDAKAAKFRYFFNFVGEPKS	550
Nme1Cas9	551	KDILKRLRYEQQHGKCLYSGKEINLGRLENGSYVEIDNALPFSRTWDDSF	600
Nme3Cas9	551	KDILKRLRYEQQHGKCLYSGKEINLGRLENGSYVEIDNALPFSRTWDDSF	600
Nme1Cas9	601	NNKVVLVLSSENQNKGNQIPYEYFNGKDNSEWQEFKARVEISRFPKSKQ	650
Nme3Cas9	601	NNKVVLVLSSENQNKGNQIPYEYFNGKDNSEWQEFKARVEISRFPKSKQ	650
Nme1Cas9	651	RILLQKFDEDDGFKERNLNDTRYVNRFLCQFVADRMALIGWGNKRVFASNG	700
Nme3Cas9	651	RILLQKFDEDDGFKERNLNDTRYVNRFLCQFVADRMALIGWGNKRVFASNG	700
Nme1Cas9	701	QITNLLRGFWGLKRVRAENDRHHALDAVVVACSTVAMQQNITRFVRYKEM	750
Nme3Cas9	701	QITNLLRGFWGLKRVRAENDRHHALDAVVVACSTVAMQQNITRFVRYKEM	750
Nme1Cas9	751	NAFDGNTIDKETGEVLHQHIFFPQWEPFAQEVMIIPVFGHPLGKPEFEAA	800
Nme3Cas9	751	NAFDGNTIDKETGEVLHQHIFFPQWEPFAQEVMIIPVFGHPLGKPEFEAA	800
Nme1Cas9	801	DTLEKRLTLLAEKLSRPEAVHEYVITPLFVSRAPNRKMSQGHMETVKSAA	850
Nme3Cas9	801	DTLEKRLTLLAEKLSRPEAVHEYVITPLFVSRAPNRKMSQGHMETVKSAA	850
Nme1Cas9	851	KRLDEGVSVLRVPLTQLKLKLEKMNVREREKPLYEALKAPLEAHKDDPA	900
Nme3Cas9	851	KRLDEGVSVLRVPLTQLKLKLEKMNVREREKPLYEALKAPLEAHKDDPA	900
Nme1Cas9	901	KAFLEFFVYKDKAGNRTQQVKAVRVEQVQKIGVWVRNHNHGIADNATMVRV	950
Nme3Cas9	901	KAFLEFFVYKDKAGNRTQQVKAVRVEQVQKIGVWVRNHNHGIADNATMVRV	950
Nme1Cas9	951	DVFEKGDKNYLVFIYSWQVAKGILFDRAVVADEEDWQIIDSFFNFATF	1000
Nme3Cas9	951	DVFEKGDKNYLVFIYSWQVAKGILFDRAVVADEEDWQIIDSFFNFATF	1000
Nme1Cas9	1001	LHENDLKEVEITKKAPMEGYFASCHRGIGNIRIHLELDHRIKMGILEGI	1050
Nme3Cas9	1001	LHENDLKEVEITKKAPMEGYFASCHRGIGNIRIHLELDHRIKMGILEGI	1050
Nme1Cas9	1051	GVKTALSFQKYQIDSEKHEIRPCPLKRRPFVR	1062
Nme3Cas9	1050	GVKTALSFQKYQIDSEKHEIRPCPLKRRPFVR	1061

Figure 60



MAAFKPNPINYILGLDIGIASVGWAMVEIDEEENPIRLIDLGV RVFERAEV PKTGDSL A  
 MARRLARSVRRLTRRRRAHRLLRARRLLKREGVLQAADFDEGLIKSLPNTPWQLRA  
 AALDRKLTPLEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGVANNAHALQT  
 GDFRTPAELALNKFEEKESGHIRNQRGDYSHTF SRKDLQAELILLFEKQKEFGNPHVS  
 GGLKEGIETLLMTQRPALSGDAVQKMLGHCTFEPAEPKAAKNTYTAERFIWLT KLN  
 NLRILEQGSERPLTDTERATLMDEPYRKSKLT YAQARKLLGLEDTAFFKGLRYGKDN  
 AEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSSELQDEIGTAFSLFKTDEDITGRL  
 KDRVQPEILEALLKHISFDKFVQJSLKALRRIVPLMEQ GKRYDEACAEIYGDHYGKKN  
 TEEKIYLPPIPADEIRNPVVLRA LSQARKVINGV VRRY GSPARIHIETAREVGKSFKDR  
 KEIEKRQFENRKRDKREKAAAKFREYFPNFVGEPKSKDILKLRLYEQQHGKCLYSGKEI  
 NLVRLNEKGYVEIDHALPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNS  
 REWQEFKARVETSRFPRSKKQRILLQKFDEDDGFKECNLNDTRYVNRFLCQFVADHIL  
 LTGKGKRRVFASNGQITNLLRGFWGLRKVRAENDRH HALDAVVVACSTVAMQQKI  
 TRFVRYKEMNAFDGKTIDKETGKVLHQKTHFPQPWEFTAQEVMIRVFGKPDGKPEF  
 EEADTPEKLRRTLLAEKLSSRPEAVHEYYVTPLFVSRAPNRKMSGAHKDTLRS AKRFVK  
 HNEKISVKRVWLTEIKLADLENMVNYKNGREIELYEALKARLEAYGGNAKQAFDPK  
 DNPFYKKGGLVKA VRVEKTQESGVLLNKKNAYTIADNGDMVRVDVFCKVDKKG  
 KNQYFIVPIYAWQVAENILPDIDCKGYRIDDSYTFCSLHKYDLIAFQKDEKSKVEFAY  
 YINCDSSNGRFYLAWHDKGSKEOQFRISTONLVLIOKYQVNELGKEIRPCRLKKRPP  
 VR  P K K K R K V Y P Y D V P D Y A G Y P Y D V P D Y A G S Y P Y D V P D Y A  A A P A A K K K K L  
 FESG\*

Figure 61

MVPKKKRKV ██████████ MAAFKPNPINYILGLDIGIASVGMAMVEI  
 DEENPIRLIDLGVRFERAEVPKTGDSLAMARRLARSVRRLTRRRRAHRLLRARRLL  
 KREGVLQAADFENGLIKSLPNTWPQLRAAALDRKLTPLEWSAVLLHLIKHRGYLSQ  
 RKNEGETADKELGALLKGVANNAHALQTGDFRTPAELALNKFEKESGHIRNQRGDY  
 SHTFSRKDLQAEILILFEKQKEFGNPHVSGGLKEGIEITLLMTQRPALSGDAVQKMLG  
 HCTFEPAEPKAAKNTYTAERFIWLTCLNNLRILEQGSERPLTDTERATLMDEPYRKS  
 KLTYAQARKLLGLEDTAFFKGLRYGKDNAAEASTLMEMKAYHAISRALEKEGLKDKK  
 SPLNLSELQDEIGTAFSLFKTDEDITGRLKDRVQPEILEALLKHISFDKFFVQISLKALR  
 RIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPVVLRAALSQARKV  
 INGVERRYCGSPARIHIETAREVGKSFKDRKEIEKROEENRKDREKAAAKFREYFPNFV  
 GEPKSKDILKLRLYEQQHKGKCLYSGKEINLVRLEKGYVEIDHALPFSRTWDDSFNN  
 KVLVLGSENNQKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQKFD  
 EDGFKECNLDTRYVNRFLCQFVADHILLTGKGKRRVFASNGQFTNLLRGFWGLRK  
 VRAENDRHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGKVLHQ  
 KTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTPEKLRITLLAEKLSSRPEAVHEYVT  
 PLFVSRAPNRKMSGAHKDTLRSKRFRVKHNEKISVKRVWLTEIKLADLENMVNYKN  
 GREIELYEALKARLEAYGGNAKQAFDPKDNPFYKKGGLVKA VRVEKTQESGVLLN  
 KKNAYTIADNGDMVRVDVFCVKVDKKGKNQYFIVPIYAWQVAENILPDIDCKGYRID  
 DSYTFCPSLHKYDLIAFQKDEKSKVEFAYYINCDSSNGRFYLA WHDKGSKEQQFRIST  
 ONLVLIOKYQVNELGKEIRPCRLKKRPPVR ██████████  
 AGYPYDVDPDYAGSYYPYDVDPDYA ██████████ PAAKKKKLD\*

Figure 62

PKKKRKV MAAFKPNPINYILGLDIGIASVGWAMVEIDEEENPIRLIDLGV RVFERAE  
 VPKTGDSLAMARRIARSVRRRLTRRRRAHRIILRARRLKREGVLQAADFDEGLIKSLP  
 NTPWQLRAAALDRKLTPLWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGVA  
 NNAHALQTGDFRTPAELALNKFESGHIRNQRGDYSHTFSRKDLQAEIILLFEKQK  
 EFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKMLGHCTFEPAEPKAAKNTYTAER  
 FTWLTKLNNLRILEQGSRPLTDTERATLMDEPYRKSKLTYAQARKLLGLEDTAFFK  
 GLRYGKDNAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSSELQDEIGTAFSLFKT  
 DEDITGRLKDRVQPEILEALLKHISFDKFVQISLKALRRIVPLMEQGKRYDEACAEIYG  
 DHYGGKNTEEKIYLPPIPADEIRNPVVLRAISQARKVINGVVRRYGSPARIHIETAREV  
 GKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVGEPKSKDILKLRLYEQQHGK  
 GLYSGKEINLVRLEKGYVEIDHALPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEY  
 FNGKDNSREWQEFKARVETSRFPRSKKQRILLQKFDEDEGFKECNLNDTRYVNRFLC  
 QFVADHILLTGKGGKRRVFASNGQITNLLRGFWGLRKVRAENDRHHALDAVVVACS  
 TVAMQQKITRFRVRYKEMNAFDGKTIDKETGKVLHQKTHFPQPWEFFAQEVMIRVF  
 GKPDGKPEFEEADTPEKLRITLLAEKLSSRPEAVHEYVTPLFVSRAPNRKMSGAHKDT  
 LRSKRFRVKHNEKISVKRVWLTEIKLADLENMVNYKNGREIELYEALKARLEAYGGN  
 AKQAFDPKDNPFYKKGGQLVKAVRVEKTQESGVLLNKKNAYTIADNGDMVRVDVF  
 CKVDKKGKNQYFIVPIYAWQVAENILPDIDCKGYRIDDSYTFCSLHKYDLIAFQKDE  
 KSKVEFAYYINCDSSNGRFYLAWHDKGSKEQQFRISTONLVLIOKYOVNELGKEIRP  
 CRLKKRPPVR PAAKKKKLD

\*

Figure 63

Figure 64